{
  "letters": 940989,
  "pages": 241,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Bionano Genomics, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 3,
          "title": "Form 10-K Table of Contents",
          "data": [
            {
              "key": "Item 1B.",
              "value": "Unresolved Staff Comments"
            },
            {
              "key": "Item 2.",
              "value": "Properties"
            },
            {
              "key": "Item 3.",
              "value": "Legal Proceedings"
            },
            {
              "key": "Item 4.",
              "value": "Mine Safety Disclosures"
            },
            {
              "key": "PART II",
              "value": ""
            },
            {
              "key": "Item 5.",
              "value": "Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities"
            },
            {
              "key": "Item 6.",
              "value": "[Reserved]"
            },
            {
              "key": "Item 7.",
              "value": "Management's Discussion and Analysis of Financial Condition and Results of Operations"
            },
            {
              "key": "Item 7A.",
              "value": "Quantitative and Qualitative Disclosures About Market Risk"
            },
            {
              "key": "Item 8.",
              "value": "Financial Statements and Supplementary Data"
            },
            {
              "key": "Item 9.",
              "value": "Changes in and Disagreements With Accountants on Accounting and Financial Disclosure"
            },
            {
              "key": "Item 9A.",
              "value": "Controls and Procedures"
            },
            {
              "key": "Item 9B.",
              "value": "Other Information"
            },
            {
              "key": "Item 9C.",
              "value": "Disclosure Regarding Foreign Jurisdictions that Prevent Inspections"
            },
            {
              "key": "PART III",
              "value": ""
            },
            {
              "key": "Item 10.",
              "value": "Directors, Executive Officers and Corporate Governance"
            },
            {
              "key": "Item 11.",
              "value": "Executive Compensation"
            },
            {
              "key": "Item 12.",
              "value": "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters"
            },
            {
              "key": "Item 13.",
              "value": "Certain Relationships and Related Transactions, and Director Independence"
            },
            {
              "key": "Item 14.",
              "value": "Principal Accountant Fees and Services"
            },
            {
              "key": "PART IV",
              "value": ""
            },
            {
              "key": "Item 15. Item 16.",
              "value": "Exhibit and Financial Statement Schedules Form 10-K Summary"
            },
            {
              "key": "signatures",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 7,
          "title": "Business Overview",
          "data": [
            {
              "key": "Company",
              "value": "Bionano Genomics"
            },
            {
              "key": "Acquisitions",
              "value": "Lineagen (August 2020), BioDiscovery (October 2021), Purigen (November 2022)"
            },
            {
              "key": "Transformation",
              "value": "Transformed from an instrument company to a provider of a full suite of genomic solutions"
            },
            {
              "key": "Business Focus",
              "value": "Genomic solutions including optical genome mapping, nucleic acid purification, software for genomic data interpretation, and clinical testing services."
            },
            {
              "key": "Clinical Testing Services",
              "value": "- Testing for neurodevelopmental disorders (NDDs) such as autism spectrum disorders (ASDs) \n- Laboratory developed tests (LDTs) for facioscapulohumeral muscular dystrophy type 1 (FSHD1) \n- Genetic counseling services"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 10,
          "title": "Acquisitions by OGM Systems",
          "data": [
            {
              "key": "Acquisition 1",
              "value": "BioDiscovery in 2021"
            },
            {
              "key": "Acquisition 2",
              "value": "Purigen in 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 34,
          "title": "Acquisition challenges and risks",
          "data": [
            {
              "key": "diversion_of_management_time",
              "value": "Diversion of management time and focus from operating our business to acquisition integration challenges."
            },
            {
              "key": "increased_expenses",
              "value": "Increases in our expenses and reductions in our cash available for operations and other uses."
            },
            {
              "key": "possible_write_offs",
              "value": "Possible write-offs or impairment charges relating to acquired businesses or assets."
            },
            {
              "key": "foreign_acquisition_risks",
              "value": "Foreign acquisitions involve unique risks including integration of operations across different cultures and languages, currency risks, and economic, political, and regulatory risks."
            },
            {
              "key": "equity_securities_issued",
              "value": "In connection with acquisitions, may issue equity securities in a dilutive manner, incur additional debt, or expend significant cash."
            },
            {
              "key": "share_issuance_Lineagen",
              "value": "Issued 6.2 million shares of common stock for acquisition of Lineagen."
            },
            {
              "key": "cash_payment_BioDiscovery",
              "value": "Paid approximately $52.3 million in cash and issued 2.7 million shares of common stock for acquisition of BioDiscovery."
            },
            {
              "key": "cash_payment_Purigen",
              "value": "Paid approximately $32.0 million in cash for acquisition of Purigen."
            },
            {
              "key": "headcount_increase",
              "value": "Headcount increased by more than 75 employees as a result of all three acquisitions."
            },
            {
              "key": "operating_expenses_increase",
              "value": "Acquisitions have increased operating expenses and net losses."
            },
            {
              "key": "due_diligence_outcomes",
              "value": "Due diligence may not have identified all matters that could adversely affect business."
            },
            {
              "key": "market_acceptance_concerns",
              "value": "Concern regarding market acceptance of products and technologies that may face reluctance from customers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 39,
          "title": "Regulatory and Market Risks for RUO Products",
          "data": [
            {
              "key": "current_limitations",
              "value": "Limited to RUO materials and components for consumables"
            },
            {
              "key": "business_strategy",
              "value": "Expand product line to clinical diagnostics and precision healthcare"
            },
            {
              "key": "regulatory_clearance_requirement",
              "value": "Need regulatory clearance for diagnostic products"
            },
            {
              "key": "FDA_guidance",
              "value": "FDA evaluates circumstances surrounding RUO marketing claims"
            },
            {
              "key": "risks_of_noncompliance",
              "value": "Potential enforcement actions by the FDA for misbranding"
            },
            {
              "key": "marketing_experience",
              "value": "Limited experience in marketing and selling products"
            },
            {
              "key": "manufacturer_reliance",
              "value": "Reliance on single contract manufacturer for key products"
            },
            {
              "key": "potential_impacts",
              "value": "May affect business and operating results negatively"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 76,
          "title": "Contingent Consideration",
          "data": [
            {
              "key": "Acquisition of BioDiscovery",
              "value": "Agreed to pay a milestone payment of $10.0 million contingent on achieving a commercial milestone within eighteen months."
            },
            {
              "key": "Fair Value of Milestone Consideration",
              "value": "Determined using a scenario-based technique with a 95% probability."
            },
            {
              "key": "Acquisition of Purigen",
              "value": "Agreed to pay milestone payments up to $32.0 million with evaluations on a quarterly basis."
            },
            {
              "key": "Fair Value of Contingent Consideration Liabilities",
              "value": "Determined to be $22.4 million as of December 31, 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 77,
          "title": "Business Combinations and Goodwill Impairment",
          "data": [
            {
              "key": "Significant Assumptions for Fair Value",
              "value": "Management's assumptions required for fair value assessments of acquired assets and liabilities."
            },
            {
              "key": "Goodwill Review Process",
              "value": "Annual assessment of goodwill impairment based on qualitative and quantitative analysis."
            },
            {
              "key": "Measurement Period for Adjustments",
              "value": "Adjustments to acquired assets and liabilities may occur up to one year from acquisition date."
            },
            {
              "key": "Accounting Approach for Business Combinations",
              "value": "ASC 805 provisions applied for accounting of acquisitions."
            },
            {
              "key": "Contingent Consideration",
              "value": "Recorded at fair value at acquisition and revalued quarterly."
            },
            {
              "key": "Impact of Assumptions on Estimates",
              "value": "Estimates are subject to change and can materially impact results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 80,
          "title": "Acquisition of Purigen Biosystems, Inc.",
          "data": [
            {
              "key": "Acquisition Price",
              "value": "$44.9 million"
            },
            {
              "key": "Contingent Consideration",
              "value": "Estimated future payments upon achievement of certain milestones"
            },
            {
              "key": "Assets Acquired",
              "value": "Estimated fair values of the assets acquired including identifiable intangible assets such as developed technology."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 89,
          "title": "Business Combinations",
          "data": [
            {
              "key": "Acquired Companies",
              "value": "BioDiscovery and Purigen"
            },
            {
              "key": "Acquisition Method",
              "value": "Acquisition method of accounting"
            },
            {
              "key": "ASC Reference",
              "value": "ASC 805"
            },
            {
              "key": "Fair Value Measurement",
              "value": "Based on estimated fair values as of acquisition date"
            },
            {
              "key": "Goodwill",
              "value": "Excess purchase price over estimated fair value recorded to goodwill"
            },
            {
              "key": "Transaction Costs",
              "value": "Expensed in statements of operations"
            },
            {
              "key": "Description of Restricted Cash",
              "value": "Funds restricted related to lease assumed in acquisition of Purigen"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 92,
          "title": "Impairment Assessment and Revenue Recognition",
          "data": [
            {
              "key": "Operating Segment",
              "value": "The Company has a single operating segment and a single reporting unit."
            },
            {
              "key": "Goodwill Impairment Analysis",
              "value": "Goodwill will first be tested for impairment through a qualitative assessment."
            },
            {
              "key": "Quantitative Analysis",
              "value": "If qualitative assessment indicates impairment, the fair value is compared to carrying value."
            },
            {
              "key": "Impairment Charge",
              "value": "An impairment charge is recognized for the amount where carrying value exceeds fair value."
            },
            {
              "key": "Reported Impairment Losses",
              "value": "No impairment losses on goodwill were recognized for the years ended December 31, 2022 and 2021."
            },
            {
              "key": "Lease Accounting",
              "value": "ROU assets and liabilities represent the Company's obligation from lease payments."
            },
            {
              "key": "Lease Terms",
              "value": "Options to extend or terminate leases are recognized when it is reasonably certain the option will be exercised."
            },
            {
              "key": "Revenue Generation",
              "value": "Revenue is primarily generated from the sale of products and services."
            },
            {
              "key": "Revenue Recognition Criteria",
              "value": "Revenue is recognized when contract terms, transaction price, and control are fulfilled."
            },
            {
              "key": "Performance Obligations",
              "value": "A performance obligation is a promise to transfer a distinct good or service."
            },
            {
              "key": "Warranties",
              "value": "Assurance-type warranties are not separate performance obligations."
            },
            {
              "key": "Payment Terms",
              "value": "Typically 30 days, may vary for international sales."
            },
            {
              "key": "Shipping Costs",
              "value": "Shipping/handling costs are recorded within s.g.a. expenses."
            },
            {
              "key": "Revenue Recording",
              "value": "Recorded net of discounts and sales tax and generally includes no product returns."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 97,
          "title": "Investments and Fair Value Measurements",
          "data": [
            {
              "key": "Total Fair Value of Investments",
              "value": "$108,095,000"
            },
            {
              "key": "Key Assets",
              "value": "Corporate notes/bonds and Commercial paper"
            },
            {
              "key": "Fair Value Classification",
              "value": "Level 1, Level 2, and Level 3"
            },
            {
              "key": "Contingent Consideration (Liabilities)",
              "value": "$22,352,001"
            },
            {
              "key": "Discount Rate Used",
              "value": "3%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 100,
          "title": "Prepaid Expenses and Other Current Assets",
          "data": [
            {
              "key": "Total current assets increase",
              "value": "4,481,000 to 7,329,000"
            },
            {
              "key": "Largest individual item",
              "value": "Other current assets: 2,412,000"
            },
            {
              "key": "Prepaid software subscriptions in current period",
              "value": "1,601,000"
            },
            {
              "key": "New line items in current period",
              "value": "Employee-related expenses, cloud computing costs"
            },
            {
              "key": "Decrease in prepaid insurance",
              "value": "1,461,000 to 948,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 100,
          "title": "Property and Equipment Breakdown",
          "data": [
            {
              "key": "Net property and equipment value increase",
              "value": "10.3M to 18.0M"
            },
            {
              "key": "Largest component 2022",
              "value": "Lab equipment: 15.1M"
            },
            {
              "key": "Accumulated depreciation increase",
              "value": "9.1M to 13.1M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 100,
          "title": "Intangible Assets Comparison",
          "data": [
            {
              "key": "Net carrying amount increase",
              "value": "26.8M to 41.0M"
            },
            {
              "key": "Significant asset category current period",
              "value": "Developed technology intangibles: 88% of total"
            },
            {
              "key": "Increased amortization",
              "value": "Across all categories in current period"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 103,
          "title": "Merger Details and Stock Offerings",
          "data": [
            {
              "key": "Merger Date",
              "value": "Not specified"
            },
            {
              "key": "Company involved",
              "value": "Lineagen"
            },
            {
              "key": "Third Amendment",
              "value": "Third Amendment to the Innovatus LSA"
            },
            {
              "key": "Stock Proceeds",
              "value": "Company will not receive proceeds from the Merger"
            },
            {
              "key": "Shelf Registration Filed",
              "value": "August 2020"
            },
            {
              "key": "Shelf Registration Amount",
              "value": "$125 million"
            },
            {
              "key": "Common Stock Sold under Cowen ATM",
              "value": "9.5 million shares"
            },
            {
              "key": "Average Share Price (Cowen ATM)",
              "value": "$1.60"
            },
            {
              "key": "Total Proceeds (Cowen ATM)",
              "value": "$15.2 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 111,
          "title": "Purigen Acquisition",
          "data": [
            {
              "key": "Purchase price finalized",
              "value": "during the year ended December 31, 2022"
            },
            {
              "key": "Net deferred tax asset",
              "value": "$11.5 million"
            },
            {
              "key": "Deferred tax liabilities for non-deductible intangibles",
              "value": "$4.4 million"
            },
            {
              "key": "Deferred tax assets for pre-acquisition tax loss and credit carryforwards",
              "value": "$15.4 million"
            },
            {
              "key": "Acquisition completion date",
              "value": "November 2022"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 112,
          "title": "Acquisition of Purigen",
          "data": [
            {
              "key": "Company",
              "value": "The Company"
            },
            {
              "key": "Acquired Company",
              "value": "Purigen"
            },
            {
              "key": "Merger Agreement",
              "value": "Purigen Merger Agreement"
            },
            {
              "key": "Purchase Price",
              "value": "$32.0 million cash upfront"
            },
            {
              "key": "Additional Cash Consideration",
              "value": "up to $32.0 million based on milestones"
            },
            {
              "key": "Escrow Fund",
              "value": "$1.2 million"
            },
            {
              "key": "Goodwill",
              "value": "$22,651,000"
            },
            {
              "key": "Net Assets Acquired",
              "value": "$44,914,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 113,
          "title": "BioDiscovery Acquisition",
          "data": [
            {
              "key": "Cash",
              "value": "$52,291,000"
            },
            {
              "key": "Fair value of milestone consideration",
              "value": "$9,000,000"
            },
            {
              "key": "Return of cash to buyer from escrow",
              "value": "-$694,000"
            },
            {
              "key": "Shares common stock issued as consideration",
              "value": "$2,723,000"
            },
            {
              "key": "Stock price per share on closing date",
              "value": "$5.20"
            },
            {
              "key": "Value of common stock consideration",
              "value": "$14,159,000"
            },
            {
              "key": "Total purchase price",
              "value": "$74,756,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 114,
          "title": "Purchase Price Allocation",
          "data": [
            {
              "key": "Cash and cash equivalents",
              "value": "3205000"
            },
            {
              "key": "Accounts receivable",
              "value": "1782000"
            },
            {
              "key": "Right-of-use assets",
              "value": "3987000"
            },
            {
              "key": "Other assets",
              "value": "280000"
            },
            {
              "key": "Intangible assets",
              "value": "26800000"
            },
            {
              "key": "Goodwill",
              "value": "47466000"
            },
            {
              "key": "Accounts payable and other accrued liabilities",
              "value": "-193000"
            },
            {
              "key": "Right-of-use liabilities (short-term and long-term)",
              "value": "-3987000"
            },
            {
              "key": "Deferred tax liability",
              "value": "-4016000"
            },
            {
              "key": "Contract liabilities",
              "value": "-568000"
            },
            {
              "key": "Net assets acquired",
              "value": "74756000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 114,
          "title": "Intangible Assets Valuation",
          "data": [
            {
              "key": "Customer relationships",
              "value": "3000000"
            },
            {
              "key": "Developed technology",
              "value": "22800000"
            },
            {
              "key": "Tradename Fair value of identifiable intangible assets",
              "value": "1000000"
            },
            {
              "key": "Tradename Fair value of identifiable intangible assets",
              "value": "26800000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 114,
          "title": "Revenue and Loss Comparison 2022-2021",
          "data": [
            {
              "key": "Revenue 2021",
              "value": "24086000"
            },
            {
              "key": "Revenue 2022",
              "value": "29893000"
            },
            {
              "key": "Net loss 2021",
              "value": "91505000"
            },
            {
              "key": "Net loss 2022",
              "value": "143309000"
            },
            {
              "key": "Basic and diluted net loss per share 2021",
              "value": "0.32"
            },
            {
              "key": "Basic and diluted net loss per share 2022",
              "value": "0.50"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 117,
          "title": "Agreement and Plan of Merger between companies",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "2.1"
            },
            {
              "key": "Description",
              "value": "Agreement and Plan of Merger, dated October 8, 2021, by and among the Company, Starship Merger Sub I, Inc., Starship Merger Sub II, LLC, BioDiscovery, Inc. and Soheil Shams."
            },
            {
              "key": "Exhibit Number",
              "value": "2.2"
            },
            {
              "key": "Description",
              "value": "Agreement and Plan of Merger, dated November 23, 2022, by and among the Company, Mazdan Merger Sub, Inc., Purigen Biosystems, Inc. and Shareholder Representative Services LLC."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 156,
          "title": "Merger Event Summary",
          "data": [
            {
              "key": "merger_id",
              "value": "179425913 v2"
            },
            {
              "key": "version",
              "value": "8"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 160,
          "title": "Basic Lease Information",
          "data": [
            {
              "key": "Lease Name",
              "value": "LEASE"
            },
            {
              "key": "Address",
              "value": "5700 Stoneridge Drive, Pleasanton, California"
            },
            {
              "key": "Document Version",
              "value": "v2"
            },
            {
              "key": "Exhibit Number",
              "value": "10.14"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 164,
          "title": "Commercial Lease Agreement Table of Contents",
          "data": [
            {
              "key": "clause_id",
              "value": "CLE 1"
            },
            {
              "key": "title",
              "value": "Premises"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 2"
            },
            {
              "key": "title",
              "value": "Term"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 3"
            },
            {
              "key": "title",
              "value": "Rent"
            },
            {
              "key": "notes",
              "value": "CODRDANNE"
            },
            {
              "key": "clause_id",
              "value": "CLE 4"
            },
            {
              "key": "title",
              "value": "Operating Expenses and Property Taxes Definitions"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 5"
            },
            {
              "key": "title",
              "value": "Other Taxes Payable by Tenant"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 6"
            },
            {
              "key": "title",
              "value": "Use; Environmental Matters"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 7"
            },
            {
              "key": "title",
              "value": "Services and Landlord's Repair Obligations"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 8"
            },
            {
              "key": "title",
              "value": "Alterations"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 9"
            },
            {
              "key": "title",
              "value": "Liens"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Tenant's Maintenance and Repairs"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE CONDURWNHRO"
            },
            {
              "key": "title",
              "value": "Damage or Destruction"
            },
            {
              "key": "notes",
              "value": "NNNYONNNNHNNNNNNYNPRP EEE PBNIBADDRKRVVNSSSSOCOBHBAIUYDADRANNFPRE"
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Subrogation"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Indemnification and Insurance"
            },
            {
              "key": "notes",
              "value": "BeBe"
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Compliance With Legal Requirements"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Assignment and Subletting"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Rules and Regulations"
            },
            {
              "key": "notes",
              "value": "RRB"
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Entry by Landlord"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Events of Default"
            },
            {
              "key": "notes",
              "value": "BBP"
            },
            {
              "key": "clause_id",
              "value": "CLE"
            },
            {
              "key": "title",
              "value": "Remedies Upon Default"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 20"
            },
            {
              "key": "title",
              "value": "Landlord's Right to Cure Defaults"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 21"
            },
            {
              "key": "title",
              "value": "Eminent Domain"
            },
            {
              "key": "notes",
              "value": "RPE"
            },
            {
              "key": "clause_id",
              "value": "CLE 22"
            },
            {
              "key": "title",
              "value": "Subordination to Mortgages"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 23"
            },
            {
              "key": "title",
              "value": "Surrender of Premises; Ownership and Removal of Trade Fixtures"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 24"
            },
            {
              "key": "title",
              "value": "Sale"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 25"
            },
            {
              "key": "title",
              "value": "Estoppel Certificate"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 26"
            },
            {
              "key": "title",
              "value": "Holding Over"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 27"
            },
            {
              "key": "title",
              "value": "Letter of Credit"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 28"
            },
            {
              "key": "title",
              "value": "Signage"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 29"
            },
            {
              "key": "title",
              "value": "Waiver"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 30"
            },
            {
              "key": "title",
              "value": "Notices"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 31"
            },
            {
              "key": "title",
              "value": "Miscellaneous"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 32"
            },
            {
              "key": "title",
              "value": "Real Estate Brokers"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 33"
            },
            {
              "key": "title",
              "value": "Authority"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 34"
            },
            {
              "key": "title",
              "value": "Complete Agreement"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 35"
            },
            {
              "key": "title",
              "value": "Option to Renew"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 36"
            },
            {
              "key": "title",
              "value": "Right of First Offer"
            },
            {
              "key": "notes",
              "value": ""
            },
            {
              "key": "clause_id",
              "value": "CLE 37"
            },
            {
              "key": "title",
              "value": "Emergency Generator"
            },
            {
              "key": "notes",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 194,
          "title": "EXHIBIT A Plan Outlining the Premises",
          "data": [
            {
              "key": "Document Version",
              "value": "279330373 v2"
            },
            {
              "key": "Exhibit Title",
              "value": "EXHIBIT A"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 195,
          "title": "Initial Improvement of the Premises",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "279330373 v2"
            },
            {
              "key": "Document Type",
              "value": "EXHIBIT B"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 197,
          "title": "EXHIBIT D FORM OF LETTER OF CREDIT",
          "data": [
            {
              "key": "document_number",
              "value": "279330373 v2"
            },
            {
              "key": "exhibit",
              "value": "D"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 198,
          "title": "EXHIBIT E Appraisal Procedure",
          "data": [
            {
              "key": "document_id",
              "value": "279330373"
            },
            {
              "key": "version",
              "value": "v2"
            },
            {
              "key": "exhibit",
              "value": "E"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 201,
          "title": "Exhibit 10.14A",
          "data": [
            {
              "key": "Tenant's Request for CASp Inspection",
              "value": "Requested within ten (10) days after the date this Amendment is executed."
            },
            {
              "key": "CASp's Liability",
              "value": "Shall not be limited by the contract for failure to perform inspections according to standard."
            },
            {
              "key": "Tenant's Responsibilities",
              "value": "Conduct inspection at Tenant's cost, by CASp approved by Landlord, after hours."
            },
            {
              "key": "Confidentiality of Inspection Results",
              "value": "Tenant may only disclose results to certain parties with a need to know."
            },
            {
              "key": "Waiver of Rights",
              "value": "Tenant waives rights under Section 1938 of California Civil Code."
            },
            {
              "key": "Broker Representation",
              "value": "Colliers International represents Tenant, Newmark represents Landlord."
            },
            {
              "key": "No Offer Statement",
              "value": "Submission for examination does not constitute an offer to amend the Lease."
            },
            {
              "key": "Lease Status",
              "value": "Lease remains unmodified and in full force."
            },
            {
              "key": "Counterparts Clause",
              "value": "Multiple copies may be executed and exchanged; discrepancies favor Landlord's copy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 203,
          "title": "Amended and Restated Exclusive License Agreement",
          "data": [
            {
              "key": "Parties",
              "value": "THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY and Purigen Biosystems"
            },
            {
              "key": "Effective Date",
              "value": "July 16, 2021"
            },
            {
              "key": "Background",
              "value": "Stanford has assignments of inventions which improve sample preparation and analysis of biological and chemical samples."
            },
            {
              "key": "Original Agreement Date",
              "value": "October 4, 2013"
            },
            {
              "key": "Amendment #1 Date",
              "value": "April 7, 2014"
            },
            {
              "key": "Amendment #2 Date",
              "value": "January 9, 2017"
            },
            {
              "key": "Amendment #3 Date",
              "value": "May 1, 2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 206,
          "title": "Amended and Restated Exclusive License Agreement with Equity",
          "data": [
            {
              "key": "Grant Date",
              "value": "8/3/2021"
            },
            {
              "key": "Parties Involved",
              "value": "Stanford, Purigen, Stanford Health Care, Lucile Packard Children's Hospital"
            },
            {
              "key": "License Agreement Type",
              "value": "Exclusive License"
            },
            {
              "key": "Licensed Patents",
              "value": "Stanford's Licensed Patents"
            },
            {
              "key": "Sublicense Definition",
              "value": "Any agreement between Purigen or its Affiliates and a third party that contains a grant to Stanford's Licensed Patents."
            },
            {
              "key": "Research Tools Definition",
              "value": "Any product sold, where the result is not reported to a patient, caregiver or veterinarian for use in a therapeutic decision."
            },
            {
              "key": "Terms of Grant",
              "value": "License to make, have made, use, import, offer to sell and sell Licensed Products."
            },
            {
              "key": "Retained Rights",
              "value": "Right to practice the Licensed Patent for any non-profit purpose."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 207,
          "title": "CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "Agreement Date",
              "value": "8/3/2021"
            },
            {
              "key": "Specific Exclusions",
              "value": "Stanford does not grant to Purigen any other licenses, implied or otherwise, to any patents or other rights of Stanford..."
            },
            {
              "key": "Sublicensing Permitted",
              "value": "Purigen or its Affiliates may grant Sublicenses in the Licensed Field of Use only if Purigen or its Affiliates are developing or selling Licensed Products."
            },
            {
              "key": "Sublicense Requirements",
              "value": "Any Sublicense is subject to this Agreement and will include various prohibitions and obligations related to sublicensing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 212,
          "title": "CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "Effective Date",
              "value": "8/3/2021"
            },
            {
              "key": "Audit by Stanford",
              "value": "Purigen will allow Stanford or its designee to examine Purigen’s records to verify payments made by Purigen under this Agreement."
            },
            {
              "key": "Paying for Audit",
              "value": "Stanford will pay for any audit done under Section 8.5. If underreporting of earned royalties due to Stanford is 10% or more, Purigen will pay the audit costs."
            },
            {
              "key": "Self-audit Frequency",
              "value": "at least every [***] if annual sales of Licensed Product are over $[***]."
            },
            {
              "key": "Warranties by Stanford",
              "value": "Stanford represents that it has the lawful right to grant the rights and licenses granted herein, and it is the owner of the entire right, title, and interest in the Licensed Patents."
            },
            {
              "key": "Negation of Warranties",
              "value": "Stanford provides rights granted in this Agreement AS IS and WITH ALL FAULTS, with no warranties of merchantability or fitness for a particular purpose."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 213,
          "title": "Indemnification and Export Compliance",
          "data": [
            {
              "key": "Indemnification Clause",
              "value": "Purigen will indemnify, hold harmless, and defend all Stanford Indemnitees against any claim of any kind arising out of or related to the exercise of any rights granted Purigen under this Agreement."
            },
            {
              "key": "No Indirect Liability",
              "value": "Purigen is not liable for any special, consequential, lost profit, expectation, punitive or other indirect damages related to this Agreement."
            },
            {
              "key": "Workers’ Compensation",
              "value": "Purigen will comply with all statutory workers' compensation and employers' liability requirements."
            },
            {
              "key": "Insurance Requirements",
              "value": "Purigen will maintain Comprehensive General Liability Insurance, including Product Liability Insurance, with minimum limits of liability and include all Stanford Indemnitees as additional insureds."
            },
            {
              "key": "Export Compliance",
              "value": "Purigen and its Affiliates must comply with all United States laws and regulations controlling the export of licensed commodities and technical data, assuring compliance and indemnification for violations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 217,
          "title": "Change of Control and Assignment in License Agreement",
          "data": [
            {
              "key": "Change of Control Fee",
              "value": "$[***]"
            },
            {
              "key": "Assignment Fee",
              "value": "$[***]"
            },
            {
              "key": "Conditions of Assignment",
              "value": "Purigen must give Stanford [***] days prior written notice of the assignment, including the new assignee's contact information."
            },
            {
              "key": "Bankruptcy Conditions",
              "value": "Assignment is permitted only to a party that can provide adequate assurance of future performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 224,
          "title": "CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "Date",
              "value": "8/3/2021"
            },
            {
              "key": "Region",
              "value": "Developing Nations"
            },
            {
              "key": "Appendix",
              "value": "C"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 227,
          "title": "S05-338: CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY 8/3/2021",
          "data": [
            {
              "key": "Investor Rights Provision",
              "value": "Stanford's purchase right shall be on the same terms as the other investors, with certain conditions."
            },
            {
              "key": "Notification Period",
              "value": "Stanford must exercise purchase right within specified business days after receiving notice."
            },
            {
              "key": "Conflict Resolution",
              "value": "This Agreement prevails over any conflicting Purigen investor rights."
            },
            {
              "key": "Termination of Rights",
              "value": "Rights under Sections 7.4 and 7.5 terminate upon closing of a public offering."
            },
            {
              "key": "Financial Statements Provision",
              "value": "Purigen must furnish Stanford with annual financial statements and operating plans."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 229,
          "title": "CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "Agreement Date",
              "value": "8/3/2021"
            },
            {
              "key": "Appendix",
              "value": "F – Patent List"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 234,
          "title": "Milestones for CDT Amendment",
          "data": [
            {
              "key": "Date",
              "value": "11/12/2022"
            },
            {
              "key": "Appendix",
              "value": "A"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 235,
          "title": "Subsidiaries of Bionano Genomics, Inc.",
          "data": [
            {
              "key": "Bionano Genomics UK, Ltd.",
              "value": "A private limited company organized under the laws of the United Kingdom"
            },
            {
              "key": "Bionano Genomics (Shanghai) Trading Co., Ltd.",
              "value": "A private limited company organized under the laws of China"
            },
            {
              "key": "BioDiscovery, Inc.",
              "value": "A California limited liability company"
            },
            {
              "key": "Lineagen, Inc.",
              "value": "A Delaware corporation doing business as Bionano Laboratories"
            },
            {
              "key": "Purigen Biosystems, Inc.",
              "value": "A Delaware corporation"
            },
            {
              "key": "PURIGEN BIOSYSTEMS UK LTD",
              "value": "A private limited company organized under the laws of the United Kingdom"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 1,
          "title": "Form 10-K Filing Information",
          "data": [
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Company Name",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Address",
              "value": "9540 Towne Centre Drive, Suite 100, San Diego, CA 92121"
            },
            {
              "key": "Phone Number",
              "value": "(858) 888-7600"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 1,
          "title": "Securities Listing Information",
          "data": [
            {
              "key": "Common Stock Symbol",
              "value": "BNGO"
            },
            {
              "key": "Warrant Symbol",
              "value": "BNGOW"
            },
            {
              "key": "Stock Exchange",
              "value": "The Nasdaq Stock Market, LLC"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 1,
          "title": "Company Filing Status",
          "data": [
            {
              "key": "Large Accelerated Filer",
              "value": "No"
            },
            {
              "key": "Accelerated Filer",
              "value": "Yes"
            },
            {
              "key": "Non-Accelerated Filer",
              "value": "Yes"
            },
            {
              "key": "Emerging Growth Company",
              "value": "Yes"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 22,
          "title": "Coverage and Reimbursement",
          "data": [
            {
              "key": "Overview",
              "value": "OGM products are for research use only, but clinical laboratories may acquire instrumentation through capital purchase or lease."
            },
            {
              "key": "FDA Approval",
              "value": "Customers may seek FDA approval for their products related to testing services."
            },
            {
              "key": "Reimbursement",
              "value": "Reimbursement is determined by third-party payors, including government programs and private health plans."
            },
            {
              "key": "Market Variability",
              "value": "In the U.S., coverage and reimbursement vary significantly from one payor to another."
            },
            {
              "key": "CLIA Certification",
              "value": "CLIA mandates compliance with quality standards for clinical laboratories."
            },
            {
              "key": "Facility Locations",
              "value": "Facilities are located in Salt Lake City, Utah and San Diego, California."
            },
            {
              "key": "CAP Accreditation",
              "value": "Pending CAP accreditation for San Diego facility."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 119,
          "title": "Form 10-K Summary and Signatures",
          "data": [
            {
              "key": "Registrant",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "By",
              "value": "R. Erik Holmlin, Ph.D."
            },
            {
              "key": "Title",
              "value": "President and Chief Executive Officer"
            },
            {
              "key": "Power of Attorney",
              "value": "Appointment of R. Erik Holmlin, Ph.D. and Christopher Stewart as attorneys-in-fact for signing Annual Report."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 120,
          "title": "Corporate Officers and Directors Signatures",
          "data": [
            {
              "key": "Name",
              "value": "R. Erik Holmlin, Ph.D."
            },
            {
              "key": "Position",
              "value": "Chief Executive Officer and Director, Principal Executive Officer"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Christopher Stewart"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer, Principal Financial and Accounting Officer"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "David L. Barker, Ph.D."
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Albert A. Luderer, Ph.D."
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Yvonne Linney, Ph.D."
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Hannah Mamuszka"
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Aleksandar Rajkovic, M.D., Ph.D."
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Christopher Twomey"
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Kristiina Vuori, M.D., Ph.D."
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Name",
              "value": "Vincent Wong, J.D., M.B.A."
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 9, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 123,
          "title": "Provisions Related to Board Governance and Control",
          "data": [
            {
              "key": "Voting Rights",
              "value": "Do not provide stockholders with cumulative voting rights."
            },
            {
              "key": "Stockholder Actions",
              "value": "Stockholder actions to be taken at a duly called meeting."
            },
            {
              "key": "Special Meeting Calls",
              "value": "Can only be called by a majority of the board, chair, or CEO."
            },
            {
              "key": "Advance Notice Procedure",
              "value": "Establish an advance notice procedure for stockholder proposals."
            },
            {
              "key": "Board Composition",
              "value": "Divide the board into three classes with staggered three-year terms."
            },
            {
              "key": "Change of Directors",
              "value": "Authorized number of directors can only be changed by a majority resolution."
            },
            {
              "key": "Removal of Directors",
              "value": "Directors can only be removed with cause and 66 2/3% vote."
            },
            {
              "key": "Filling Vacancies",
              "value": "Vacancies to be filled by a majority vote of directors in office."
            },
            {
              "key": "Preferred Stock Authorization",
              "value": "Authorization of undesignated preferred stock to impede control changes."
            },
            {
              "key": "Forum for Legal Actions",
              "value": "Exclusive forum for derivative actions in Delaware Court of Chancery."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 163,
          "title": "Document Signature Block",
          "data": [
            {
              "key": "Entity 1",
              "value": "PURIGEN BIOSYSTEMS, INC."
            },
            {
              "key": "Entity 2",
              "value": "SEF BBC, LLC"
            },
            {
              "key": "Entity 1 Type",
              "value": "Delaware corporation"
            },
            {
              "key": "Entity 2 Type",
              "value": "a California limited liability company"
            },
            {
              "key": "Entity 1 Signature",
              "value": "/s/ Klint Rose"
            },
            {
              "key": "Entity 2 Signature",
              "value": "/s/ Erik A. Foraker"
            },
            {
              "key": "Entity 1 Name",
              "value": "Klint Rose"
            },
            {
              "key": "Entity 1 Position",
              "value": ""
            },
            {
              "key": "Entity 1 Title",
              "value": "CEO"
            },
            {
              "key": "Entity 2 Details",
              "value": "By: SSF II REIT, LLC, a Delaware limited liability company, its Manager"
            },
            {
              "key": "Entity 2 Name",
              "value": "Erik A. Foraker"
            },
            {
              "key": "Entity 2 Title",
              "value": "Co-Admin. Member"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 166,
          "title": "Lease Agreement",
          "data": [
            {
              "key": "Lease Commencement Date",
              "value": "SPECIFIED IN THE BASIC LEASE INFORMATION"
            },
            {
              "key": "Landlord",
              "value": "Landlord specified in the Basic Lease Information"
            },
            {
              "key": "Tenant",
              "value": "Tenant specified in the Basic Lease Information"
            },
            {
              "key": "Property Location",
              "value": "5700 and 5720 Stoneridge Drive, Pleasanton, California"
            },
            {
              "key": "Project Name",
              "value": "Britannia Business Center II"
            },
            {
              "key": "Common Areas Usage",
              "value": "Tenant's nonexclusive right to use common areas with other tenants"
            },
            {
              "key": "Inspection Acknowledgment",
              "value": "Tenant acknowledges inspecting the Premises"
            },
            {
              "key": "Condition of Premises",
              "value": "Accepted as is"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 187,
          "title": "Signage and Waiver Provisions in Lease Agreement",
          "data": [
            {
              "key": "Tangible Net Worth",
              "value": "Total Assets of Tenant less liabilities, computed in accordance with GAAP."
            },
            {
              "key": "Tenant's Building Signage",
              "value": "Entitlement of Tenant at sole cost and subject to Landlord's approval."
            },
            {
              "key": "Signage Obligations",
              "value": "Tenant must remove signage at their expense upon termination of rights."
            },
            {
              "key": "Tenant's Rights to Signage",
              "value": "Terminate upon expiration or earlier termination of Lease."
            },
            {
              "key": "Landlord Responsibilities",
              "value": "Landlord to cooperate for obtaining governmental permits without cost."
            },
            {
              "key": "Costs of Removal",
              "value": "Costs borne by Tenant if signage is removed by Landlord after notice."
            },
            {
              "key": "Project Standard Sign",
              "value": "Tenant entitled to identify business on the monument sign installed by Landlord."
            },
            {
              "key": "Waiver Provisions",
              "value": "Acceptance of rent does not waive preceding breaches."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 191,
          "title": "Lease Terms and Conditions",
          "data": [
            {
              "key": "Base Rent during renewal period",
              "value": "Less than the aggregate of the amounts of Base Rent for the calendar month immediately preceding the commencement of the renewal period."
            },
            {
              "key": "Tenant's Right of First Offer",
              "value": "One-time right regarding contiguous space located adjacent to the Premises that becomes available."
            },
            {
              "key": "Exercise of Right",
              "value": "Tenant must deliver written notice of exercise to Landlord within five business days after the date of the Advice."
            },
            {
              "key": "Conditions for Right of First Offer",
              "value": "Tenant must not be in default and certain conditions about subletting and assignment must be met."
            },
            {
              "key": "Fair Market Rent Definition",
              "value": "Rental rate for comparable space to new tenants considering various building qualities and conditions."
            },
            {
              "key": "Possession of Offering Space",
              "value": "Commencement of term is postponed until Landlord delivers possession free from occupancy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 193,
          "title": "Indemnification and Rights of Landlord and Tenant",
          "data": [
            {
              "key": "Tenant",
              "value": "Purigen Biosystems, Inc."
            },
            {
              "key": "Landlord",
              "value": "SFF BBC, LLC, a Delaware corporation"
            },
            {
              "key": "Manager",
              "value": "SFF II REIT, LLC, a Delaware limited liability company"
            },
            {
              "key": "CEO",
              "value": "Klint Rose"
            },
            {
              "key": "Co-Admin. Member",
              "value": "Erik A. Foraker"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 202,
          "title": "Document Signature Block",
          "data": [
            {
              "key": "left_party",
              "value": "BBC, LLC, alifornia limited liability company"
            },
            {
              "key": "right_party",
              "value": "PURIGEN BIOSYSTEMS, INC., a Delaware corporation"
            },
            {
              "key": "entity",
              "value": "SFF II REIT, LLC"
            },
            {
              "key": "description",
              "value": "a Delaware limited liability company, its Manager"
            },
            {
              "key": "left_signatory",
              "value": "/s/ Erik Foraker"
            },
            {
              "key": "right_signatory",
              "value": "/s/ Barney Saunders"
            },
            {
              "key": "right_signatory_title",
              "value": "CEO"
            },
            {
              "key": "sign_date",
              "value": "08/30/2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 218,
          "title": "Legal Action and Notices Section of License Agreement",
          "data": [
            {
              "key": "Document Title",
              "value": "Amended and Restated Exclusive License Agreement"
            },
            {
              "key": "Parties Involved",
              "value": "Purigen, Stanford University"
            },
            {
              "key": "Arbitration Location",
              "value": "[***]"
            },
            {
              "key": "Court Location for Patent Validity Dispute",
              "value": "[***]"
            },
            {
              "key": "Written Notice Requirement",
              "value": "At least [***] prior to action"
            },
            {
              "key": "General Notices Email",
              "value": "Technical contact for Purigen, Office of Technology Licensing at Stanford University"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 219,
          "title": "CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "Name",
              "value": "Scott Elrod"
            },
            {
              "key": "Title",
              "value": "Associate Director"
            },
            {
              "key": "Date",
              "value": "August 3, 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 220,
          "title": "Executive Information: Barney Saunders",
          "data": [
            {
              "key": "Name",
              "value": "Barney Saunders"
            },
            {
              "key": "Title",
              "value": "CEO"
            },
            {
              "key": "Date",
              "value": "August 3, 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 223,
          "title": "CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "Agreement Date",
              "value": "8/3/2021"
            },
            {
              "key": "Type",
              "value": "Earned Royalty Report"
            },
            {
              "key": "Page",
              "value": "21 of #NUM_PAGES#"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 233,
          "title": "Leadership Change Notice",
          "data": [
            {
              "key": "Company",
              "value": "PURIGEN BIOSYSTEMS, INC."
            },
            {
              "key": "Date",
              "value": "11/12/2022"
            },
            {
              "key": "Signature",
              "value": "Klint Rose"
            },
            {
              "key": "Document Type",
              "value": "CDT Amendment"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 239,
          "title": "Certification by CEO",
          "data": [
            {
              "key": "Title",
              "value": "Certification by R. Erik Holmlin, CEO"
            },
            {
              "key": "Company",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Position",
              "value": "Chief Executive Officer"
            },
            {
              "key": "Certification Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Annual Report Date",
              "value": "Filed on the date hereof"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Compliance Statement",
              "value": "The Annual Report complies with the Exchange Act."
            },
            {
              "key": "Financial Condition Statement",
              "value": "The information in the Annual Report fairly presents the financial condition and results of operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 240,
          "title": "Certification of Chief Financial Officer",
          "data": [
            {
              "key": "CFO Name",
              "value": "Christopher Stewart"
            },
            {
              "key": "Company Name",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Certification Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Compliance Statement",
              "value": "The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act."
            },
            {
              "key": "Financial Condition Statement",
              "value": "The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company."
            },
            {
              "key": "Exhibit Number",
              "value": "32.2"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 179,
          "title": "Landlord's Consent for Assignment or Subletting",
          "data": [
            {
              "key": "New Requirements",
              "value": "Tenant must pay Landlord's estimate of Processing Costs for assigning or subletting."
            },
            {
              "key": "Tenant's Obligations",
              "value": "Tenant remains liable under the Lease regardless of any assignment or subletting."
            },
            {
              "key": "Excess Rent Sharing",
              "value": "Excess rent from assignment or sublease is split 50% to Tenant and 50% to Landlord."
            },
            {
              "key": "Subordination of Subleases",
              "value": "Any sublease is subordinate to the Lease provisions."
            },
            {
              "key": "Affiliate Assignment Conditions",
              "value": "Tenant can assign or sublet to Affiliates under certain conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 180,
          "title": "Lease Agreement - Default and Permitted Transfers",
          "data": [
            {
              "key": "Permitted Transfers",
              "value": "A sale or transfer of the memberships, interests, shares, or stock of Tenant shall be deemed a Permitted Transfer if it occurs in connection with a bona fide financing or capitalization for the benefit of Tenant without changing the CEO or President."
            },
            {
              "key": "Event of Default",
              "value": "Occurrence of any one or more events shall constitute a breach of this Lease."
            },
            {
              "key": "Requirements for Event of Default",
              "value": "Includes failing to pay rent, failing to observe agreements, and financial insolvency."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 16,
          "title": "Sales and Marketing Strategy Overview",
          "data": [
            {
              "key": "Current Sales Team Size",
              "value": "168"
            },
            {
              "key": "Regions of Sales Support Staff",
              "value": "North America, Europe, China"
            },
            {
              "key": "Sales Strategy",
              "value": "Direct sales force, combination of sales managers and representatives"
            },
            {
              "key": "Market Opportunities",
              "value": "Significant market opportunities in North America, Europe, China, India"
            },
            {
              "key": "Sales Cycle Duration",
              "value": "9 to 12 months"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 43,
          "title": "Executive Compensation Challenges",
          "data": [
            {
              "key": "Key Personnel Recruitment",
              "value": "The need to recruit, train, retain, and motivate key personnel is critical due to intense competition for qualified individuals."
            },
            {
              "key": "Impact of Great Resignation",
              "value": "Employee turnover has been exacerbated by the ongoing ‘great resignation,’ impacting our ability to retain highly-trained personnel."
            },
            {
              "key": "Effects on Operational Costs",
              "value": "Adjustments in employee cash and equity compensation may affect operating costs and margins."
            },
            {
              "key": "Need for Technical Support Staff",
              "value": "There's a competitive need for hiring highly trained technical support personnel."
            },
            {
              "key": "Cybersecurity Risks",
              "value": "Potential compromises of information technology systems can lead to significant business and reputational harm."
            },
            {
              "key": "Dependence on Third-Party Services",
              "value": "Reliance on third-party service providers for processing sensitive data introduces various cybersecurity threats."
            },
            {
              "key": "Impacts of Military Conflicts",
              "value": "Ongoing military conflicts may lead to heightened vulnerability to cyber-attacks affecting operations."
            },
            {
              "key": "Diverse Cyber Threat Landscape",
              "value": "Cyber threats include malware, ransomware, social-engineering, and traditional hacking, as well as threats from state and non-state actors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 79,
          "title": "Financial Statement Components",
          "data": [
            {
              "key": "Reports of Independent Registered Public Accounting Firm",
              "value": "BDO USA, LLP; San Diego, California."
            },
            {
              "key": "Consolidated Balance Sheets",
              "value": ""
            },
            {
              "key": "Consolidated Statements of Operations",
              "value": ""
            },
            {
              "key": "Consolidated Statements of Comprehensive Loss",
              "value": ""
            },
            {
              "key": "Consolidated Statements of Stockholders' Equity",
              "value": ""
            },
            {
              "key": "Consolidated Statements of Cash Flows",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 98,
          "title": "Contingent Consideration Liability (Level 3 Measurement)",
          "data": [
            {
              "key": "Balance as of December 31, 2021",
              "value": "9066000"
            },
            {
              "key": "Liability recorded as a result of current period acquisition",
              "value": "12970000"
            },
            {
              "key": "Change in estimated fair value, recorded in selling, general and administrative expenses",
              "value": "316000"
            },
            {
              "key": "Cash payments",
              "value": "null"
            },
            {
              "key": "Balance as of December 31, 2022",
              "value": "22352000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 98,
          "title": "Consideration Liability Movement",
          "data": [
            {
              "key": "Balance as of December 31, 2020",
              "value": ""
            },
            {
              "key": "Liability recorded as a result of current period acquisition",
              "value": "9000000"
            },
            {
              "key": "Change in estimated fair value, recorded in selling, general and administrative expenses",
              "value": "66000"
            },
            {
              "key": "Cash payments",
              "value": ""
            },
            {
              "key": "Balance as of December 31, 2021",
              "value": "9066000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 98,
          "title": "Maturity Analysis of Financial Instruments",
          "data": [
            {
              "key": "Maturity Less than 1 year - Amortized Cost 1",
              "value": "20093000"
            },
            {
              "key": "Maturity Less than 1 year - Unrealized Gain/Loss 1",
              "value": "-73000"
            },
            {
              "key": "Maturity Less than 1 year - Amortized Cost 2",
              "value": "72823000"
            },
            {
              "key": "Maturity Less than 1 year - Unrealized Gain/Loss 2",
              "value": "-910000"
            },
            {
              "key": "Maturity Less than 1 year - Amortized Cost 3",
              "value": "1998000"
            },
            {
              "key": "Maturity Less than 1 year - Unrealized Gain/Loss 3",
              "value": "-16000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 104,
          "title": "Stock Options Activity Summary 2022",
          "data": [
            {
              "key": "Outstanding at January 1, 2022",
              "value": "12,765,000 shares"
            },
            {
              "key": "Granted",
              "value": "16,148,000 shares"
            },
            {
              "key": "Exercised",
              "value": "-467,000 shares"
            },
            {
              "key": "Canceled",
              "value": "-4,424,000 shares"
            },
            {
              "key": "Outstanding at December 31, 2022",
              "value": "24,022,000 shares"
            },
            {
              "key": "Vested and exercisable at December 31, 2022",
              "value": "7,791,000 shares"
            },
            {
              "key": "Weighted average exercise price at January 1, 2022",
              "value": "$4.97"
            },
            {
              "key": "Weighted average exercise price at December 31, 2022",
              "value": "$3.28"
            },
            {
              "key": "Aggregate intrinsic value at January 1, 2022",
              "value": "$7,891,000"
            },
            {
              "key": "Aggregate intrinsic value at December 31, 2022",
              "value": "$2,068,000"
            },
            {
              "key": "Weighted-average grant date fair value for 2022",
              "value": "$1.35"
            },
            {
              "key": "Weighted-average grant date fair value for 2021",
              "value": "$4.35"
            },
            {
              "key": "Total intrinsic value exercised in 2022",
              "value": "$0.6 million"
            },
            {
              "key": "Total intrinsic value exercised in 2021",
              "value": "$2.5 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 105,
          "title": "Stock Units Movement and Fair Value Analysis 2022",
          "data": [
            {
              "key": "Outstanding at January 1, 2022",
              "value": "361000"
            },
            {
              "key": "Granted",
              "value": "null"
            },
            {
              "key": "Released",
              "value": "-265000"
            },
            {
              "key": "Forfeited",
              "value": "null"
            },
            {
              "key": "Outstanding at December 31, 2022",
              "value": "96000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 105,
          "title": "Per Share Outstanding Values 2022",
          "data": [
            {
              "key": "Outstanding at January 1, 2022",
              "value": "4.74"
            },
            {
              "key": "Granted",
              "value": "—"
            },
            {
              "key": "Released",
              "value": ""
            },
            {
              "key": "Forfeited",
              "value": ""
            },
            {
              "key": "Outstanding at December 31, 2022",
              "value": "4.74"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Stock-Based Compensation Expense Breakdown",
          "data": [
            {
              "key": "Research and development (2022)",
              "value": "$13.4M"
            },
            {
              "key": "Research and development (2021)",
              "value": "$3.53M"
            },
            {
              "key": "General and administrative (2022)",
              "value": "$9.02M"
            },
            {
              "key": "General and administrative (2021)",
              "value": "$6.19M"
            },
            {
              "key": "Total stock-based compensation expense (2022)",
              "value": "$22.42M"
            },
            {
              "key": "Total stock-based compensation expense (2021)",
              "value": "$9.72M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Black-Scholes-Merton Option Pricing Model Assumptions",
          "data": [
            {
              "key": "Risk-free interest rate (2022)",
              "value": "2.4%"
            },
            {
              "key": "Risk-free interest rate (2021)",
              "value": "1.1%"
            },
            {
              "key": "Expected volatility (2022)",
              "value": "68.0%"
            },
            {
              "key": "Expected volatility (2021)",
              "value": "76.2%"
            },
            {
              "key": "Expected term (in years) (2022)",
              "value": "5.8"
            },
            {
              "key": "Expected term (in years) (2021)",
              "value": "6.0"
            },
            {
              "key": "Expected dividend yield (2022)",
              "value": "0.0%"
            },
            {
              "key": "Expected dividend yield (2021)",
              "value": "0.0%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Unrecognized Stock-Based Compensation Expense",
          "data": [
            {
              "key": "Unrecognized compensation expense (2022)",
              "value": "$31.8M"
            },
            {
              "key": "Expected recognition period (in years)",
              "value": "2.7"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Employee Stock Purchase Plan Details",
          "data": [
            {
              "key": "Initial number of shares reserved for ESPP",
              "value": "0.2 million"
            },
            {
              "key": "Shares authorized for future grants under ESPP (as of December 31, 2022)",
              "value": "0.1 million"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Executive Option Grants and RSUs",
          "data": [
            {
              "key": "Stock options granted (February 15, 2023)",
              "value": "3.3 million shares"
            },
            {
              "key": "Exercise price per share",
              "value": "$1.63"
            },
            {
              "key": "RSUs granted (February 15, 2023)",
              "value": "0.7 million shares"
            },
            {
              "key": "Grant date fair value per share",
              "value": "$1.63"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 110,
          "title": "Income Tax Reconciliation",
          "data": [
            {
              "key": "Income taxes at statutory rate",
              "value": "-27,447,000"
            },
            {
              "key": "State income taxes, net of federal benefits",
              "value": "-1,321,000"
            },
            {
              "key": "Change in valuation allowance",
              "value": "27,342,000"
            },
            {
              "key": "Stock-based compensation",
              "value": "1,345,000"
            },
            {
              "key": "Section 162(m)",
              "value": "2,447,000"
            },
            {
              "key": "Other permanent differences",
              "value": "434,000"
            },
            {
              "key": "Research credits",
              "value": "-1,733,000"
            },
            {
              "key": "Other",
              "value": "817,000"
            },
            {
              "key": "Income tax expense (benefit)",
              "value": "1,884,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 110,
          "title": "Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Net operating loss carryforwards",
              "value": "109,612,000"
            },
            {
              "key": "Research and development credits",
              "value": "9,816,000"
            },
            {
              "key": "Stock-based compensation",
              "value": "1,639,000"
            },
            {
              "key": "ASC 842 - lease liability",
              "value": "2,599,000"
            },
            {
              "key": "UNICAP",
              "value": "1,049,000"
            },
            {
              "key": "Other",
              "value": "1,944,000"
            },
            {
              "key": "Total gross",
              "value": "126,659,000"
            },
            {
              "key": "Amortization",
              "value": "-2,202,000"
            },
            {
              "key": "ASC 842 - ROU asset",
              "value": "-2,441,000"
            },
            {
              "key": "Valuation allowance",
              "value": "-122,016,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 116,
          "title": "Executive Compensation",
          "data": [
            {
              "key": "Executive Officers",
              "value": "The information required by this item will be set forth under the caption 'Executive and Director Compensation' in the Proxy Statement."
            },
            {
              "key": "Incorporation Reference",
              "value": "This information is incorporated in this Annual Report by reference."
            },
            {
              "key": "Code of Business Conduct",
              "value": "We have adopted a code of business conduct and ethics (Ethics Code) that applies to all employees, officers, and directors."
            },
            {
              "key": "Website Availability",
              "value": "The full text of the Ethics Code is available on our website."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 124,
          "title": "Standard Form Bionano Genomics, Inc. Stock Option Grant Notice",
          "data": [
            {
              "key": "Optionholder",
              "value": "[Name of the optionholder]"
            },
            {
              "key": "Date of Grant",
              "value": "[Date]"
            },
            {
              "key": "Vesting Commencement Date",
              "value": "[Date]"
            },
            {
              "key": "Number of Shares Subject to Option",
              "value": "[Number]"
            },
            {
              "key": "Exercise Price (Per Share)",
              "value": "[Price]"
            },
            {
              "key": "Total Exercise Price",
              "value": "[Total Price]"
            },
            {
              "key": "Expiration Date",
              "value": "[Date]"
            },
            {
              "key": "Type of Grant",
              "value": "Incentive Stock Option/Nonstatutory Stock Option"
            },
            {
              "key": "Exercise Schedule",
              "value": "Same as Vesting Schedule"
            },
            {
              "key": "Vesting Schedule",
              "value": "[Vesting details]"
            },
            {
              "key": "Payment Options",
              "value": "By cash, check, bank draft or money order; Pursuant to Regulation T Program; By delivery of already-owned shares; By a net exercise arrangement if applicable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 125,
          "title": "Stock Option Grant Notice Overview",
          "data": [
            {
              "key": "Acknowledgement",
              "value": "Optionholder acknowledges receipt of and understands the documents."
            },
            {
              "key": "Modification Clause",
              "value": "This Stock Option Grant Notice and the Option Agreement may not be modified except as provided."
            },
            {
              "key": "Entire Agreement Clause",
              "value": "This agreement supersedes all prior agreements on the subject with some exceptions."
            },
            {
              "key": "Consent to Electronic Delivery",
              "value": "Optionholder consents to receive documents electronically."
            },
            {
              "key": "Company Name",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Attachments",
              "value": "Option Agreement, 2018 Equity Incentive Plan and Notice of Exercise"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 126,
          "title": "Bionano Genomics, Inc. Option Agreement (2018 Equity Incentive Plan)",
          "data": [
            {
              "key": "Type of Option",
              "value": "Incentive Stock Option or Nonstatutory Stock Option"
            },
            {
              "key": "Vesting Conditions",
              "value": "Subject to provisions in Grant Notice; ceases upon termination of Continuous Service"
            },
            {
              "key": "Exercise Restrictions",
              "value": "Non-Exempt Employees may not exercise until completing six months of Continuous Service"
            },
            {
              "key": "Payment Methods",
              "value": "Cash, check, bank draft, broker-assisted exercise, or delivery of already-owned shares"
            },
            {
              "key": "Common Stock Adjustments",
              "value": "Number of shares and exercise price will be adjusted for Capitalization Adjustments"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 127,
          "title": "Option Exercise and Securities Law Compliance",
          "data": [
            {
              "key": "Option Type",
              "value": "Nonstatutory Stock Option"
            },
            {
              "key": "Exercise Payment Method",
              "value": "Net exercise arrangement"
            },
            {
              "key": "Compliance Requirement",
              "value": "Shares must be registered under the Securities Act or exempt from registration"
            },
            {
              "key": "Termination Conditions",
              "value": "Option expires upon termination of Continuous Service for Cause, or within specified timeframes after other terminations"
            },
            {
              "key": "Vesting Condition",
              "value": "May not expire until certain conditions met for Non-Exempt Employees"
            },
            {
              "key": "Survivor Rights",
              "value": "Option valid for 18 months after death if certain conditions are met"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 128,
          "title": "Stock Option Exercise Guidelines",
          "data": [
            {
              "key": "Expiration Date",
              "value": "indicated in your Grant Notice"
            },
            {
              "key": "Incentive Stock Options Requirements",
              "value": "Must be an employee of the Company or an Affiliate at all times between Date of Grant and three months before exercise."
            },
            {
              "key": "Extended Exercisability",
              "value": "Provided for certain circumstances but no guarantee for Incentive Stock Option treatment."
            },
            {
              "key": "Exercise Conditions",
              "value": "Must deliver Notice of Exercise and pay exercise price and taxes."
            },
            {
              "key": "Tax Withholding Obligation",
              "value": "Company may require payment arrangements for tax withholding resulting from exercises."
            },
            {
              "key": "Notification of Disposition",
              "value": "Must notify the Company within 15 days after shares are disposed within specified periods."
            },
            {
              "key": "Lock-Up Period",
              "value": "180 days following registration statement effective date."
            },
            {
              "key": "Transferee Agreement",
              "value": "Any transferee will be bound by the same conditions."
            },
            {
              "key": "Beneficiaries of Agreement",
              "value": "Underwriters of the Company’s stock are intended beneficiaries of this section."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 129,
          "title": "Transferability of Options and Withholding Obligations",
          "data": [
            {
              "key": "Transferability",
              "value": "Your option is not transferable except by will or by the laws of descent and distribution."
            },
            {
              "key": "Certain Trusts",
              "value": "You may transfer your option to a trust with written permission from the Board."
            },
            {
              "key": "Domestic Relations Orders",
              "value": "You may transfer your option pursuant to a domestic relations order with written permission from the Board."
            },
            {
              "key": "Beneficiary Designation",
              "value": "You can designate a third party to exercise your option upon your death with written notice to the Company."
            },
            {
              "key": "Option Not a Service Contract",
              "value": "Your option is not an employment or service contract."
            },
            {
              "key": "Withholding Obligations",
              "value": "Authorization of withholding to cover tax obligations related to the exercise of the option."
            },
            {
              "key": "Nonstatutory Stock Option Tax Withholding",
              "value": "The Company may withhold shares of Common Stock for tax upon your request."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 130,
          "title": "Tax Consequences and Employee Option Provisions",
          "data": [
            {
              "key": "Tax Withholding Obligations",
              "value": "You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied."
            },
            {
              "key": "Duty to Minimize Tax Liabilities",
              "value": "The Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities."
            },
            {
              "key": "Notice for Option or Plan",
              "value": "Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt."
            },
            {
              "key": "Governing Plan Document",
              "value": "Your option is subject to all provisions of the Plan, which are made a part of your option."
            },
            {
              "key": "Clawback Policies",
              "value": "Your option is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act."
            },
            {
              "key": "Other Employee Benefit Plans",
              "value": "The value of this option will not be included as compensation when calculating your benefits under any employee benefit plan."
            },
            {
              "key": "Voting Rights",
              "value": "You will not have voting or any other rights as a stockholder until the shares are issued to you."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 131,
          "title": "Option Agreement Severability and Miscellaneous Clauses",
          "data": [
            {
              "key": "Severability Clause",
              "value": "If any part of this Option Agreement is declared unlawful or invalid, the remaining parts will remain valid."
            },
            {
              "key": "Transferability",
              "value": "The rights under the option are transferable to others."
            },
            {
              "key": "Legal Compliance",
              "value": "This Option Agreement will be subject to applicable laws and regulations."
            },
            {
              "key": "Binding Obligations",
              "value": "Obligations of the Company will bind successors in the event of purchase, merger, or consolidation."
            },
            {
              "key": "Review and Understanding",
              "value": "The individual acknowledges understanding the agreement after reviewing it in entirety."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 132,
          "title": "2018 Equity Incentive Plan",
          "data": [
            {
              "key": "Plan ID",
              "value": "173074160"
            },
            {
              "key": "Version",
              "value": "v6"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 134,
          "title": "Lock-Up Period Agreement",
          "data": [
            {
              "key": "Option Grant Period",
              "value": "Within two years after the grant or one year after shares are issued"
            },
            {
              "key": "Restriction Details",
              "value": "Will not sell, dispose of, or enter into hedging transactions for 180 days following registration statement"
            },
            {
              "key": "Regulation Reference",
              "value": "FACILITATE COMPLIANCE WITH FINRA Rule 2241"
            },
            {
              "key": "Transfer Instructions",
              "value": "Company may impose stop-transfer instructions on securities affected by these restrictions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 135,
          "title": "Non-Employee Director Stock Option Grant Notice",
          "data": [
            {
              "key": "Company",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Plan",
              "value": "2018 Equity Incentive Plan"
            },
            {
              "key": "Optionholder",
              "value": ""
            },
            {
              "key": "Date of Grant",
              "value": ""
            },
            {
              "key": "Vesting Commencement Date",
              "value": ""
            },
            {
              "key": "Number of Shares Subject to Option",
              "value": ""
            },
            {
              "key": "Exercise Price (Per Share)",
              "value": ""
            },
            {
              "key": "Total Exercise Price",
              "value": ""
            },
            {
              "key": "Expiration Date",
              "value": ""
            },
            {
              "key": "Type of Grant",
              "value": "Incentive Stock Option / Nonstatutory Stock Option"
            },
            {
              "key": "Exercise Schedule",
              "value": "Same as Vesting Schedule"
            },
            {
              "key": "Vesting Schedule",
              "value": "[______________]"
            },
            {
              "key": "Payment Options",
              "value": "By cash, check, bank draft or money order, Pursuant to a Regulation T Program, By delivery of already-owned shares, Net exercise arrangement if Nonstatutory Option"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 136,
          "title": "Stock Option Grant Notice",
          "data": [
            {
              "key": "Acknowledgement",
              "value": "Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan."
            },
            {
              "key": "Modification Clause",
              "value": "This Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan."
            },
            {
              "key": "Entire Understanding",
              "value": "This Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award."
            },
            {
              "key": "Supersede Clause",
              "value": "Supersede all prior oral and written agreements, promises and/or representations."
            },
            {
              "key": "Conditions",
              "value": "By accepting this option, Optionholder acknowledges having received and read the documents and agrees to all terms."
            },
            {
              "key": "Consent",
              "value": "Optionholder consents to receive Plan and related documents by electronic delivery."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 137,
          "title": "Option Agreement Pursuant to your Stock Option Grant Notice",
          "data": [
            {
              "key": "Company",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Plan",
              "value": "2018 Equity Incentive Plan"
            },
            {
              "key": "Vesting Conditions",
              "value": "Vesting will cease upon the termination of your Continuous Service."
            },
            {
              "key": "Change in Control",
              "value": "If a Change in Control occurs, the vesting and exercisability of the option will be accelerated in full."
            },
            {
              "key": "280G Payment",
              "value": "Any payment that constitutes a ‘parachute payment’ will be reduced to avoid Excise Tax."
            },
            {
              "key": "Reduction Method Priority",
              "value": "1. Preserve greatest economic benefit; 2. Reduce payments contingent on future events first; 3. Reduce deferred compensation before other payments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 139,
          "title": "Securities Law Compliance and Option Exercise Terms",
          "data": [
            {
              "key": "Restriction on Exercise of Option",
              "value": "You may not exercise your option if doing so would violate any laws, regulations or agreements."
            },
            {
              "key": "Nonstatutory Stock Option",
              "value": "Subject to company's consent and net exercise arrangement."
            },
            {
              "key": "Exercise Price Payment",
              "value": "Any remaining balance must be paid in cash or other permitted form."
            },
            {
              "key": "Securities Law Compliance",
              "value": "Shares must be registered under the Securities Act or exempt from registration."
            },
            {
              "key": "Expiration of Option",
              "value": "The option expires after certain conditions related to termination of Continuous Service."
            },
            {
              "key": "Incentive Stock Option Conditions",
              "value": "Employee status is required for the tax advantages, exceptions for death or disability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 140,
          "title": "Option Exercise and Transferability Guidelines",
          "data": [
            {
              "key": "Exercise Conditions",
              "value": "You may exercise the vested portion of your option by delivering a Notice of Exercise and paying the exercise price and any applicable withholding taxes."
            },
            {
              "key": "Tax Withholding Agreement",
              "value": "By exercising your option, you agree the Company may require you to enter an arrangement providing for payment of any tax withholding obligations."
            },
            {
              "key": "Incentive Stock Option Notification",
              "value": "If your option is an Incentive Stock Option, you must notify the Company of any share disposals within 15 days."
            },
            {
              "key": "Lock-Up Period",
              "value": "You agree not to sell or transfer shares for 180 days following the effective date of a registration statement."
            },
            {
              "key": "Transfer Restrictions",
              "value": "Your option is not transferable except by will or laws of descent; with conditions for trusts and domestic relations orders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 141,
          "title": "Stock Option Agreement Terms and Conditions",
          "data": [
            {
              "key": "Incentive Stock Option",
              "value": "This option may be deemed to be a Nonstatutory Stock Option as a result of such transfer."
            },
            {
              "key": "Beneficiary Designation",
              "value": "Entitled third party upon death to exercise the option."
            },
            {
              "key": "Option Definition",
              "value": "Not an employment or service contract."
            },
            {
              "key": "Withholding Obligations",
              "value": "Authorized withholding from payroll for tax obligations."
            },
            {
              "key": "Tax Consequences",
              "value": "No duty of the Company to minimize tax liabilities."
            },
            {
              "key": "Exemption from Section 409A",
              "value": "Exempt only if exercise price is at least fair market value on the Date of Grant."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 142,
          "title": "Option Agreement Provisions",
          "data": [
            {
              "key": "Notices",
              "value": "Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company."
            },
            {
              "key": "Governing Plan Document",
              "value": "Your option is subject to all the provisions of the Plan, further subject to all interpretations, amendments, rules and regulations which may be adopted pursuant to the Plan."
            },
            {
              "key": "Recoupment",
              "value": "Your option, and any compensation paid or shares issued under your option, is subject to recoupment according to The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations."
            },
            {
              "key": "Receipt of Documents",
              "value": "You acknowledge receipt of the document providing information required by Rule 428(b)(1) under the Securities Act, including the Plan prospectus."
            },
            {
              "key": "Effect on Employee Benefit Plans",
              "value": "The value of this option will not be included as compensation under any employee benefit plan unless expressly provided otherwise."
            },
            {
              "key": "Voting Rights",
              "value": "You will not have voting rights until shares are issued pursuant to this option. Upon issuance, you will obtain full voting and other rights."
            },
            {
              "key": "Severability",
              "value": "If any part of this Option Agreement is declared unlawful or invalid, it will not affect other portions which remain lawful."
            },
            {
              "key": "Miscellaneous",
              "value": "The rights and obligations of the Company under your option will be transferable and enforceable by the Company's successors and assigns."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 143,
          "title": "Option Agreement Provisions",
          "data": [
            {
              "key": "Acknowledgment and Agreement",
              "value": "You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option."
            },
            {
              "key": "Subject to Law",
              "value": "This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required."
            },
            {
              "key": "Binding Obligations",
              "value": "All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company."
            },
            {
              "key": "Deemed Signature",
              "value": "This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 144,
          "title": "2018 Equity Incentive Plan",
          "data": [
            {
              "key": "Plan ID",
              "value": "179426020 v2"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 145,
          "title": "Stock Option Exercise Form",
          "data": [
            {
              "key": "Type of option",
              "value": ""
            },
            {
              "key": "Stock option dated",
              "value": ""
            },
            {
              "key": "Number of Shares as to which option is exercised",
              "value": ""
            },
            {
              "key": "Certificates to be issued in name of",
              "value": ""
            },
            {
              "key": "Total exercise price",
              "value": "$_____"
            },
            {
              "key": "Cash payment delivered herewith",
              "value": "$_____"
            },
            {
              "key": "Value of Shares delivered herewith",
              "value": "$_____"
            },
            {
              "key": "Value of Shares pursuant to net exercise",
              "value": "$_____"
            },
            {
              "key": "Regulation T Program (cashless exercise)",
              "value": "$_____"
            },
            {
              "key": "Description",
              "value": "A form for recording stock option exercise details with two columns for Incentive and Nonstatutory options"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 146,
          "title": "Stock Option Agreement and Lock-Up Agreement",
          "data": [
            {
              "key": "Option Grant Period",
              "value": "Two (2) years after the date of grant or one (1) year after Shares are issued upon exercise"
            },
            {
              "key": "Lock-Up Period",
              "value": "One hundred eighty (180) days after effective date of registration statement"
            },
            {
              "key": "Covenant",
              "value": "Agreement not to sell or dispose of shares during Lock-Up Period"
            },
            {
              "key": "Compliance",
              "value": "Facilitate compliance with FINRA Rule 2241"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 147,
          "title": "Exhibit 10.2C Double-Trigger Form Bionano Genomics, Inc. Stock Option Grant Notice",
          "data": [
            {
              "key": "Company",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Type of Grant",
              "value": "Incentive Stock Option / Nonstatutory Stock Option"
            },
            {
              "key": "Exercise Schedule",
              "value": "Same as Vesting Schedule"
            },
            {
              "key": "Vesting Schedule",
              "value": "[______________]"
            },
            {
              "key": "Payment Methods",
              "value": "By cash, check, bank draft or money order payable to the Company; Pursuant to a Regulation T Program if the shares are publicly traded; By delivery of already-owned shares if the shares are publicly traded; By net exercise arrangement (for Nonstatutory Stock Option)."
            },
            {
              "key": "Important Terms",
              "value": "If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 148,
          "title": "Stock Option Grant Notice and Acknowledgements",
          "data": [
            {
              "key": "Optionholder",
              "value": ""
            },
            {
              "key": "Signature",
              "value": ""
            },
            {
              "key": "Title",
              "value": "__"
            },
            {
              "key": "Date",
              "value": "__"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 149,
          "title": "Option Agreement (2018 Equity Incentive Plan)",
          "data": [
            {
              "key": "Company Name",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Plan Name",
              "value": "2018 Equity Incentive Plan"
            },
            {
              "key": "Option Type",
              "value": "Incentive Stock Option or Nonstatutory Stock Option"
            },
            {
              "key": "Conditions for Vesting",
              "value": "Subject to provisions in Grant Notice; ceases upon termination of Continuous Service; acceleration under certain conditions."
            },
            {
              "key": "Definition of Good Reason",
              "value": "Material reduction in salary, breach of employment agreement, increase in commute exceeding 35 miles, or material reduction in duties."
            },
            {
              "key": "280G Payment Conditions",
              "value": "Payments tied to Change in Control may be considered parachute payments and subject to excise tax if above certain thresholds; payments may be reduced to avoid tax."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 150,
          "title": "Payment Reduction and Tax Implications",
          "data": [
            {
              "key": "Payment Reduction Method",
              "value": "The manner that results in the greatest economic benefit."
            },
            {
              "key": "Pro Rata Reduction Method",
              "value": "Items reduced will be reduced pro rata if multiple methods provide the same benefit."
            },
            {
              "key": "Section 409A Code",
              "value": "Modifications to avoid taxes on Payments subject to Section 409A."
            },
            {
              "key": "Reduction Priorities",
              "value": "1st: Preserve greatest economic benefit; 2nd: Payments contingent on future events are reduced first; 3rd: Deferred compensation reduced before non-deferred."
            },
            {
              "key": "Accounting Firm Responsibilities",
              "value": "Engaged accounting firm handles determinations unless serving conflicting interests."
            },
            {
              "key": "Expense Responsibilities",
              "value": "Company bears all accountant determination expenses."
            },
            {
              "key": "Timing of Determinations",
              "value": "Calculations provided within 15 days of entitlement to a 280G Payment."
            },
            {
              "key": "IRS Determination Obligations",
              "value": "Return sufficient Payment portion if previously reduced Payment is found subject to Excise Tax."
            },
            {
              "key": "Capitalization Adjustments",
              "value": "Number of shares and exercise price adjusted for such changes."
            },
            {
              "key": "Exercise Restrictions for Non-Exempt Employees",
              "value": "Option cannot be exercised until six months of Continuous Service is completed."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 151,
          "title": "Method of Payment for Options Exercise",
          "data": [
            {
              "key": "Payment Methods",
              "value": "Cash, check, bank draft, money order, or other permitted methods based on Grant Notice."
            },
            {
              "key": "Broker-assisted Exercise",
              "value": "If the Common Stock is publicly traded, payment can occur via a program developed under Regulation T."
            },
            {
              "key": "Delivery of Shares",
              "value": "Delivery of owned shares free of liens to be used as payment."
            },
            {
              "key": "Net Exercise Arrangement",
              "value": "Reduction of shares issued upon exercise by the Fair Market Value corresponding to the exercise price."
            },
            {
              "key": "Compliance with Securities Law",
              "value": "Option exercise must comply with applicable laws and cannot be executed unless shares are registered or exempt."
            },
            {
              "key": "Term Limits",
              "value": "Options cannot be exercised before the Date of Grant or after the expiration of the term."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 152,
          "title": "Executive Stock Option Terms and Conditions",
          "data": [
            {
              "key": "Exercise Period",
              "value": "Options are subject to a specific exercise period based on various conditions."
            },
            {
              "key": "Non-Exempt Employee Rules",
              "value": "Special provisions apply if you are a Non-Exempt Employee."
            },
            {
              "key": "Expiration Conditions",
              "value": "Options do not expire until certain conditions related to termination are met."
            },
            {
              "key": "Incentive Stock Option Tax Rules",
              "value": "Tax advantages require you to be an employee for a specified period."
            },
            {
              "key": "Tax Withholding Responsibilities",
              "value": "Obligation for tax withholding upon exercise."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 153,
          "title": "Lock-Up Agreement and Transferability of Options",
          "data": [
            {
              "key": "Lock-Up Period",
              "value": "180 days following the effective date of a registration statement."
            },
            {
              "key": "Transferability Restrictions",
              "value": "Not transferable, except by will or laws of descent and distribution."
            },
            {
              "key": "Beneficiary Designation",
              "value": "Option can be designated to a third party by written notice to the Company."
            },
            {
              "key": "Non-Employment",
              "value": "The option is not an employment or service contract."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 154,
          "title": "Withholding Obligations and Tax Consequences",
          "data": [
            {
              "key": "Withholding Obligations",
              "value": "At the time you exercise your option, you authorize withholding from payroll and any amounts payable to you for tax obligations."
            },
            {
              "key": "Nonstatutory Stock Option",
              "value": "If this option is a Nonstatutory Stock Option, the Company may withhold shares of Common Stock to satisfy tax obligations."
            },
            {
              "key": "Exercise Restrictions",
              "value": "You may not exercise your option unless tax withholding obligations are satisfied."
            },
            {
              "key": "Tax Consequences",
              "value": "The Company does not have a duty to minimize your tax liabilities related to your option."
            },
            {
              "key": "Exemption from Section 409A",
              "value": "The option is exempt from Section 409A if the exercise price is at least equal to the fair market value."
            },
            {
              "key": "Notices",
              "value": "Notices will be deemed effectively given upon receipt or five days after being mailed."
            },
            {
              "key": "Governing Plan Document",
              "value": "Your option is subject to provisions of the Plan and any amendments or regulations."
            },
            {
              "key": "Recoupment",
              "value": "Your option is subject to recoupment in accordance with Dodd-Frank Act and any clawback policy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 155,
          "title": "Stock Option Agreement Terms",
          "data": [
            {
              "key": "Policy on Selling Shares",
              "value": "Permits certain individuals to sell shares only during specified window periods."
            },
            {
              "key": "Compensation Calculation",
              "value": "The value of the options will not be included as compensation for employee benefit plan calculations, unless specifically provided."
            },
            {
              "key": "Voting Rights Notification",
              "value": "Stockholder rights obtained only upon issuance of shares."
            },
            {
              "key": "Severability Clause",
              "value": "Invalidity of any part does not render the agreement invalid as a whole."
            },
            {
              "key": "Transferability of Rights",
              "value": "Company's rights and obligations under option are transferable to successors."
            },
            {
              "key": "Acknowledgment of Understanding",
              "value": "The recipient acknowledges full understanding of the option agreement."
            },
            {
              "key": "Governing Laws",
              "value": "Subject to all applicable laws and governmental approvals."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 157,
          "title": "2018 Equity Incentive Plan",
          "data": [
            {
              "key": "Plan ID",
              "value": "179425913 v2"
            },
            {
              "key": "Plan Name",
              "value": "Equity Incentive Plan"
            },
            {
              "key": "Year",
              "value": "2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 158,
          "title": "Stock Option Exercise Form",
          "data": [
            {
              "key": "Type of option",
              "value": ""
            },
            {
              "key": "Stock option dated",
              "value": ""
            },
            {
              "key": "Number of Shares as to which option is exercised",
              "value": ""
            },
            {
              "key": "Certificates to be issued in name of",
              "value": ""
            },
            {
              "key": "Total exercise price",
              "value": ""
            },
            {
              "key": "Cash payment delivered herewith",
              "value": ""
            },
            {
              "key": "Value of Shares delivered herewith",
              "value": ""
            },
            {
              "key": "Value of Shares pursuant to net exercise",
              "value": ""
            },
            {
              "key": "Regulation T Program (cashless exercise)",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 159,
          "title": "Executive Compensation Agreement",
          "data": [
            {
              "key": "option_grant_terms",
              "value": "Occurs within two (2) years after the date of grant or within one (1) year after Shares are issued upon exercise."
            },
            {
              "key": "lock_up_period",
              "value": "One hundred eighty (180) days post effective date of registration statement."
            },
            {
              "key": "covenant_enforcement",
              "value": "The Company may impose stop-transfer instructions on securities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 173,
          "title": "Landlord's Obligations and Tenant Cooperation",
          "data": [
            {
              "key": "Section 7.5",
              "value": "Landlord’s obligation to provide utilities and services are subject to Rules and Regulations and applicable laws."
            },
            {
              "key": "Section 7.6",
              "value": "Compliance with new governmental Controls related to energy or utilities does not constitute eviction or liability."
            },
            {
              "key": "Section 7.7",
              "value": "Tenant must disclose information regarding energy consumption as required by California Energy Disclosure Regulations."
            },
            {
              "key": "Section 8.1",
              "value": "Tenant cannot make alterations without Landlord’s written consent, unless cost is $5,000 or less."
            },
            {
              "key": "Section 8.1(a)",
              "value": "Tenant must submit plans for alterations for Landlord's approval; Landlord must respond within 10 business days."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 184,
          "title": "Letter of Credit Provisions",
          "data": [
            {
              "key": "Letter of Credit Amount",
              "value": "$400,000.00"
            },
            {
              "key": "Qualified Bank Requirements",
              "value": "Must have local San Francisco Bay Area office, acceptable to Landlord, and meet specified credit rating thresholds."
            },
            {
              "key": "Events of Default",
              "value": "Conditions under which Landlord can draw from Letter of Credit, including Tenant bankruptcy and lease termination."
            },
            {
              "key": "Tenant Responsibilities",
              "value": "Renew Letter of Credit at least 60 days prior to expiration."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 189,
          "title": "Tenant Financial Statement Requirements and Confidentiality Clauses",
          "data": [
            {
              "key": "Section 31.6",
              "value": "Intentionally Omitted"
            },
            {
              "key": "Section 31.7",
              "value": "Landlord reserves the right to make improvements and/or additions to portions of the Building."
            },
            {
              "key": "Section 31.8",
              "value": "Tenant must furnish audited financial statements within 180 days of fiscal year end."
            },
            {
              "key": "Section 31.9",
              "value": "Landlord's liability limited to their interest in the Project."
            },
            {
              "key": "Section 31.10",
              "value": "Terms of Lease are confidential."
            },
            {
              "key": "Section 31.11",
              "value": "Rentable area of the Premises is accurately calculated."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 210,
          "title": "Amended and Restated Exclusive License Agreement with Stanford",
          "data": [
            {
              "key": "License Maintenance Fee",
              "value": "Purigen will pay Stanford a yearly license maintenance fee of $[***]."
            },
            {
              "key": "Milestone Payment",
              "value": "Purigen will pay Stanford $[***] upon annual Net Sales from all Licensed Products reaching at least $[***]."
            },
            {
              "key": "Earned Royalty",
              "value": "Purigen will pay Stanford earned royalties of [***]% on Net Sales of Licensed Products."
            },
            {
              "key": "Royalty Stacking",
              "value": "Purigen shall be entitled to set off as a credit against Earned Royalty."
            },
            {
              "key": "Creditable Payments",
              "value": "The license maintenance fee for a year may be offset against earned royalty payments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 211,
          "title": "Royalty Obligations and Payments",
          "data": [
            {
              "key": "Agreement Date",
              "value": "8/3/2021"
            },
            {
              "key": "Obligations",
              "value": "Purigen must pay additional earned royalties to Stanford depending on sales."
            },
            {
              "key": "Currency of Payment",
              "value": "USD"
            },
            {
              "key": "Non-U.S. Taxes Responsibility",
              "value": "Purigen to pay all non-U.S. taxes on royalty payments."
            },
            {
              "key": "Interest on Late Payments",
              "value": "Interest at lower of Prime Rate + 200 basis points or maximum legal rate."
            },
            {
              "key": "Reporting Timeline",
              "value": "Written Royalty Report due [***] days after each [***]."
            },
            {
              "key": "Termination Reporting",
              "value": "Report and royalty payments due within [***] days after license termination."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 222,
          "title": "Amended and Restated Exclusive License Agreement with Equity",
          "data": [
            {
              "key": "agreement_date",
              "value": "2021-08-03"
            },
            {
              "key": "license_milestones",
              "value": "Appendix A - Milestones"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 225,
          "title": "Appendix D – Progress Report",
          "data": [
            {
              "key": "Agreement Type",
              "value": "Exclusive License Agreement"
            },
            {
              "key": "Parties Involved",
              "value": "CDT, Equity"
            },
            {
              "key": "Amendment Date",
              "value": "8/3/2021"
            },
            {
              "key": "Document Purpose",
              "value": "Progress Report"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 228,
          "title": "Amended and Restated Exclusive License Agreement with Equity",
          "data": [
            {
              "key": "Section",
              "value": "7.3 to 7.7"
            },
            {
              "key": "Agreement Date",
              "value": "8/3/2021"
            },
            {
              "key": "Purpose",
              "value": "Valuing interest in Purigen"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 237,
          "title": "CERTIFICATION",
          "data": [
            {
              "key": "CEO Name",
              "value": "R. Erik Holmlin, Ph.D."
            },
            {
              "key": "Title",
              "value": "President and Chief Executive Officer"
            },
            {
              "key": "Certification Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Affirmation",
              "value": "Certified financial statements and internal controls."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 15,
          "title": "Investment in Research and Development of Optical Genome Mapping (OGM) Technology",
          "data": [
            {
              "key": "Estimated market potential for OGM",
              "value": "Approximately $10.0 billion annually"
            },
            {
              "key": "Market potential attributed to cell bioprocessing QC",
              "value": "$3.0 billion"
            },
            {
              "key": "Number of cytogenetics labs worldwide",
              "value": "Approximately 10,000"
            },
            {
              "key": "Emerging market opportunity in cellular stability evaluation",
              "value": "Up to $3.0 billion annually"
            },
            {
              "key": "Focus on driving adoption through Saphyr system",
              "value": "Streamlining SV identification for genomics research"
            },
            {
              "key": "Clinical studies intended for",
              "value": "Postnatal, prenatal, hematologic malignancies and solid tumor analyses"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 8,
          "title": "Recent Highlights Achievement of 2022 ELEVATE! Milestones",
          "data": [
            {
              "key": "Milestone Achievements",
              "value": "Bionano executed on its 2022 ELEVATE! milestones and achieved or exceeded all publicly stated milestones."
            },
            {
              "key": "Product Releases",
              "value": "Released pre-commercial version of NxClinical software, version 7.0, enabled OGM data analysis in the field."
            },
            {
              "key": "Labeling Protocols",
              "value": "Released labeling protocol 2.0 and the SP Next DNA isolation protocol."
            },
            {
              "key": "OGM Test Menu Launch",
              "value": "Bionano Laboratories launched an OGM test menu for genetic disease and hematologic malignancies."
            },
            {
              "key": "Commercial Adoption",
              "value": "Grew installed base of Saphyr systems to 240, an increase of approximately 46% from previous year."
            },
            {
              "key": "Sales Increase",
              "value": "Sold 4,781 flowcells in Q4 2022, a 49% increase over Q4 2021."
            },
            {
              "key": "Utility Validation Studies",
              "value": "Published and validated results from extensive benchmarking of Saphyr system against traditional methods."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 11,
          "title": "Saphyr System Introduction",
          "data": [
            {
              "key": "Product Name",
              "value": "Saphyr System"
            },
            {
              "key": "Product Features",
              "value": "Genome wide structural variation detection, high sensitivity and specificity, cost-effective workflow"
            },
            {
              "key": "Target Users",
              "value": "Researchers and clinicians"
            },
            {
              "key": "Competitive Advantage",
              "value": "High resolution analysis compared to traditional techniques"
            },
            {
              "key": "Product Applications",
              "value": "Genetic disease and cancer analysis"
            },
            {
              "key": "Replacement for",
              "value": "Traditional cytogenetic tools"
            },
            {
              "key": "Current Customer Base",
              "value": "Nucleic acid isolation and purification"
            },
            {
              "key": "Technology Used",
              "value": "Isotachophoresis (ITP) for nucleic acid isolation"
            },
            {
              "key": "Market Strategy",
              "value": "Pay-per-sample model for software monetization"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 12,
          "title": "Bionano Laboratories Product Launch - Saphyr System",
          "data": [
            {
              "key": "Product Name",
              "value": "Saphyr System"
            },
            {
              "key": "Type",
              "value": "Genomic Analysis System"
            },
            {
              "key": "Application",
              "value": "SV Analysis by OGM"
            },
            {
              "key": "Features",
              "value": "Highly sensitive, Cost effective, Scalable and fast"
            },
            {
              "key": "Unique Selling Proposition",
              "value": "Empowers comprehensive genome analysis and facilitates a deeper understanding of genetic variation and function."
            },
            {
              "key": "Price per Genome",
              "value": "Approximately $500"
            },
            {
              "key": "Throughput",
              "value": "Up to 5,000 human genomes per year at 30x coverage"
            },
            {
              "key": "Technology",
              "value": "Single-molecule imaging and automated sample loading"
            },
            {
              "key": "Target Market",
              "value": "Labs conducting genomic analyses for diagnostic testing"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 13,
          "title": "Saphyr Sample Prep and Labeling Kits",
          "data": [
            {
              "key": "Description",
              "value": "Our Bionano Prep™ kits and DNA labeling kits provide the reagents and protocols needed to extract and label UHMW DNA for use with the Saphyr system."
            },
            {
              "key": "Applications",
              "value": "Genome mapping applications on a variety of sample types."
            },
            {
              "key": "Workflow",
              "value": "Isolation of UHMW DNA followed by labeling."
            },
            {
              "key": "Labeling Technology",
              "value": "Direct Label and Stain (DLS) kit for sequence motif labeling."
            },
            {
              "key": "Acquisition",
              "value": "Acquired the Ionic Purification system through November 2022 acquisition of Purigen."
            },
            {
              "key": "System Details",
              "value": "Uses proprietary ITP method for nucleic acid purification."
            },
            {
              "key": "Yield",
              "value": "Higher yield of pure nucleic acid, less fragmented."
            },
            {
              "key": "Optimization Goals",
              "value": "Optimize for use in an OGM workflow."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 14,
          "title": "Software Solutions",
          "data": [
            {
              "key": "Overview",
              "value": "Our data solutions offering includes a complete suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps and algorithms and databases for bioinformatics processing."
            },
            {
              "key": "Proprietary Algorithms",
              "value": "We have a suite of proprietary algorithms and databases that fully enable our proprietary bioinformatic and SV analysis pipelines."
            },
            {
              "key": "Hardware Solutions",
              "value": "Our hardware solution includes the Saphyr Compute Server and the Bionano Compute Server."
            },
            {
              "key": "Software Solutions",
              "value": "Our NxClinical software is among the most comprehensive solutions for cytogenetics and molecular genetics."
            },
            {
              "key": "Laboratory Services",
              "value": "Bionano Laboratories offers OGM data to researchers and has introduced OGM-based tests for genetic testing."
            },
            {
              "key": "Market Opportunity",
              "value": "The worldwide market for genomics products and services is expected to reach approximately $54.4 billion by 2025."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 17,
          "title": "Bionano Laboratories Overview",
          "data": [
            {
              "key": "Sales Model",
              "value": "Bionano Laboratories primarily sells a suite of LDTs to pediatric physicians through a physician-directed 'in-person' sales model."
            },
            {
              "key": "Target Audience",
              "value": "The sales and marketing efforts are primarily targeted at specialty pediatricians, including pediatric neurologists, medical geneticists, and developmental and behavioral pediatricians."
            },
            {
              "key": "Manufacturing Strategy",
              "value": "The manufacturing strategy includes outsourcing instrument and chip manufacturing while internally developing and assembling reagent kits."
            },
            {
              "key": "Testing Location",
              "value": "Bionano Laboratories’ OGM testing is performed at their lab in San Diego, or at partner labs in the United States and Europe."
            },
            {
              "key": "Contract Laboratories",
              "value": "Bionano Laboratories maintains contracts with a network of laboratories to perform wet lab services for various non-OGM LDT tests."
            },
            {
              "key": "CLIA Certification",
              "value": "Bionano Laboratories has CLIA certification for its San Diego lab."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 18,
          "title": "Bionano Laboratories New Product Launches",
          "data": [
            {
              "key": "New Products",
              "value": "OGM-based LDTs planned to be launched at the San Diego facility."
            },
            {
              "key": "Key Agreements",
              "value": "License Agreement with Princeton University."
            },
            {
              "key": "Royalty Obligations",
              "value": "Royalty payments to Princeton and Stanford based on net sales and service revenue."
            },
            {
              "key": "Termination Clause",
              "value": "Princeton License Agreement can be terminated upon material breach."
            },
            {
              "key": "Manufacturer Agreements",
              "value": "Agreement for the manufacture of instruments and chip consumables with third-party manufacturers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 36,
          "title": "Market Acceptance and Product Development Risks",
          "data": [
            {
              "key": "Market Acceptance Factors",
              "value": "The successful marketing of products and diagnostic assays depends on several factors including clinical utility studies, support from partners, the success of the sales force, acceptance of the medical community, and reimbursement from insurers."
            },
            {
              "key": "Peer Review Process",
              "value": "The publication of study results in peer-reviewed journals is critical for gaining acceptance in the medical community."
            },
            {
              "key": "Impact of Geopolitical Factors",
              "value": "Geopolitical developments like the COVID-19 pandemic may increase risks and uncertainty in achieving market acceptance."
            },
            {
              "key": "Revenue Sources",
              "value": "Revenue is expected primarily from sales to academic and governmental research institutions and commercial laboratories."
            },
            {
              "key": "Conditions Affecting Demand",
              "value": "The demand for products depends on the research and development budgets of customers which are influenced by multiple external factors."
            },
            {
              "key": "Potential Adverse Effects",
              "value": "Failures to achieve market acceptance may materially harm the business and financial results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 37,
          "title": "Sales Cycle and Product Development",
          "data": [
            {
              "key": "Sales Cycle Length Variation",
              "value": "The sales cycle for systems can be lengthy and variable, making it difficult to forecast revenue."
            },
            {
              "key": "Evaluation Factors",
              "value": "Customers' evaluation processes often involve factors beyond the company's control."
            },
            {
              "key": "Importance of New Products",
              "value": "Long-term results depend on improvement and innovation in products and technologies."
            },
            {
              "key": "Investment in R&D",
              "value": "Significant capital is needed for product development and refinement."
            },
            {
              "key": "Market Acceptance Risks",
              "value": "Market acceptance of new products cannot be predicted."
            },
            {
              "key": "Technological Changes",
              "value": "Selling products in industries characterized by rapid technological changes."
            },
            {
              "key": "Customer Preferences",
              "value": "Success depends on correct identification of customer needs and preferences."
            },
            {
              "key": "Competitive Response",
              "value": "Ability to respond to competitors' new product developments is crucial."
            },
            {
              "key": "Integration of Technologies",
              "value": "Need to integrate new technologies like Ionic Purification system into existing offerings."
            },
            {
              "key": "Acquisition Impact",
              "value": "BioDiscovery and Purigen acquisitions are significant for future product offerings."
            },
            {
              "key": "Profitability Risks",
              "value": "Costs to develop new technologies may adversely affect profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 38,
          "title": "Product Launch Risks and Assumptions",
          "data": [
            {
              "key": "Product Development Risks",
              "value": "Risks associated with launching new products and technologies include potential delays due to development or manufacturing challenges, or errors discovered during the product development cycle."
            },
            {
              "key": "Market Demand Uncertainty",
              "value": "The market size for our products and technologies may be smaller than estimated, and new markets may not develop as quickly as expected."
            },
            {
              "key": "Sales and Marketing Challenges",
              "value": "Challenges in attracting and retaining the sales, marketing, and service personnel necessary to expand market acceptance for our technology."
            },
            {
              "key": "Market Opportunity Estimates",
              "value": "Estimates of the total addressable market are forward-looking statements subject to significant risks and uncertainties."
            },
            {
              "key": "Economic Conditions Impact",
              "value": "Rising interest rates may limit customers' ability to purchase products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 133,
          "title": "Stock Option Exercise Form",
          "data": [
            {
              "key": "Type of option (check one)",
              "value": ""
            },
            {
              "key": "Stock option dated",
              "value": ""
            },
            {
              "key": "Number of Shares as to which option is exercised",
              "value": ""
            },
            {
              "key": "Certificates to be issued in name of",
              "value": ""
            },
            {
              "key": "Total exercise price",
              "value": "$"
            },
            {
              "key": "Cash payment delivered herewith",
              "value": "$"
            },
            {
              "key": "Value of Shares delivered herewith",
              "value": "$"
            },
            {
              "key": "Value of Shares pursuant to net exercise",
              "value": "$"
            },
            {
              "key": "Regulation T Program (cashless exercise)",
              "value": "$"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 190,
          "title": "Lease Agreement",
          "data": [
            {
              "key": "Landlord",
              "value": "unknown"
            },
            {
              "key": "Tenant",
              "value": "unknown"
            },
            {
              "key": "Option to Renew",
              "value": "Yes"
            },
            {
              "key": "Renewal Term",
              "value": "5 years"
            },
            {
              "key": "Exercise Notice Period",
              "value": "9 to 12 months prior to expiration of initial Lease Term"
            },
            {
              "key": "Conditions for Renewal",
              "value": "Tenant not in default, < 25% of Premises sublet, Lease not assigned, Tenant occupying the Premises, Premises for Tenant's exclusive use"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 205,
          "title": "CDT Amended and Restated Exclusive License Agreement",
          "data": [
            {
              "key": "Effective Date",
              "value": "8/3/2021"
            },
            {
              "key": "Licensed Field of Use",
              "value": "Licensed Field of Use"
            },
            {
              "key": "Licensed Territory",
              "value": "worldwide"
            },
            {
              "key": "Net Sales Definition",
              "value": "Amounts invoiced by Purigen or Sublicensees from sales of Licensed Products excluding certain deductions."
            },
            {
              "key": "Nonroyalty Sublicensing Consideration",
              "value": "Consideration received by Purigen from a sublicensee directly related to the Licensed Patents, excluding royalties and certain other considerations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 209,
          "title": "CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "agreement_date",
              "value": "8/3/2021"
            },
            {
              "key": "milestones",
              "value": "Purigen will meet the milestones shown in Appendix A."
            },
            {
              "key": "annual_report",
              "value": "Purigen will submit a written annual report by [***] of each year covering the preceding calendar year."
            },
            {
              "key": "clinical_trial_notice",
              "value": "Purigen will notify the Stanford University Office of Technology Licensing prior to commencing any clinical trials."
            },
            {
              "key": "issue_fee",
              "value": "Purigen will pay a non-creditable, non-refundable license issue fee of $[***] within [***] days of signing this Agreement."
            },
            {
              "key": "equity_interest",
              "value": "Purigen has granted to Stanford [***] shares of common stock."
            },
            {
              "key": "purchase_right",
              "value": "Stanford exercised its [***]% Purchase Right according to the terms of the Original Agreement."
            },
            {
              "key": "repurchase_obligation",
              "value": "Purigen will repurchase all Stanford's equity interest if Stanford conducts any clinical trial on behalf of Purigen."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 214,
          "title": "Amended and Restated Exclusive License Agreement",
          "data": [
            {
              "key": "Effective Date",
              "value": "8/3/2021"
            },
            {
              "key": "Marking Requirements",
              "value": "If required by law, mark Licensed Product with \"Patent Pending\"."
            },
            {
              "key": "Prohibition on Use of Stanford Names",
              "value": "Prohibition on using Stanford's name or trademarks without prior written consent."
            },
            {
              "key": "Patent Prosecution Responsibilities",
              "value": "Stanford responsible for preparing, filing, prosecuting and maintaining the Licensed Patents."
            },
            {
              "key": "Reimbursement for Patent Costs",
              "value": "Purigen will reimburse Stanford for patent expenses related to Licensed Patents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 230,
          "title": "Amendment to Exclusive License Agreement",
          "data": [
            {
              "key": "Effective Date",
              "value": "November 14, 2022"
            },
            {
              "key": "Parties",
              "value": "Stanford University and Purigen Biosystems, Inc."
            },
            {
              "key": "Original Agreement Date",
              "value": "July 16, 2021"
            },
            {
              "key": "Inventions",
              "value": "Improvements in sample preparation and analysis of biological and chemical samples"
            },
            {
              "key": "Details",
              "value": "Purigen plans to develop a second product line related to DNA/RNA separation."
            },
            {
              "key": "Amendment Purpose",
              "value": "To distinguish between the diligence milestones for the development of a specific invention from those related to overall net sales."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 73,
          "title": "Future Capital Requirements",
          "data": [
            {
              "key": "Expected growth in operations and capacity",
              "value": "We expect that our near and longer-term liquidity requirements will consist of working capital and general corporate expenses associated with the growth of our business."
            },
            {
              "key": "Short-term capital expenditure needs",
              "value": "Our short-term capital expenditure needs relate primarily to the ongoing build out of our facilities, service lab and service-related capabilities."
            },
            {
              "key": "Additional research and development expenses",
              "value": "Expenses associated with continuing to build out our corporate infrastructure and expenses associated with being a public company."
            },
            {
              "key": "Continuing expenditures",
              "value": "We expect such expenditures to continue throughout 2023."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 107,
          "title": "Lease Commitments and Contingencies",
          "data": [
            {
              "key": "Operating cash flows from operating leases (2022)",
              "value": "$1,622,000"
            },
            {
              "key": "Operating cash flows from operating leases (2021)",
              "value": "$447,000"
            },
            {
              "key": "Operating cash flows from finance leases (2022)",
              "value": "$278,000"
            },
            {
              "key": "Operating cash flows from finance leases (2021)",
              "value": "$47,000"
            },
            {
              "key": "Financing cash flows from finance leases (2022)",
              "value": "$36,000"
            },
            {
              "key": "Financing cash flows from finance leases (2021)",
              "value": "$5,000"
            },
            {
              "key": "Operating leases (Weighted-average remaining lease term, 2022)",
              "value": "3.41 years"
            },
            {
              "key": "Finance leases (Weighted-average remaining lease term, 2022)",
              "value": "18.17 years"
            },
            {
              "key": "Operating leases (Weighted-average discount rate, 2022)",
              "value": "8.3%"
            },
            {
              "key": "Finance leases (Weighted-average discount rate, 2022)",
              "value": "71%"
            },
            {
              "key": "Operating leases (Noncash lease liabilities, 2022)",
              "value": "$517,000"
            },
            {
              "key": "Operating leases (Noncash lease liabilities, 2021)",
              "value": "$4,751,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Operating and Finance Lease Costs Comparison",
          "data": [
            {
              "key": "Operating lease costs (2022)",
              "value": ". $2,084,000"
            },
            {
              "key": "Operating lease costs (2021)",
              "value": ". $1,118,001"
            },
            {
              "key": "Variable lease costs (2022)",
              "value": ". $940,000"
            },
            {
              "key": "Variable lease costs (2021)",
              "value": ". $386,001"
            },
            {
              "key": "Total rent expense (2022)",
              "value": ". $3,024,000"
            },
            {
              "key": "Total rent expense (2021)",
              "value": ". $1,504,001"
            },
            {
              "key": "Amortization of right of use assets (2022)",
              "value": ". $219,000"
            },
            {
              "key": "Amortization of right of use assets (2021)",
              "value": ". $19,001"
            },
            {
              "key": "Interest on lease liabilities (2022)",
              "value": ". $278,000"
            },
            {
              "key": "Interest on lease liabilities (2021)",
              "value": ". $47,001"
            },
            {
              "key": "Total finance lease costs (2022)",
              "value": ". $529,000"
            },
            {
              "key": "Total finance lease costs (2021)",
              "value": ". $66,001"
            },
            {
              "key": "Gross sublease income (2022)",
              "value": ". -$106,000"
            },
            {
              "key": "Gross sublease income (2021)",
              "value": ". -$18,001"
            },
            {
              "key": "Total lease costs (2022)",
              "value": ". $3,447,000"
            },
            {
              "key": "Total lease costs (2021)",
              "value": ". $1,552,001"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Future Minimum Payments under Lease Agreements",
          "data": [
            {
              "key": "2023 (amount 1)",
              "value": "$2,586,000"
            },
            {
              "key": "2024 (amount 1)",
              "value": "$2,684,000"
            },
            {
              "key": "2025 (amount 1)",
              "value": "$2,788,000"
            },
            {
              "key": "2026 (amount 1)",
              "value": "$729,000"
            },
            {
              "key": "2027 (amount 1)",
              "value": "$255,000"
            },
            {
              "key": "Thereafter (amount 1)",
              "value": "$0"
            },
            {
              "key": "Total future lease payments (amount 1)",
              "value": "$9,042,000"
            },
            {
              "key": "Less: imputed interest (amount 1)",
              "value": "-$1,278,000"
            },
            {
              "key": "Total lease liabilities (amount 1)",
              "value": "$7,764,000"
            },
            {
              "key": "Less: lease liability, current portion (amount 1)",
              "value": "$2,260,000"
            },
            {
              "key": "Lease liability, net of current portion (amount 1)",
              "value": "$5,504,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 138,
          "title": "Accounting Firm Engagement and Share Exercise Procedures",
          "data": [
            {
              "key": "Effective Date of Change of Control",
              "value": "Day prior to the effective date of the change of control transaction where a Payment is triggered."
            },
            {
              "key": "Accounting Firm Responsibilities",
              "value": "Engaged accounting firm to perform calculations unless an alternative is agreed upon."
            },
            {
              "key": "Payment Return Conditions",
              "value": "Payment must be returned if a portion is subject to Excise Tax based on IRS determinations."
            },
            {
              "key": "Adjustment of Shares",
              "value": "Shares subject to option and exercise price will be adjusted for Capitalization Adjustments."
            },
            {
              "key": "Exercise Restrictions for Non-Exempt Employees",
              "value": "Non-Exempt Employees must complete 6 months of Continuous Service before exercising options."
            },
            {
              "key": "Method of Payment for Exercise Price",
              "value": "Payments can be made in cash, check, broker-assisted exercise, or delivery of already-owned shares."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 161,
          "title": "Commercial Lease Agreement Terms",
          "data": [
            {
              "key": "Landlord",
              "value": "SEF BBC, LLC, a California limited liability company"
            },
            {
              "key": "Tenant",
              "value": "PURIGEN BIOSYSTEMS, INC., a Delaware corporation"
            },
            {
              "key": "Building",
              "value": "5700 Stoneridge Drive, Pleasanton, California"
            },
            {
              "key": "Premises",
              "value": "First floor Suite 100, 16,165 square feet of rentable area"
            },
            {
              "key": "Lease Term",
              "value": "Approximately sixty-three (63) months"
            },
            {
              "key": "Parking",
              "value": "3.8 unreserved spaces per 1,000 sq ft (61 spaces total)"
            },
            {
              "key": "Base Rent Schedule",
              "value": "Scheduled payments increasing from $27,965.45 in months 01-15 to $31,521.75 in months 52-63."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Exhibit A Plan Outlining the Premises",
          "data": [
            {
              "key": "Description",
              "value": "Plan outlining the premises."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Exhibit B Initial Improvement of the Premises",
          "data": [
            {
              "key": "Description",
              "value": "Details regarding initial improvements of the premises."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Exhibit C Rules and Regulations",
          "data": [
            {
              "key": "Description",
              "value": "Rules and regulations governing the premises."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Exhibit D Form of Letter of Credit",
          "data": [
            {
              "key": "Description",
              "value": "Template for the letter of credit."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Exhibit E Appraisal Procedure",
          "data": [
            {
              "key": "Description",
              "value": "Procedure for appraisal of the premises."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Exhibit F Hazardous Substances Questionnaire",
          "data": [
            {
              "key": "Description",
              "value": "Questionnaire related to hazardous substances."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Other Attachments",
          "data": [
            {
              "key": "Description",
              "value": "Any additional attachments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 169,
          "title": "Operating Expenses Definition",
          "data": [
            {
              "key": "management_expenses",
              "value": "management, operation, maintenance or repair of the Project"
            },
            {
              "key": "insurance_costs",
              "value": "premiums and other charges for fire, liability insurance and other necessary insurance"
            },
            {
              "key": "repair_costs",
              "value": "costs of repairing an insured casualty to the extent of the deductible amount"
            },
            {
              "key": "utilities_costs",
              "value": "costs for electricity, water, sewer, and other energy-related utilities"
            },
            {
              "key": "maintenance_services",
              "value": "window cleaning, security, and other maintenance services"
            },
            {
              "key": "professional_fees",
              "value": "accounting, legal and other professional fees"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 200,
          "title": "Exhibit 10.14A FIRST AMENDMENT TO LEASE",
          "data": [
            {
              "key": "Lease Date",
              "value": "August 22, 2016"
            },
            {
              "key": "Premises",
              "value": "5700 Stoneridge Drive, Pleasanton, California"
            },
            {
              "key": "Initial Lease Term End Date",
              "value": "May 1, 2022"
            },
            {
              "key": "Extension Term End Date",
              "value": "July 31, 2027"
            },
            {
              "key": "Base Rent Schedule",
              "value": "May 1, 2022 - April 30, 2023: $37,179.50*\nMay 1, 2023 - April 30, 2024: $38,294.89\nMay 1, 2024 - April 30, 2025: $39,443.73\nMay 1, 2025 - April 30, 2026: $40,627.04\nMay 1, 2026 - April 30, 2027: $41,845.85\nMay 1, 2027 - July 31, 2027: $43,101.23*"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 63,
          "title": "Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Significant stockholder control",
              "value": "The management and principal stockholders own a significant percentage of stock and can exert control over stockholder approval matters."
            },
            {
              "key": "Impact of ineffective internal control",
              "value": "Failure to maintain effective internal control may adversely affect business and investor confidence."
            },
            {
              "key": "Reporting requirements",
              "value": "The company is subject to Exchange Act, Sarbanes-Oxley Act, and Nasdaq rules."
            },
            {
              "key": "Assessment of internal controls",
              "value": "An independent assessment of internal controls could detect problems that management’s assessment might miss."
            },
            {
              "key": "Smaller reporting company",
              "value": "As of June 30, 2022, the company qualified as a smaller reporting company again, allowing exemptions from certain requirements."
            },
            {
              "key": "Legal and compliance costs",
              "value": "Despite using scaled disclosures applicable to smaller reporting companies, the company will incur substantial legal and financial compliance costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 65,
          "title": "Financial Performance Indications",
          "data": [
            {
              "key": "Losses",
              "value": "Recurring operating losses since inception."
            },
            {
              "key": "Cash Flows",
              "value": "Negative cash flows from operating activities."
            },
            {
              "key": "Accumulated Deficit",
              "value": "Significant accumulated deficit."
            },
            {
              "key": "Going Concern Doubt",
              "value": "Substantial doubt regarding ability to continue as a going concern."
            },
            {
              "key": "Impact of Financing Needs",
              "value": "If funding is insufficient, business operations may be materially affected."
            },
            {
              "key": "Asset Liquidation",
              "value": "May have to liquidate assets at values less than carried on financial statements."
            },
            {
              "key": "Investor Risk",
              "value": "Investors may lose all or part of their investment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Revenue Breakdown 2021-2022",
          "data": [
            {
              "key": "Product revenue",
              "value": "20,425,000"
            },
            {
              "key": "Service and other revenue",
              "value": "7,377,000"
            },
            {
              "key": "Total",
              "value": "27,802,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Regional Revenue Distribution",
          "data": [
            {
              "key": "Americas 2022 Amount",
              "value": "13,862,000"
            },
            {
              "key": "Americas 2022 Percentage",
              "value": "50%"
            },
            {
              "key": "EMEA 2022 Amount",
              "value": "8,960,000"
            },
            {
              "key": "EMEA 2022 Percentage",
              "value": "32%"
            },
            {
              "key": "Asia Pacific 2022 Amount",
              "value": "4,980,000"
            },
            {
              "key": "Asia Pacific 2022 Percentage",
              "value": "18%"
            },
            {
              "key": "Total 2022 Amount",
              "value": "27,802,000"
            },
            {
              "key": "Total 2022 Percentage",
              "value": "100%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 71,
          "title": "Revenue and Financial Performance Comparison",
          "data": [
            {
              "key": "Product revenue",
              "value": "$20,425,000 (2022), $12,686,000 (2021), Change: $7,739,000, Change %: 61%"
            },
            {
              "key": "Service and other revenue",
              "value": "$7,377,000 (2022), $5,295,000 (2021), Change: $2,082,000, Change %: 39%"
            },
            {
              "key": "Total revenue",
              "value": "$27,802,000 (2022), $17,981,000 (2021), Change: $9,821,000, Change %: 55%"
            },
            {
              "key": "Loss from operations",
              "value": "-$131,698,000 (2022), -$77,101,000 (2021), Change: -$54,597,000, Change %: 71%"
            },
            {
              "key": "Net loss",
              "value": "-$132,596,000 (2022), -$72,435,000 (2021), Change: -$60,161,000, Change %: 83%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 71,
          "title": "Revenue Comparison 2022 vs 2021",
          "data": [
            {
              "key": "Instruments",
              "value": "$8,567,000 (2022), $5,887,000 (2021), Change: $2,680,000, Change %: 46%"
            },
            {
              "key": "Consumables",
              "value": "$6,731,000 (2022), $5,808,000 (2021), Change: $923,000, Change %: 16%"
            },
            {
              "key": "Software",
              "value": "$5,127,000 (2022), $991,000 (2021), Change: $4,136,000, Change %: 417%"
            },
            {
              "key": "Total product revenue",
              "value": "$20,425,000 (2022), $12,686,000 (2021), Change: $7,739,000, Change %: 61%"
            },
            {
              "key": "Services and other Total revenue",
              "value": "$7,377,000 (2022), $5,295,000 (2021), Change: $2,082,000, Change %: 39%"
            },
            {
              "key": "Total revenue",
              "value": "$27,802,000 (2022), $17,981,000 (2021), Change: $9,821,000, Change %: 55%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 74,
          "title": "Cash Flow Activities",
          "data": [
            {
              "key": "Net cash used in operating activities (2022)",
              "value": "$124.8 million"
            },
            {
              "key": "Net cash used in operating activities (2021)",
              "value": "$71.9 million"
            },
            {
              "key": "Net cash provided by investing activities (2022)",
              "value": "$82.8 million"
            },
            {
              "key": "Net cash provided by investing activities (2021)",
              "value": "-$278.1 million"
            },
            {
              "key": "Net cash provided by financing activities (2022)",
              "value": "$23.0 million"
            },
            {
              "key": "Net cash provided by financing activities (2021)",
              "value": "$336.1 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 75,
          "title": "Financial Overview and Capital Resources",
          "data": [
            {
              "key": "Cash and Cash Equivalents",
              "value": "$5.1 million"
            },
            {
              "key": "Available-for-Sale Securities",
              "value": "$108.1 million"
            },
            {
              "key": "Working Capital",
              "value": "$121.4 million"
            },
            {
              "key": "Gross Proceeds from Cowen ATM (2022)",
              "value": "$23.1 million"
            },
            {
              "key": "Proceeds from Stock Sale (2020)",
              "value": "$22.1 million"
            },
            {
              "key": "Underwritten Public Offering (January 2021)",
              "value": "$101.8 million"
            },
            {
              "key": "Underwritten Public Offering (January 2021) Price to Public",
              "value": "$3.05"
            },
            {
              "key": "Shelf Registration Statement Filing Date",
              "value": "January 19, 2021"
            },
            {
              "key": "Future Offerings Assurance",
              "value": "No assurance on future offerings"
            },
            {
              "key": "Common Stock Sales (3 Q 2021)",
              "value": "$13.9 million"
            },
            {
              "key": "Common Stock Sales (3 Q 2022)",
              "value": "$23.1 million"
            },
            {
              "key": "Equity Sales (Jan-Mar 2023)",
              "value": "$15.2 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 82,
          "title": "Balance Sheet Assets and Liabilities",
          "data": [
            {
              "key": "Total current assets",
              "value": "157,298,000"
            },
            {
              "key": "Total assets",
              "value": "307,502,000"
            },
            {
              "key": "Total liabilities",
              "value": "58,104,000"
            },
            {
              "key": "Cash and cash equivalents 2022",
              "value": "5,091,000"
            },
            {
              "key": "Cash and cash equivalents 2021",
              "value": "24,571,000"
            },
            {
              "key": "Investments 2022",
              "value": "108,095,000"
            },
            {
              "key": "Investments 2021",
              "value": "226,041,000"
            },
            {
              "key": "Inventory 2022",
              "value": "29,761,000"
            },
            {
              "key": "Inventory 2021",
              "value": "12,387,000"
            },
            {
              "key": "Prepaid expenses and other current assets 2022",
              "value": "7,329,000"
            },
            {
              "key": "Prepaid expenses and other current assets 2021",
              "value": "4,481,000"
            },
            {
              "key": "Property and equipment, net 2022",
              "value": "18,029,000"
            },
            {
              "key": "Property and equipment, net 2021",
              "value": "10,318,000"
            },
            {
              "key": "Operating lease right-of-use assets 2022",
              "value": "7,222,000"
            },
            {
              "key": "Operating lease right-of-use assets 2021",
              "value": "6,691,000"
            },
            {
              "key": "Intangible assets, net 2022",
              "value": "41,143,000"
            },
            {
              "key": "Intangible assets, net 2021",
              "value": "26,842,000"
            },
            {
              "key": "Goodwill 2022",
              "value": "77,289,000"
            },
            {
              "key": "Goodwill 2021",
              "value": "56,160,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 82,
          "title": "Stockholders' Equity and Liabilities Statement",
          "data": [
            {
              "key": "Common stock 2022",
              "value": "30,000"
            },
            {
              "key": "Common stock 2021",
              "value": "29,000"
            },
            {
              "key": "Additional paid-in capital 2022",
              "value": "599,207,000"
            },
            {
              "key": "Additional paid-in capital 2021",
              "value": "553,747,000"
            },
            {
              "key": "Accumulated deficit 2022",
              "value": "(348,715,000)"
            },
            {
              "key": "Accumulated deficit 2021",
              "value": "(216,119,000)"
            },
            {
              "key": "Total stockholders' equity 2022",
              "value": "249,398,000"
            },
            {
              "key": "Total stockholders' equity 2021",
              "value": "337,118,000"
            },
            {
              "key": "Total liabilities and stockholders' equity 2022",
              "value": "307,502,000"
            },
            {
              "key": "Total liabilities and stockholders' equity 2021",
              "value": "377,100,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 83,
          "title": "Revenue and Operating Results Comparison 2021-2022",
          "data": [
            {
              "key": "Product revenue",
              "value": "20,425,000"
            },
            {
              "key": "Service and other revenue",
              "value": "7,377,000"
            },
            {
              "key": "Total revenue",
              "value": "27,802,000"
            },
            {
              "key": "Cost of product revenue",
              "value": "15,966,000"
            },
            {
              "key": "Cost of service and other revenue",
              "value": "5,891,000"
            },
            {
              "key": "Total cost of revenue",
              "value": "21,857,000"
            },
            {
              "key": "Research and development",
              "value": "49,047,000"
            },
            {
              "key": "Selling, general and administrative",
              "value": "88,596,000"
            },
            {
              "key": "Total operating expenses",
              "value": "137,643,000"
            },
            {
              "key": "Loss from operations",
              "value": "-131,698,000"
            },
            {
              "key": "Net loss",
              "value": "-132,596,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 84,
          "title": "Consolidated Statements of Comprehensive Loss",
          "data": [
            {
              "key": "Net Loss",
              "value": "(132,596,000) in 2022, (72,435,000) in 2021"
            },
            {
              "key": "Other comprehensive loss:",
              "value": "N/A"
            },
            {
              "key": "Unrealized gain (loss) on investment securities",
              "value": "(548,000) in 2022, (539,000) in 2021"
            },
            {
              "key": "Foreign currency translation adjustments",
              "value": "(37,000) in 2022, N/A"
            },
            {
              "key": "Other comprehensive loss Total comprehensive loss",
              "value": "(585,000) in 2022, (539,000) in 2021"
            },
            {
              "key": "Other comprehensive loss Total comprehensive loss",
              "value": "(133,181,000) in 2022, (72,974,000) in 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 85,
          "title": "Stockholders' Equity Statement",
          "data": [
            {
              "key": "Balance at January 1, 2021",
              "value": "Total stockholders' equity: $35,082,000, Shares: 189953000, Additional paid-in capital: $178747000, Accumulated deficit: -$143684000"
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "Total stockholders' equity: $337118000, Shares: 289602000, Additional paid-in capital: $553747000, Accumulated deficit: -$216119000"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "Total stockholders' equity: $249398000, Shares: 297183000, Additional paid-in capital: $599207000, Accumulated deficit: -$348715000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 86,
          "title": "Statement of Cash Flows",
          "data": [
            {
              "key": "Operating Activities Net loss",
              "value": "-132596000"
            },
            {
              "key": "Operating Activities Depreciation and amortization",
              "value": "9621000"
            },
            {
              "key": "Operating Activities Stock-based compensation",
              "value": "22417000"
            },
            {
              "key": "Operating Activities Net cash used in operating activities",
              "value": "-124816000"
            },
            {
              "key": "Investing Activities Purigen acquisition",
              "value": "-31344000"
            },
            {
              "key": "Investing Activities Sale and maturities of securities",
              "value": "200888000"
            },
            {
              "key": "Investing Activities Net cash provided by investing activities",
              "value": "82767000"
            },
            {
              "key": "Financing Activities Proceeds from sale of common stock",
              "value": "23128000"
            },
            {
              "key": "Financing Activities Net cash provided by financing activities",
              "value": "23007000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 87,
          "title": "Statement of Cash Flows and Supplemental Disclosures",
          "data": [
            {
              "key": "Net increase (decrease) in cash, cash equivalents and restricted cash",
              "value": "-19,080,000"
            },
            {
              "key": "Cash, cash equivalents and restricted cash at beginning of period",
              "value": "24,571,000"
            },
            {
              "key": "Cash, cash equivalents and restricted cash at end of period",
              "value": "5,491,000"
            },
            {
              "key": "Cash and cash equivalents",
              "value": "5,091,000"
            },
            {
              "key": "Restricted cash",
              "value": "400,000"
            },
            {
              "key": "Total cash, cash equivalents and restricted cash at end of period",
              "value": "5,491,000"
            },
            {
              "key": "Cash paid for interest",
              "value": "298,000"
            },
            {
              "key": "Cash paid for operating lease liabilities",
              "value": "1,622,000"
            },
            {
              "key": "Fair value of common stock issued related to BioDiscovery acquisition",
              "value": "0"
            },
            {
              "key": "Contingent consideration related to BioDiscovery acquisition",
              "value": "0"
            },
            {
              "key": "Contingent consideration related to Purigen acquisition",
              "value": "12,970,000"
            },
            {
              "key": "Operating lease liabilities resulting from obtaining and modifying right-of-use assets",
              "value": "517,000"
            },
            {
              "key": "Transfer of instruments and servers from inventory into property and equipment, net",
              "value": "7,244,000"
            },
            {
              "key": "Property and equipment included in accounts payable",
              "value": "90,000"
            },
            {
              "key": "Forgiveness of PPP Loan",
              "value": "0"
            },
            {
              "key": "Stock issued for services",
              "value": "0"
            },
            {
              "key": "Warrant exercise pursuant to cashless exercise",
              "value": "0"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 93,
          "title": "Revenue Recognition and Performance Obligations",
          "data": [
            {
              "key": "Product Revenue",
              "value": "Sales of Saphyr system, related consumables, and software."
            },
            {
              "key": "Revenue from Diagnostic Testing",
              "value": "Revenue includes diagnostics testing services, license maintenance agreements, software hosting, support, repair, and extended warranties."
            },
            {
              "key": "Revenue Recognized Over-time (2022)",
              "value": "Rental revenue: $0.4 million; Software revenue: $0.4 million; Service revenue: $0.7 million."
            },
            {
              "key": "Estimated Future Revenue",
              "value": "$1.0 million from unsatisfied performance obligations, to be recognized approximately 87.4% in 2023."
            },
            {
              "key": "Warranty Expense (2022)",
              "value": "Totaled $1.0 million."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 94,
          "title": "Financial Performance Overview",
          "data": [
            {
              "key": "Revenue for 2022",
              "value": "$0.7 million"
            },
            {
              "key": "Revenue for 2021",
              "value": "$0.4 million"
            },
            {
              "key": "Cost of Revenue Description",
              "value": "Cost includes raw materials, freight, salaries, and direct costs related to product revenue."
            },
            {
              "key": "Research and Development Costs",
              "value": "Expensed as incurred."
            },
            {
              "key": "Stock-based Compensation Approach",
              "value": "Recognized net of forfeitures on a straight-line basis over the vesting period."
            },
            {
              "key": "Income Tax Accounting Method",
              "value": "Asset and liability method recognizing deferred tax assets and liabilities."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 95,
          "title": "Net Loss Per Share",
          "data": [
            {
              "key": "Basic net loss per share",
              "value": "Calculated by dividing the net loss by the weighted-average number of common shares outstanding."
            },
            {
              "key": "Diluted net loss per share",
              "value": "Calculated by dividing the net loss by the weighted-average number of common shares and common share equivalents."
            },
            {
              "key": "Common share equivalents",
              "value": "Only included when their effect is dilutive."
            },
            {
              "key": "Potentially dilutive securities",
              "value": "Excluded from diluted net loss computation as they would be anti-dilutive."
            },
            {
              "key": "Total potentially dilutive securities",
              "value": "28,764,000 for 2022, 22,778,000 for 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 95,
          "title": "Equity Instruments Comparison Table",
          "data": [
            {
              "key": "Common stock options 2022",
              "value": "4,356,000"
            },
            {
              "key": "Common stock options 2021",
              "value": "4,356,000"
            },
            {
              "key": "Unvested restricted stock 2022",
              "value": "_"
            },
            {
              "key": "Unvested restricted stock 2021",
              "value": "5,006,000"
            },
            {
              "key": "RSUs 2022",
              "value": "96,000"
            },
            {
              "key": "RSUs 2021",
              "value": "361,000"
            },
            {
              "key": "PSUs 2022",
              "value": "290,000"
            },
            {
              "key": "PSUs 2021",
              "value": "290,000"
            },
            {
              "key": "Total 2022",
              "value": "28,764,000"
            },
            {
              "key": "Total 2021",
              "value": "22,778,000"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 96,
          "title": "Revenue from Contracts with Customers",
          "data": [
            {
              "key": "Instruments",
              "value": "Instruments"
            },
            {
              "key": "2022",
              "value": "8,567,000"
            },
            {
              "key": "2021",
              "value": "5,887,000"
            },
            {
              "key": "Instruments",
              "value": "Consumables"
            },
            {
              "key": "2022",
              "value": "6,731,000"
            },
            {
              "key": "2021",
              "value": "5,808,000"
            },
            {
              "key": "Instruments",
              "value": "Software"
            },
            {
              "key": "2022",
              "value": "5,127,000"
            },
            {
              "key": "2021",
              "value": "991,000"
            },
            {
              "key": "Instruments",
              "value": "Total product revenue"
            },
            {
              "key": "2022",
              "value": "20,425,000"
            },
            {
              "key": "2021",
              "value": "12,686,000"
            },
            {
              "key": "Instruments",
              "value": "Services and other Total revenue"
            },
            {
              "key": "2022",
              "value": "7,377,000"
            },
            {
              "key": "row2",
              "value": "27,802,000"
            },
            {
              "key": "2021",
              "value": "5,295,000"
            },
            {
              "key": "row2",
              "value": "17,981,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 96,
          "title": "Regional Revenue Distribution 2021-2022",
          "data": [
            {
              "key": "region",
              "value": "Americas"
            },
            {
              "key": "2022_amount",
              "value": "13862000"
            },
            {
              "key": "2022_percentage",
              "value": "50%"
            },
            {
              "key": "2021_amount",
              "value": "9329000"
            },
            {
              "key": "2021_percentage",
              "value": "52%"
            },
            {
              "key": "region",
              "value": "EMEA"
            },
            {
              "key": "2022_amount",
              "value": "8960000"
            },
            {
              "key": "2022_percentage",
              "value": "32%"
            },
            {
              "key": "2021_amount",
              "value": "5604000"
            },
            {
              "key": "2021_percentage",
              "value": "31%"
            },
            {
              "key": "region",
              "value": "Asia Pacific"
            },
            {
              "key": "2022_amount",
              "value": "4980000"
            },
            {
              "key": "2022_percentage",
              "value": "18%"
            },
            {
              "key": "2021_amount",
              "value": "3048000"
            },
            {
              "key": "2021_percentage",
              "value": "17%"
            },
            {
              "key": "region",
              "value": "Total"
            },
            {
              "key": "2022_amount",
              "value": "27802000"
            },
            {
              "key": "2022_percentage",
              "value": "100%"
            },
            {
              "key": "2021_amount",
              "value": "17981000"
            },
            {
              "key": "2021_percentage",
              "value": "100%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 99,
          "title": "Financial Instruments Maturity and Unrealized Gains/Losses Analysis",
          "data": [
            {
              "key": "Total amortized cost for commercial paper",
              "value": "$100.9M"
            },
            {
              "key": "Total unrealized loss for commercial paper",
              "value": "-$69,000"
            },
            {
              "key": "Total amortized cost for corporate notes/bonds",
              "value": "$125.7M"
            },
            {
              "key": "Total unrealized loss for corporate notes/bonds",
              "value": "-$470,000"
            },
            {
              "key": "Total fair value of the portfolio",
              "value": "$106,114,000"
            },
            {
              "key": "Total unrealized losses in total portfolio",
              "value": "-$1,087,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 99,
          "title": "Securities Fair Value and Unrealized Losses",
          "data": [
            {
              "key": "Total fair value of securities",
              "value": "$226,041,000"
            },
            {
              "key": "Total unrealized loss",
              "value": "-$539,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 101,
          "title": "Amortization Expense for Intangible Assets",
          "data": [
            {
              "key": "Amortization expense 2022",
              "value": "$5.8 million"
            },
            {
              "key": "Amortization expense 2021",
              "value": "$1.4 million"
            },
            {
              "key": "Future amortization 2023",
              "value": "$7.169 million"
            },
            {
              "key": "Future amortization 2024",
              "value": "$7.169 million"
            },
            {
              "key": "Future amortization 2025",
              "value": "$7.064 million"
            },
            {
              "key": "Future amortization 2026",
              "value": "$5.737 million"
            },
            {
              "key": "Future amortization 2027",
              "value": "$1.473 million"
            },
            {
              "key": "Future amortization thereafter",
              "value": "$12.429 million"
            },
            {
              "key": "Total future amortization",
              "value": "$41.041 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 101,
          "title": "Accrued Expenses",
          "data": [
            {
              "key": "Compensation expenses current",
              "value": "$7.002 million"
            },
            {
              "key": "Compensation expenses previous",
              "value": "$4.529 million"
            },
            {
              "key": "Taxes payable current",
              "value": "$0.825 million"
            },
            {
              "key": "Taxes payable previous",
              "value": "$0.677 million"
            },
            {
              "key": "Insurance current",
              "value": "$0.613 million"
            },
            {
              "key": "Insurance previous",
              "value": "$1.011 million"
            },
            {
              "key": "Professional fees current",
              "value": "$0.210 million"
            },
            {
              "key": "Professional fees previous",
              "value": "$0.288 million"
            },
            {
              "key": "Warranty liabilities current",
              "value": "$0.489 million"
            },
            {
              "key": "Warranty liabilities previous",
              "value": "$0.175 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 109,
          "title": "Domestic and Foreign Financial Performance Comparison",
          "data": [
            {
              "key": "Domestic Loss 2021",
              "value": "-78,356,000"
            },
            {
              "key": "Domestic Loss 2022",
              "value": "-131,237,000"
            },
            {
              "key": "Foreign Income 2021",
              "value": "204,000"
            },
            {
              "key": "Foreign Income 2022",
              "value": "525,000"
            },
            {
              "key": "Total Loss Before Taxes 2021",
              "value": "-78,152,000"
            },
            {
              "key": "Total Loss Before Taxes 2022",
              "value": "-130,712,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 109,
          "title": "Income Tax Provision Comparison 2021-2022",
          "data": [
            {
              "key": "Federal Provision 2021",
              "value": "—"
            },
            {
              "key": "Federal Provision 2022",
              "value": "—"
            },
            {
              "key": "Foreign Provision 2021",
              "value": "39,000"
            },
            {
              "key": "Foreign Provision 2022",
              "value": "123,000"
            },
            {
              "key": "State and Local Provision 2021",
              "value": "21,000"
            },
            {
              "key": "State and Local Provision 2022",
              "value": "1,000"
            },
            {
              "key": "Total Current Tax Provision 2021",
              "value": "60,000"
            },
            {
              "key": "Total Current Tax Provision 2022",
              "value": "124,000"
            },
            {
              "key": "Deferred Federal 2021",
              "value": "(4,055,000)"
            },
            {
              "key": "Deferred Federal 2022",
              "value": "(277,000)"
            },
            {
              "key": "Total Deferred Provision 2021",
              "value": "(5,777,000)"
            },
            {
              "key": "Total Deferred Provision 2022",
              "value": "1,760,000"
            },
            {
              "key": "Overall Tax Provision 2021",
              "value": "(5,717,000)"
            },
            {
              "key": "Overall Tax Provision 2022",
              "value": "1,884,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 168,
          "title": "Lease Agreement Summary",
          "data": [
            {
              "key": "Rent Commencement Date",
              "value": "Date tenant begins paying rent."
            },
            {
              "key": "Additional Rent",
              "value": "Additional costs agreed upon in the Lease."
            },
            {
              "key": "Lease Term",
              "value": "Duration of the lease during which payments are made."
            },
            {
              "key": "Base Rent",
              "value": "Primary rental amount before additional costs."
            },
            {
              "key": "Operating Expenses",
              "value": "Costs incurred by Landlord for property management."
            },
            {
              "key": "Property Taxes",
              "value": "Taxes incurred during the Lease term."
            },
            {
              "key": "Monthly Rent Payment",
              "value": "Payments tenant makes monthly before the due date."
            },
            {
              "key": "Proration",
              "value": "Adjustment of rent based on the length of the lease term."
            },
            {
              "key": "Tenant Inspection Rights",
              "value": "Tenant's rights to review landlord's books within certain conditions."
            },
            {
              "key": "Year-End Statement",
              "value": "Annual financial statement of costs and payments."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 238,
          "title": "Certification of Financial Reporting",
          "data": [
            {
              "key": "Certifier",
              "value": "Christopher Stewart"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer (Principal Financial and Accounting Officer)"
            },
            {
              "key": "Report Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Company",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Compliance",
              "value": "Reviewed Annual Report on Form 10-K"
            },
            {
              "key": "Material Fact Statement",
              "value": "The report does not contain any untrue statement of a material fact."
            },
            {
              "key": "Financial Condition Statement",
              "value": "The financial statements fairly present the financial condition and results of operations."
            },
            {
              "key": "Control Procedures",
              "value": "Established and maintained disclosure controls and procedures."
            },
            {
              "key": "Internal Control Evaluation",
              "value": "Evaluated the effectiveness of internal controls over financial reporting."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 67,
          "title": "Dividend Policy",
          "data": [
            {
              "key": "Dividend Declaration",
              "value": "We have never declared or paid cash dividends on our capital stock."
            },
            {
              "key": "Future Earnings Retention",
              "value": "We currently intend to retain any future earnings for use in the operation of our business and do not intend to declare or pay any cash dividends in the foreseeable future."
            },
            {
              "key": "Future Determination on Dividends",
              "value": "Any future determination to pay dividends on our capital stock would be at the discretion of our board of directors, subject to applicable laws, and would depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 221,
          "title": "Amended and Restated Exclusive License Agreement with Equity",
          "data": [
            {
              "key": "Agreement Date",
              "value": "8/3/2021"
            },
            {
              "key": "Appendices",
              "value": "Appendix A – Milestones, Appendix B – Earned Royalty Report, Appendix C – Developing Nations, Appendix D – Progress Report, Appendix E – Equity Purchase Rights, Appendix F – Patent List"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 121,
          "title": "Description of Securities",
          "data": [
            {
              "key": "Common Stock Authorization",
              "value": "400,000,000 shares of common stock, par value $0.0001 per share"
            },
            {
              "key": "Preferred Stock Authorization",
              "value": "10,000,000 shares of preferred stock, par value $0.0001 per share"
            },
            {
              "key": "Voting Rights",
              "value": "One vote per share held, no cumulative voting rights"
            },
            {
              "key": "Classification of Board of Directors",
              "value": "Classified board divided into three classes with staggered three-year terms"
            },
            {
              "key": "Dividend Entitlement",
              "value": "Entitled to receive dividends as declared by the board of directors"
            },
            {
              "key": "Liquidation Rights",
              "value": "Share ratably in the net assets after payment of debts and liabilities"
            },
            {
              "key": "Preemptive Rights",
              "value": "No preemptive rights for holders of common stock"
            },
            {
              "key": "Issuance of Preferred Stock",
              "value": "Board may authorize issuance of preferred stock that could affect voting power"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 186,
          "title": "Analysis of Current Assets and Total Assets",
          "data": [
            {
              "key": "Definition of Cash and Cash Equivalents",
              "value": "Cash and Cash Equivalents are rated A-1 or better by S&P or P-1 or better by Moody’s; maturities shall not exceed one year from the date of calculation."
            },
            {
              "key": "Definition of Current Assets",
              "value": "All assets anticipated to be converted to Cash within 12 months, computed in accordance with GAAP."
            },
            {
              "key": "Definition of Total Assets",
              "value": "All tangible assets of Tenant, not including intangible assets such as goodwill."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 226,
          "title": "Equity Purchase Rights",
          "data": [
            {
              "key": "Purchase Right",
              "value": "In any private offering of Purigen's equity securities for cash, Stanford may purchase up to [***]%."
            },
            {
              "key": "Expiration of Right",
              "value": "Expires following the first round of bona fide equity investment from a single investor or group that includes at least one venture capital, corporate or institutional investor."
            },
            {
              "key": "Size of Investment",
              "value": "Must be at least $[***] or involves sale of at least [***]% of shares outstanding."
            },
            {
              "key": "Future Offerings Limitation",
              "value": "Stanford may maintain its pro rata ownership interest in Purigen on a Fully-Diluted Basis."
            },
            {
              "key": "Notice Terms",
              "value": "Purigen will notify Stanford of the terms of the offering including investor names, share allocation, pre- and post-financing capitalization table."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 5,
          "title": "Risk Factor Summary",
          "data": [
            {
              "key": "Risk relating to limited commercial history",
              "value": "We are an early commercial-stage company and have a limited commercial history, which may make it difficult to evaluate our current business and predict our future performance."
            },
            {
              "key": "Risk of recurring net losses",
              "value": "We have incurred recurring net losses since we were formed and expect to incur losses in the future. We cannot be certain that we will achieve or sustain profitability."
            },
            {
              "key": "Fluctuation in operating results",
              "value": "Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which makes our future operating results difficult to predict and could cause the market price of our securities to decline substantially."
            },
            {
              "key": "Uncertain capital needs",
              "value": "Our future capital needs are uncertain and we may require additional funding in the future to advance the commercialization of our products and technologies."
            },
            {
              "key": "Impact of geopolitical and macroeconomic factors",
              "value": "Unfavorable geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations."
            },
            {
              "key": "Effect of COVID-19 pandemic",
              "value": "The COVID-19 pandemic has materially affected and could continue to materially affect our operations globally."
            },
            {
              "key": "Risk of strategic transactions",
              "value": "Acquisitions, joint ventures and other strategic transactions could disrupt or harm our business."
            },
            {
              "key": "Dependency on market acceptance",
              "value": "If our products or technologies fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected."
            },
            {
              "key": "Impact of research spending on product sales",
              "value": "Sales will depend on levels of research and development spending by institutions, which could limit demand for our technologies."
            },
            {
              "key": "Risk in product development and launch management",
              "value": "If we do not successfully manage the development and launch of new products, our financial results could be adversely affected."
            },
            {
              "key": "Dependency on customer base",
              "value": "Our success is dependent upon our ability to further penetrate our existing customer base and retain customers from acquired businesses."
            },
            {
              "key": "Market size risk",
              "value": "The size of the markets for our products may be smaller than estimated."
            },
            {
              "key": "Regulatory risks of RUO products",
              "value": "If the FDA determines that our RUO products are medical devices, we may need regulatory clearances, which could adversely affect our business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 6,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Intellectual Property Risk",
              "value": "If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over our competitors and potential competitors, and our business may be harmed."
            },
            {
              "key": "Securities Price Volatility",
              "value": "The price of our securities has been and may in the future be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 27,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Risk of Limited Commercial History",
              "value": "We are an early commercial-stage company with limited commercial history, which complicates the evaluation of our current business and prediction of future performance."
            },
            {
              "key": "Increased Headcount Risks",
              "value": "Significantly increased headcount due to acquisitions and expansion in sales, marketing, and R&D has raised operating costs, complicating revenue and performance evaluations."
            },
            {
              "key": "General Early Commercial-Stage Risks",
              "value": "Encountering risks associated with scaling infrastructure, increasing organization size, and integrating acquired businesses."
            },
            {
              "key": "Revenue Composition Changes",
              "value": "Changes in business model and acquisitions affect revenue composition and predictability of future performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 28,
          "title": "Risk Factors and Financial Performance",
          "data": [
            {
              "key": "Recurring Net Losses",
              "value": "We have incurred recurring net losses since we were formed and expect to incur losses in the future."
            },
            {
              "key": "Net Losses 2022",
              "value": "Net losses of $132.6 million in 2022."
            },
            {
              "key": "Net Losses 2021",
              "value": "Net losses of $72.4 million in 2021."
            },
            {
              "key": "Cash Used in Operations 2022",
              "value": "Cash used in operations was $124.8 million for the year ended December 31, 2022."
            },
            {
              "key": "Cash Used in Operations 2021",
              "value": "Cash used in operations was $71.9 million for the year ended December 31, 2021."
            },
            {
              "key": "Accumulated Deficit",
              "value": "As of December 31, 2022, we had an accumulated deficit of $348.7 million."
            },
            {
              "key": "Future Profitability",
              "value": "We cannot predict if we will be profitable in the near future or at all."
            },
            {
              "key": "Expenditures Leading to Losses",
              "value": "Expect significant additional funds for expansion and research and development."
            },
            {
              "key": "Stock-Based Compensation",
              "value": "Expect significant increases in stock-based compensation expense due to higher valuations."
            },
            {
              "key": "Legal and Compliance Expenses",
              "value": "Incurring significant legal and accounting expenses due to compliance requirements as a public company."
            },
            {
              "key": "Market Risk Factors",
              "value": "Factors influencing financial performance include market acceptance, competition, product development, and others."
            },
            {
              "key": "Fluctuations in Operating Results",
              "value": "Quarterly and annual operating results might continue to fluctuate."
            },
            {
              "key": "Stock Price Volatility",
              "value": "Stock price might decline if revenue or operating results do not meet expectations."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 30,
          "title": "Future Funding Requirements and Risks",
          "data": [
            {
              "key": "Future Funding Influences",
              "value": "The future funding requirements will be influenced by many factors, including operational and regulatory costs."
            },
            {
              "key": "Potential Risks",
              "value": "Market acceptance of products, research and development costs, supply chain disruptions, geopolitical developments."
            },
            {
              "key": "Capital Raising Risks",
              "value": "The ways to raise capital carry potential risks including dilution for shareholders."
            },
            {
              "key": "Economic Conditions",
              "value": "Global economic conditions may worsen with disruptions in credit and financial markets."
            },
            {
              "key": "Impact of Insufficient Funds",
              "value": "If unable to obtain sufficient funds, delays in development or commercialization of technologies may occur."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 31,
          "title": "Economic and Supply Chain Risks Due to Geopolitical Conditions",
          "data": [
            {
              "key": "Authorized Shares Issue",
              "value": "Possible limitations on issuing new shares of common stock if authorized shares cannot be increased."
            },
            {
              "key": "Operational Impact",
              "value": "Financial condition may be negatively affected by inability to issue shares."
            },
            {
              "key": "Geopolitical and Macroeconomic Challenges",
              "value": "Risks due to inflation, interest rates, and geopolitical developments affecting business."
            },
            {
              "key": "Supply Chain Disruption",
              "value": "Potential disruptions in product distribution channels and material shortages."
            },
            {
              "key": "Impact of the Russia-Ukraine Conflict",
              "value": "Ongoing conflict may lead to increased costs, supply chain continuity issues, and decreased consumer spending."
            },
            {
              "key": "Global Economic Uncertainty",
              "value": "Business operations may be adversely affected by market conditions worldwide."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 32,
          "title": "COVID-19 Pandemic Effects",
          "data": [
            {
              "key": "Impact on Operations",
              "value": "The COVID-19 pandemic has materially affected and could continue to affect operations globally."
            },
            {
              "key": "Effects on Partners",
              "value": "Health crises could adversely affect research partners and third parties."
            },
            {
              "key": "Supply Chain Disruption",
              "value": "Significant disruptions have occurred in supply chains and business activities."
            },
            {
              "key": "Remote Work Policies",
              "value": "Continued remote work policies have materially affected business operations."
            },
            {
              "key": "Health Risks",
              "value": "Employees may face health risks from COVID-19 exposure."
            },
            {
              "key": "Long-term Effects",
              "value": "The pandemic may present long-term operational and cultural challenges."
            },
            {
              "key": "Legislative Changes",
              "value": "Changes in tax laws or regulations could adversely affect financial performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 33,
          "title": "Tax Implications and Accounting Assumptions",
          "data": [
            {
              "key": "Tax Net Operating Loss Carryforwards",
              "value": "Federal: $463.8 million, State: $197.6 million"
            },
            {
              "key": "Federal Tax Loss Carryforwards Non-Expiring",
              "value": "$282.9 million"
            },
            {
              "key": "Limitations on Utilization of Federal Tax Loss Carryforwards",
              "value": "Limited to 80% of taxable income"
            },
            {
              "key": "State Tax Loss Carryforwards Expiration",
              "value": "Begins in 2023"
            },
            {
              "key": "Federal Research Credit Carryforwards",
              "value": "$9.4 million, expiring in 2027 unless utilized"
            },
            {
              "key": "California Research Credit Carryforwards",
              "value": "$8.8 million, carry forward indefinitely"
            },
            {
              "key": "Impact of Ownership Changes on Tax Benefits",
              "value": "Potential limitations due to ownership changes"
            },
            {
              "key": "Conformity with Federal Tax Legislation",
              "value": "Uncertain for various states"
            },
            {
              "key": "Risks from Strategic Acquisitions and Joint Ventures",
              "value": "Potential disruptions and challenges in integration"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Risk Factors Related to Dependence on Key Opinion Leaders and Capital Financing",
          "data": [
            {
              "key": "Key Opinion Leaders Influence",
              "value": "The scientific community is comprised of early adopters who influence the rest of the community."
            },
            {
              "key": "Challenges in Technology Adoption",
              "value": "Inability to motivate leading researchers may slow acceptance and adoption of our systems."
            },
            {
              "key": "Negative Publications Risk",
              "value": "Risk that researchers may produce negative findings about technologies due to uncontrollable factors."
            },
            {
              "key": "Equity Financing Risks",
              "value": "Equity issuances may cause dilution to stockholders or restrict operations."
            },
            {
              "key": "Debt Financing Limitations",
              "value": "Debt financing may include agreements limiting specific actions."
            },
            {
              "key": "Public Offerings Summary",
              "value": "Completed public offerings for approximately 71.7 million shares yielding $331.8 million."
            },
            {
              "key": "Cowen Facility Details",
              "value": "At-the-market facility with Cowen allows sales of shares up to $350 million, amended to $200 million."
            },
            {
              "key": "Dilution from Shares Issuance",
              "value": "Significant sale of capital stock or use of equity in transactions leads to dilution."
            },
            {
              "key": "Employee Equity Plans Dilution",
              "value": "Employee equity benefit plans may cause significant dilution to existing stockholders."
            },
            {
              "key": "Current Share Awards Summary",
              "value": "8.6 million shares available under various equity plans."
            },
            {
              "key": "Executive Options Granted",
              "value": "Options granted for 3.3 million shares and 0.7 million RSUs on February 15, 2023."
            },
            {
              "key": "Bionano Laboratories Revenue Concerns",
              "value": "Insufficient revenue generated by Bionano Laboratories to sustain operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 40,
          "title": "Supply Chain Risks and Manufacturing Challenges",
          "data": [
            {
              "key": "Manufacturing Challenges",
              "value": "We have experienced manufacturing problems or delays that could limit the growth of our revenue or increase our losses."
            },
            {
              "key": "Supplier Reliability",
              "value": "We rely on a limited number of suppliers, which increases vulnerability to supply chain disruptions."
            },
            {
              "key": "Impact of Events",
              "value": "Natural or man-made disasters could affect our ability to perform testing services and analyze samples."
            },
            {
              "key": "Insurance Limitations",
              "value": "Our insurance may not cover all risks associated with business disruption."
            },
            {
              "key": "Rebuilding Challenges",
              "value": "Rebuilding facilities and qualifying new suppliers may be time-consuming and costly."
            },
            {
              "key": "Supplier Contracts",
              "value": "Most suppliers do not have long-term contracts, leading to risks in securing necessary materials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 41,
          "title": "Risk Factors related to Supply Chain and Product Liability",
          "data": [
            {
              "key": "Supply Chain Risk",
              "value": "Components sourced from limited or sole suppliers pose risk if supplier is lost; may affect ability to sell and deliver."
            },
            {
              "key": "Inventory Management",
              "value": "Maintain higher inventories to mitigate supply risks; possibility of holding excess due to supplier switch."
            },
            {
              "key": "Product Liability",
              "value": "Risk of liability claims if products fail to perform as designed; could damage reputation and financial condition."
            },
            {
              "key": "Insurance Limitations",
              "value": "Uncertainty whether product liability insurance will cover potential claims."
            },
            {
              "key": "International Distribution Risks",
              "value": "Reliance on distributors for sales outside the US; potential limitations for international revenue growth."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 44,
          "title": "Cybersecurity Risks and Data Privacy Obligations",
          "data": [
            {
              "key": "Cybersecurity Threats",
              "value": "Increasing prevalence and severity of threats by organized criminal actors and nation-states."
            },
            {
              "key": "Potential Impact",
              "value": "Significant interruptions in operations, loss of sensitive data, reputational harm, and diversion of funds."
            },
            {
              "key": "Extortion Payment Issues",
              "value": "Extortion payments may not be feasible due to legal or regulatory constraints."
            },
            {
              "key": "Supply Chain Attacks",
              "value": "Increased frequency and severity, risk of third-party compromise."
            },
            {
              "key": "Remote Work Risks",
              "value": "Increased exposure of IT systems and data."
            },
            {
              "key": "Business Transaction Risks",
              "value": "Acquisitions might introduce vulnerabilities."
            },
            {
              "key": "Potential Consequences of Incidents",
              "value": "Could include unauthorized data access, operational disruptions, reputational damage, and financial loss."
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Failure to comply with data privacy obligations could result in investigations, fines, and business disruption."
            },
            {
              "key": "Data Processing Obligations",
              "value": "Involves compliance with various data privacy and security laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 46,
          "title": "Assessment of Risks Related to Environmental, Health, and Safety Regulations",
          "data": [
            {
              "key": "risk_type",
              "value": "Regulatory Risks"
            },
            {
              "key": "description",
              "value": "Failure to comply with environmental, health and safety laws and regulations could lead to fines or penalties."
            },
            {
              "key": "impact",
              "value": "Potentially material adverse effect on business success."
            },
            {
              "key": "competitors",
              "value": "Significant competition in life sciences research and diagnostic markets."
            },
            {
              "key": "environmental_concerns",
              "value": "Handling, storage, and disposal of hazardous materials."
            },
            {
              "key": "liability",
              "value": "Potential liability for contamination or injury."
            },
            {
              "key": "insurance_coverage",
              "value": "Workers’ compensation insurance maintained; lacks coverage for environmental liability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 49,
          "title": "Billing Complexities and Third-Party Payor Challenges",
          "data": [
            {
              "key": "Billing Complexities Impact",
              "value": "Failure or delays in billing system changes could negatively affect collection rates and revenue."
            },
            {
              "key": "Regulatory Requirements",
              "value": "Providers must report and return overpayments under ACA regulations."
            },
            {
              "key": "Impacts of Third-Party Payors",
              "value": "Inadequate coverage and reimbursement from third-party payors could harm business."
            },
            {
              "key": "Process Complexity",
              "value": "Negotiating coverage and reimbursement agreements with payors is time-consuming and does not guarantee favorable outcomes."
            },
            {
              "key": "Audit Risks",
              "value": "Third-party payors conduct audits and may recoup funds years later, impacting revenue."
            },
            {
              "key": "Changing Policies",
              "value": "Coverage policies and reimbursement rates from payors can change unexpectedly."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 59,
          "title": "Changes in patent laws and their impact on intellectual property",
          "data": [
            {
              "key": "Patent Law Changes",
              "value": "Changes in patent laws or patent jurisprudence could diminish the value of patents."
            },
            {
              "key": "America Invents Act (AIA)",
              "value": "Transition to a 'first-to-file' system affecting patent grants."
            },
            {
              "key": "Patent Enforcement Complexity",
              "value": "Obtaining and enforcing patents involves technological and legal complexities, making it costly and uncertain."
            },
            {
              "key": "Challenges Post-AIA",
              "value": "Third-parties may more easily challenge patents, potentially invalidating claims once deemed valid."
            },
            {
              "key": "Judicial Interpretations",
              "value": "Recent Supreme Court rulings may narrow patent protection and weaken patent owners' rights."
            },
            {
              "key": "Non-compliance Risks",
              "value": "Non-compliance with patent requirements could lead to loss of patent rights."
            },
            {
              "key": "Trademark and Trade Name Risks",
              "value": "Challenges to trademarks could impair brand recognition and competitiveness."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 60,
          "title": "Risk Factors Related to Third-Party Software and Intellectual Property Rights",
          "data": [
            {
              "key": "Open Source Software Risks",
              "value": "Possible future use of third-party open source software components; risks include restrictions on commercialization, required disclosures, and competitive disadvantages."
            },
            {
              "key": "Liability Limitations",
              "value": "Third-party software may impose limitations on liability, which could harm the company's reputation."
            },
            {
              "key": "Intellectual Property Limitations",
              "value": "Uncertainty about the future protection of intellectual property rights; limitations may reduce business competitiveness."
            },
            {
              "key": "Competition from Similar Technologies",
              "value": "Potential for competitors to develop similar technologies that do not infringe on patents."
            },
            {
              "key": "Patent Application Challenges",
              "value": "Pending patent applications may not lead to fruitful outcomes such as issued patents or claims."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Risks related to ownership of our securities",
          "data": [
            {
              "key": "Volatility of securities price",
              "value": "The price of our securities has been and may in the future be volatile, and you could lose all or part of your investment."
            },
            {
              "key": "Range of stock price",
              "value": "The daily closing market price for our common stock has varied significantly, ranging between a high of $3.60 and a low of $1.23 in the last 12 months."
            },
            {
              "key": "Factors affecting stock price volatility",
              "value": "Factors such as commercial progress, changes in laws, adverse developments, increased competition, and more may affect our stock price."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 62,
          "title": "Market Risks and Legal Liabilities",
          "data": [
            {
              "key": "Market Valuations Changes",
              "value": "Changes in the market valuations of similar companies."
            },
            {
              "key": "Equity Market Performance",
              "value": "Overall performance of the equity markets."
            },
            {
              "key": "Debt or Equity Securities Issuance",
              "value": "Issuances of debt or equity securities."
            },
            {
              "key": "Securities Trading Volume",
              "value": "Sales of our securities by us or our stockholders in the future; trading volume of our securities."
            },
            {
              "key": "Accounting Practices Changes",
              "value": "Changes in accounting practices."
            },
            {
              "key": "Internal Controls Ineffectiveness",
              "value": "Ineffectiveness of our internal controls."
            },
            {
              "key": "Data Breaches",
              "value": "Data breaches of our company, providers, vendors or customers."
            },
            {
              "key": "Regulatory Developments",
              "value": "Regulatory or legal developments in the United States and other countries."
            },
            {
              "key": "Proprietary Rights Disputes",
              "value": "Disputes or other developments relating to proprietary rights."
            },
            {
              "key": "Significant Lawsuits",
              "value": "Significant lawsuits, including patent or stockholder litigation."
            },
            {
              "key": "Market Conditions",
              "value": "General political and economic conditions."
            },
            {
              "key": "Natural Disasters Impact",
              "value": "Natural disasters, infectious diseases, conflict, including ongoing military conflicts."
            },
            {
              "key": "Economic Conditions",
              "value": "General economic conditions, including economic slowdowns, inflation, rising interest rates."
            },
            {
              "key": "Stock Price Volatility",
              "value": "Stock price volatility leading to securities litigation risks."
            },
            {
              "key": "Nasdaq Listing Compliance",
              "value": "Risks associated with compliance to Nasdaq continued listing requirements."
            },
            {
              "key": "Delisting Consequences",
              "value": "Negative implications from potential delisting from Nasdaq."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 64,
          "title": "Risk Factors Related to Securities and Changes in Control",
          "data": [
            {
              "key": "Summary of Risk",
              "value": "Investors may find securities less attractive due to reliance on scaled disclosure requirements, potentially increasing market volatility."
            },
            {
              "key": "Share Sales Impact",
              "value": "Substantial sales of common stock may significantly impact market price."
            },
            {
              "key": "Registration Statements",
              "value": "Filed registration statements on Form S-8 for 36,796,518 shares subject to options."
            },
            {
              "key": "Anti-takeover Provisions",
              "value": "Provisions may delay or prevent changes in control, impacting stockholder ability to alter management."
            },
            {
              "key": "Delaware Corporate Law",
              "value": "Governed by Section 203, prohibiting certain business combinations with significant shareholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 66,
          "title": "General Risk Factors",
          "data": [
            {
              "key": "Research dependence",
              "value": "If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our securities and trading volume could decline."
            },
            {
              "key": "Limited research coverage",
              "value": "As a newer public company, we have only limited research coverage on our company by equity research analysts."
            },
            {
              "key": "Downgrades impact",
              "value": "If one or more of the analysts who covers us downgrades our securities or publishes inaccurate or unfavorable research about our business, the price of our securities may decline."
            },
            {
              "key": "Sales of common stock",
              "value": "Future sales of substantial amounts of our common stock could adversely affect the market price of our common stock."
            },
            {
              "key": "Activist stockholders",
              "value": "Our business could be negatively affected as a result of actions of activist stockholders."
            },
            {
              "key": "Proxy contests",
              "value": "A proxy contest would require us to incur significant legal and advisory fees and could divert attention from our business strategy."
            },
            {
              "key": "Litigation risks",
              "value": "We may choose to initiate, or may become subject to, litigation as a result of the proxy contest."
            },
            {
              "key": "Market fluctuations",
              "value": "The stock markets have from time to time experienced significant price and volume fluctuations."
            },
            {
              "key": "Class action litigation",
              "value": "Securities class action litigation could divert our management’s attention and harm our business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 68,
          "title": "Risks and Uncertainties",
          "data": [
            {
              "key": "Risks described in",
              "value": "Part I, Item 1A Risk Factors"
            },
            {
              "key": "Economic potential for OGM in cytogenomics, discovery research and cell bioprocessing QC",
              "value": "$10.0 billion annually"
            },
            {
              "key": "Accrued net losses",
              "value": "$132.6 million for 2022, $72.4 million for 2021"
            },
            {
              "key": "Accumulated deficit as of December 31, 2022",
              "value": "$348.7 million"
            },
            {
              "key": "Concerns about going concern status",
              "value": "Substantial doubt about ability to continue as a going concern within 12 months"
            },
            {
              "key": "Macroeconomic risks",
              "value": "Ongoing conflict between Ukraine and Russia, related sanctions, COVID-19 effects, market inflation, supply chain disruptions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 78,
          "title": "Quantitative and Qualitative Disclosures About Market Risk",
          "data": [
            {
              "key": "Interest Rate Risk",
              "value": "We had approximately $5.1 million in cash and cash equivalents and $108.1 million in available for sale securities as of December 31, 2022. We do not expect anticipated changes in interest rates to have a material effect on our interest rate risk in future reporting periods."
            },
            {
              "key": "Foreign Currency Exchange Rate Risk",
              "value": "We do not currently participate in material foreign exchange hedging activities. As of December 31, 2022, we had minimal assets and liabilities denominated in foreign currencies and expect similar levels in the next 12 months."
            },
            {
              "key": "Inflation",
              "value": "We believe inflation has not had a material effect on our business, financial condition, or results of operations, as our cost of revenue was not significantly impacted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 81,
          "title": "Critical Audit Matter Regarding Fair Value Determination",
          "data": [
            {
              "key": "Critical Audit Matter",
              "value": "Determination of the fair values of developed technology and contingent consideration."
            },
            {
              "key": "Assumptions Used",
              "value": "Revenue and expense forecasts, discount rate, probability of achieving milestones."
            },
            {
              "key": "Considerations",
              "value": "Subjective and require significant judgment."
            },
            {
              "key": "Challenges",
              "value": "Challenging auditor judgment due to nature and extent of audit effort."
            },
            {
              "key": "Procedures Performed",
              "value": "Assessing reasonableness of forecasts, evaluating milestones, utilizing specialized personnel."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 176,
          "title": "Lease Agreement - Indemnification and Insurance",
          "data": [
            {
              "key": "Lease Term",
              "value": "not specified"
            },
            {
              "key": "Damage Estimate",
              "value": "more than two(2) months"
            },
            {
              "key": "Insurance Requirement",
              "value": "Workers' compensation, automobile liability, commercial general liability"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 199,
          "title": "EXHIBIT F Hazardous Substances Questionnaire",
          "data": [
            {
              "key": "Document Version",
              "value": "279330373 v2"
            },
            {
              "key": "Exhibit Title",
              "value": "EXHIBIT F"
            },
            {
              "key": "Questionnaire Type",
              "value": "Hazardous Substances"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Forward-Looking Statements",
          "data": [
            {
              "key": "context",
              "value": "This section discusses forward-looking statements and information within the Annual Report."
            },
            {
              "key": "risk_factors",
              "value": "Known and unknown risks, uncertainties, and assumptions that could affect the forward-looking statements."
            },
            {
              "key": "keywords",
              "value": "anticipate, believe, contemplate, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 9,
          "title": "Macroeconomic and Geopolitical Developments",
          "data": [
            {
              "key": "Risks",
              "value": "Adverse geopolitical and macroeconomic developments, such as lingering effects of COVID-19, the Ukraine-Russia conflict, and uncertain market conditions like inflation and supply chain disruptions."
            },
            {
              "key": "Impact",
              "value": "Potential material impact on business and financial results."
            },
            {
              "key": "Reference Section",
              "value": "Management’s Discussion and Analysis of Financial Condition and Results of Operations - Macroeconomic and Geopolitical Developments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 29,
          "title": "Impact of External Factors on Financial Performance and Growth Prospects",
          "data": [
            {
              "key": "Geopolitical Developments",
              "value": "impact of the conflict between Ukraine and Russia and related sanctions"
            },
            {
              "key": "Economic Developments",
              "value": "impact of COVID-19 pandemic, inflation, increased costs of goods, supply chain issues"
            },
            {
              "key": "Revenue Management",
              "value": "ability to manage revenue expectations and integrate new assets"
            },
            {
              "key": "Litigation and Investigative Outcomes",
              "value": "impact of ongoing litigations or governmental investigations on operations"
            },
            {
              "key": "Operating Expenses",
              "value": "significant fixed nature of operating expenses and impact of unexpected revenue shortfalls"
            },
            {
              "key": "Growth Management",
              "value": "ability to effectively manage anticipated growth and integrate new systems"
            },
            {
              "key": "Funding Needs",
              "value": "need for future funding to support commercialization and R&D efforts"
            },
            {
              "key": "Future Performance Indicators",
              "value": "importance of not relying on past performance as an indicator for future growth"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 90,
          "title": "Accounts Receivable Analysis",
          "data": [
            {
              "key": "Accounts receivable, trade (2022)",
              "value": "$7,315,000"
            },
            {
              "key": "Accounts receivable, trade (2021)",
              "value": "$5,624,000"
            },
            {
              "key": "Less allowance for doubtful accounts (2022)",
              "value": "-$293,000"
            },
            {
              "key": "Less allowance for doubtful accounts (2021)",
              "value": "-$690,000"
            },
            {
              "key": "Net Total (2022)",
              "value": "$7,022,000"
            },
            {
              "key": "Net Total (2021)",
              "value": "$4,934,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 91,
          "title": "Inventory Comparison 2021-2022",
          "data": [
            {
              "key": "Raw materials",
              "value": "$5,319,000"
            },
            {
              "key": "Work in process",
              "value": "$7,055,000"
            },
            {
              "key": "Finished goods",
              "value": "$17,387,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 91,
          "title": "Balance and Acquisition Activity 2020-2022",
          "data": [
            {
              "key": "Balance as of December 31, 2020",
              "value": "$7,173,000"
            },
            {
              "key": "Acquisitions",
              "value": "$48,987,000"
            },
            {
              "key": "Balance as of December 31, 2021",
              "value": "$56,160,000"
            },
            {
              "key": "Acquisitions",
              "value": "$22,651,000"
            },
            {
              "key": "Measurement period adjustments",
              "value": "-$1,522,000"
            },
            {
              "key": "Balance as of December 31, 2022",
              "value": "$77,289,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 115,
          "title": "Changes in Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Management Conclusion Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Effectiveness of Disclosure Controls",
              "value": "Effective as of December 31, 2022"
            },
            {
              "key": "Assessment Context",
              "value": "Based on management evaluation, including principal executive officer and financial officer."
            },
            {
              "key": "Acquisition Effect",
              "value": "Acquisition of Purigen occurred in Q4 2022 and was excluded from internal control assessment."
            },
            {
              "key": "BioDiscovery LLC Acquisition",
              "value": "Acquired in October 2021, integrated into controls as of December 31, 2022."
            },
            {
              "key": "Purigen's Total Net Assets",
              "value": "Approximately 2% of total assets as of December 31, 2022."
            },
            {
              "key": "Purigen's Revenues Excluded",
              "value": "0.1% of total revenue for year ended December 31, 2022."
            },
            {
              "key": "Changes to Internal Control",
              "value": "No material changes except noted acquisitions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 167,
          "title": "Lease Terms and Rent Provisions",
          "data": [
            {
              "key": "Lease Term",
              "value": "Specified in the Basic Lease Information"
            },
            {
              "key": "Commencement Date",
              "value": "Specified in the Basic Lease Information"
            },
            {
              "key": "Expiration Date",
              "value": "Specified in the Basic Lease Information"
            },
            {
              "key": "Target Completion Date",
              "value": "Not specified, implies a deadline set by the landlord"
            },
            {
              "key": "Trigger Date",
              "value": "Date extended by Tenant Delay or Force Majeure"
            },
            {
              "key": "Base Rent",
              "value": "Specified in the Basic Lease Information"
            },
            {
              "key": "Tenant's Percentage Share",
              "value": "Defined within the lease payment sections"
            },
            {
              "key": "Utilities Charges",
              "value": "Tenant pays for direct electrical costs and other utility costs allocated by the landlord"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 185,
          "title": "Section 27: Letter of Credit",
          "data": [
            {
              "key": "Landlord's reliance on Letter of Credit",
              "value": "Landlord enters into Lease relying on the ability to draw upon the Letter of Credit."
            },
            {
              "key": "Letter of Credit Draw Event",
              "value": "Landlord can draw upon the Letter of Credit during a Draw Event."
            },
            {
              "key": "Proceeds use",
              "value": "Proceeds can be used to cure breaches or compensate for damages."
            },
            {
              "key": "Independent contract",
              "value": "Letter of Credit is a separate contract between Landlord and issuer."
            },
            {
              "key": "Tenant's rights",
              "value": "Tenant has no ownership or rights to the Letter of Credit."
            },
            {
              "key": "Bankruptcy implications",
              "value": "Tenant's bankruptcy does not limit Landlord's rights to Letter of Credit."
            },
            {
              "key": "Security Deposit waiver",
              "value": "Letter of Credit shall not be treated as a security deposit under law."
            },
            {
              "key": "Conditions for reduction in Letter of Credit",
              "value": "Conditions based on Tenant's financial performance."
            },
            {
              "key": "Definitions",
              "value": "Definitions related to Cash and other terms in the lease."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 192,
          "title": "Lease Terms regarding Tenant's Rights and Generator",
          "data": [
            {
              "key": "Tenant's Rights Termination Conditions",
              "value": "(a) Tenant’s failure to exercise its Right of First Offer within the period; (b) date Landlord would have provided Tenant an Advice; (c) six months prior to the expiration of the term of Lease"
            },
            {
              "key": "Generator Installation Conditions",
              "value": "Tenant can install a Generator in a designated area and must not interfere with the normal use of the building."
            },
            {
              "key": "Cost Responsibility",
              "value": "Tenant is responsible for all costs associated with the installation and maintenance of the Generator."
            },
            {
              "key": "Landlord's Approval",
              "value": "Tenant must obtain Landlord's approval for all plans and specifications related to the Generator."
            },
            {
              "key": "Indemnity",
              "value": "Tenant must repair any damage caused by the installation or removal of the Generator."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 216,
          "title": "Termination of CDTAMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT WITH EQUITY",
          "data": [
            {
              "key": "Recovery clause",
              "value": "If Purigen sues, recovery in excess of unrecovered litigation costs and fees will be shared with Stanford."
            },
            {
              "key": "Termination by Purigen",
              "value": "Purigen may terminate the agreement with 30 days written notice."
            },
            {
              "key": "Termination by Stanford",
              "value": "Stanford may terminate if Purigen is in material breach, with specific conditions for termination."
            },
            {
              "key": "Surviving provisions",
              "value": "Purigen must pay accrued royalties after termination."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 231,
          "title": "Milestones and Infringement Procedure in Agreement",
          "data": [
            {
              "key": "Milestone Extension Fee Conditions",
              "value": "Purigen may extend net sales milestones by a specified number of months with a payment."
            },
            {
              "key": "Consequence of Failure to Meet Milestone",
              "value": "Failure to pay the extension fee or meet milestones may lead to termination of the Agreement by Stanford."
            },
            {
              "key": "Rights in Case of Infringement",
              "value": "Purigen has right to sue for infringement of Licensed Patents and can name Stanford for standing."
            },
            {
              "key": "Termination Conditions",
              "value": "Stanford may convert license status from exclusive to nonexclusive or terminate license in event of missed development milestones."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 19,
          "title": "Intellectual Property and Government Regulation",
          "data": [
            {
              "key": "Intellectual Property",
              "value": "Our core technology for nucleic acid research is related to methods and devices for non-sequencing based analysis of macromolecules such as nucleic acids. We have secured and continue to pursue intellectual property rights globally, including rights related to isolation, purification and analysis of nucleic acid molecules."
            },
            {
              "key": "Patent Portfolio",
              "value": "We have developed a global patent portfolio that includes more than 160 issued patents or allowed applications across approximately 35 patent families."
            },
            {
              "key": "Government Regulation",
              "value": "Our business is subject to and impacted by extensive and frequently changing laws and regulations in the United States and internationally."
            },
            {
              "key": "FDA Regulation",
              "value": "Our OGM products are currently intended for research use only, or RUO, applications."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 20,
          "title": "FDA Regulations for Medical Devices",
          "data": [
            {
              "key": "Overview",
              "value": "FDA classifies medical devices into three classes based on the level of risk, with Class III having the highest level of scrutiny."
            },
            {
              "key": "Premarket Clearance Pathway",
              "value": "The 510(k) process allows a device to be marketed if it is substantially equivalent to a legally marketed device."
            },
            {
              "key": "PMA Requirements",
              "value": "The Premarket Approval application is more complex and requires extensive data to demonstrate safety and effectiveness."
            },
            {
              "key": "Clinical Trials",
              "value": "Clinical trials are generally required for PMA, and they may also be required for certain 510(k) pathways."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Post-market requirements include compliance with QSRs, reporting obligations, and device registration with the FDA."
            },
            {
              "key": "Potential Sanctions for Non-Compliance",
              "value": "Non-compliance with regulatory requirements can lead to enforcement actions including recalls, sanctions, and civil or criminal prosecution."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 21,
          "title": "Regulation of Laboratory Developed Tests (LDTs)",
          "data": [
            {
              "key": "Federal Agencies",
              "value": "CMS and FDA"
            },
            {
              "key": "Regulation Under CMS",
              "value": "Clinical Laboratory Improvement Amendments of 1988 (CLIA)"
            },
            {
              "key": "Regulation Under FDA",
              "value": "Federal Food, Drug, and Cosmetic Act (FDCA)"
            },
            {
              "key": "LDT Definition",
              "value": "Subset of in vitro diagnostic tests developed and used entirely within a single laboratory"
            },
            {
              "key": "Saphyr Sales Model",
              "value": "RUO basis to CLIA certified cytogenetic laboratories"
            },
            {
              "key": "Historical FDA Actions",
              "value": "Enforcement discretion historically not enforced for LDTs"
            },
            {
              "key": "Potential Changes in Regulation",
              "value": "FDA may regulate LDTs on a case-by-case basis"
            },
            {
              "key": "Impact on Business",
              "value": "Potential increase in cost and time for commercialization of LDTs"
            },
            {
              "key": "Regulation in Europe/Rest of World",
              "value": "Must obtain requisite approvals prior to clinical trials or marketing"
            },
            {
              "key": "IVD Regulation Changes",
              "value": "Greater regulation of medical devices and IVDs in the European Union"
            },
            {
              "key": "Environmental Regulations",
              "value": "Laws related to employee health and safety, hazardous materials"
            },
            {
              "key": "CLIA Compliance",
              "value": "Clinical laboratories must meet standards under CLIA"
            },
            {
              "key": "HIPAA Compliance Requirements",
              "value": "If clinical testing laboratory is operated, compliance with HIPAA is necessary"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 23,
          "title": "HIPAA and other Privacy Laws",
          "data": [
            {
              "key": "HIPAA Overview",
              "value": "The Health Insurance Portability and Accountability Act of 1996 established comprehensive federal standards for the privacy and security of health information."
            },
            {
              "key": "Covered Entities",
              "value": "The HIPAA standards apply to health plans, healthcare clearing houses, and healthcare providers conducting certain transactions electronically."
            },
            {
              "key": "Privacy Regulations",
              "value": "Protect medical records and other health information, limiting use and disclosure."
            },
            {
              "key": "HITECH Act",
              "value": "Enacted on February 17, 2009, expanded and strengthened HIPAA with new enforcement targets and breach notification requirements."
            },
            {
              "key": "Breach Notification Requirements",
              "value": "Covered Entities must report breaches in a timely manner."
            },
            {
              "key": "Bionano Laboratories Compliance",
              "value": "Subject to HIPAA with a compliance program for identifying security incidents."
            },
            {
              "key": "Penalties for Non-Compliance",
              "value": "Bionano Laboratories faces increased penalties under HITECH."
            },
            {
              "key": "State Laws",
              "value": "Various state laws governing privacy and genetic testing regulations apply."
            },
            {
              "key": "General Data Protection Regulation (GDPR)",
              "value": "Applies to operations involving EU data subjects, specifying potential liabilities for violations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 24,
          "title": "Reimbursement and Billing",
          "data": [
            {
              "key": "Complexity of Billing",
              "value": "Reimbursement and billing for diagnostic services is highly complex, requiring compliance with various laws and regulations."
            },
            {
              "key": "Regulatory Bodies",
              "value": "Enforcement by state and federal agencies including CMS, DoJ, OIG."
            },
            {
              "key": "Fraud and Abuse Laws",
              "value": "Includes broad state and federal laws prohibiting fraud in healthcare programs."
            },
            {
              "key": "Overpayment Repayment",
              "value": "Must be repaid within 60 days unless favorable appeal decision."
            },
            {
              "key": "Anti-Kickback Statute",
              "value": "Prohibits remuneration to induce referrals within healthcare."
            },
            {
              "key": "Penalties for Violations",
              "value": "Incurs criminal, civil, and administrative penalties."
            },
            {
              "key": "EKRA",
              "value": "Prohibits payments for referrals to recovery homes, applicable to private insurance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 25,
          "title": "Regulations and Compliance",
          "data": [
            {
              "key": "Federal Ban on Physician Self-Referrals (Stark Law)",
              "value": "Prohibits physician referrals of Medicare patients to certain designated health services if there is a financial relationship."
            },
            {
              "key": "Penalties for Stark Law Violation",
              "value": "Return of funds, fines, civil penalties, exclusion from federal health care programs."
            },
            {
              "key": "State Prohibitions",
              "value": "States may have their own self-referral bans."
            },
            {
              "key": "Federal False Claims Act",
              "value": "Liability for presenting false claims for payment; penalties include tripling damages and civil penalties."
            },
            {
              "key": "Qui Tam Provisions",
              "value": "Allows private individuals to bring actions on behalf of the government."
            },
            {
              "key": "Civil Monetary Penalties Law (CMP Law)",
              "value": "Prohibits remuneration to beneficiaries likely to influence provider selection."
            },
            {
              "key": "Penalties for CMP Law Violation",
              "value": "Exclusion, fines, and treble damages."
            },
            {
              "key": "International Regulations",
              "value": "Compliance with foreign regulatory requirements for laboratory testing and marketing."
            },
            {
              "key": "GDPR Compliance",
              "value": "New requirements for handling personal data of EU residents."
            },
            {
              "key": "Foreign Sales Regulations",
              "value": "Control over sales and distributor activities under the Foreign Corrupt Practices Act."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 26,
          "title": "Regulatory Requirements and Healthcare Reform",
          "data": [
            {
              "key": "Regulatory Compliance",
              "value": "Our laboratories are subject to federal, state and local regulations related to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste."
            },
            {
              "key": "Healthcare Reform Initiatives",
              "value": "There have been legislative initiatives to contain healthcare costs, including the ACA and various executive and Congressional challenges to its provisions."
            },
            {
              "key": "Acquisitions",
              "value": "Acquired BioDiscovery in October 2021 and Purigen in November 2022."
            },
            {
              "key": "Human Capital Management",
              "value": "As of December 31, 2022, had 405 employees distributed across sales, R&D, and general administration."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 42,
          "title": "International Operations and Regulatory Challenges",
          "data": [
            {
              "key": "International Business Risks",
              "value": "Involves compliance with changing foreign regulatory requirements and laws."
            },
            {
              "key": "Staffing and Management Issues",
              "value": "Difficulties in staffing and managing foreign operations."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Difficulties protecting or procuring intellectual property rights."
            },
            {
              "key": "Compliance Requirements",
              "value": "Compliance with anti-bribery laws, data privacy, security requirements, and others."
            },
            {
              "key": "Trade Barriers",
              "value": "Problems related to tariffs, customs charges, and bureaucratic requirements."
            },
            {
              "key": "Legal System Challenges",
              "value": "Longer payment cycles and difficulties in enforcing agreements."
            },
            {
              "key": "Political and Economic Risks",
              "value": "Risks including political instability and adverse tax consequences."
            },
            {
              "key": "Foreign Currency Risks",
              "value": "Potential fluctuations due to changes in foreign currency exchange rates."
            },
            {
              "key": "Anti-Corruption Compliance",
              "value": "Subject to U.S. and foreign anti-corruption and anti-money laundering laws."
            },
            {
              "key": "Penalties",
              "value": "Non-compliance could result in criminal and civil liabilities."
            },
            {
              "key": "Export and Import Controls",
              "value": "Governmental regulations could impair competitiveness in international markets."
            },
            {
              "key": "Substantial Penalties",
              "value": " Failure to comply could result in significant fines and penalties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 45,
          "title": "Data Privacy and Security Compliance Obligations",
          "data": [
            {
              "key": "CCPA",
              "value": "California Consumer Privacy Act imposes obligations on businesses regarding data privacy."
            },
            {
              "key": "CPRA",
              "value": "California Privacy Rights Act expands CCPA obligations and establishes a California Privacy Protection Agency."
            },
            {
              "key": "EU_GDPR",
              "value": "General Data Protection Regulation imposes strict requirements for processing personal data."
            },
            {
              "key": "PCI_DSS",
              "value": "Payment Card Industry Data Security Standard outlines requirements for cardholder information security."
            },
            {
              "key": "Consequences of Noncompliance",
              "value": "Noncompliance can result in significant fines, litigation, and operational impacts."
            },
            {
              "key": "Data Transfer Challenges",
              "value": "Legal challenges and restrictions on transferring personal data between jurisdictions affect business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 47,
          "title": "Regulatory Risks Related to FDA Approval",
          "data": [
            {
              "key": "Description",
              "value": "Risk of incurring substantial costs to comply with environmental, health and safety laws."
            },
            {
              "key": "Potential Consequences",
              "value": "Failure to comply may result in fines, penalties or other sanctions."
            },
            {
              "key": "Regulatory Process",
              "value": "The FDA may require regulatory clearances for RUO products that are deemed medical devices."
            },
            {
              "key": "Impact on Business",
              "value": "Failure to obtain necessary approvals could materially affect the business and financial condition."
            },
            {
              "key": "Additional Requirements for IVD Products",
              "value": "Clinical trials may be required, involving significant time and resources."
            },
            {
              "key": "Consequences of Non-compliance",
              "value": "Warning letters, civil penalties, and potentially revocation of marketing authorization."
            },
            {
              "key": "Changing Regulations",
              "value": "Changes in FDA regulation of LDTs could hinder commercial viability."
            },
            {
              "key": "Conclusion",
              "value": "Failure to obtain timely regulatory approvals could prevent successful commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 48,
          "title": "Regulatory Compliance and Challenges in Diagnostic Product Approval",
          "data": [
            {
              "key": "Summary",
              "value": "The document discusses compliance challenges related to regulatory frameworks for diagnostic products, including potential injunctions, penalties, and the impact of foreign requirements on commercial viability."
            },
            {
              "key": "Regulatory Framework Changes",
              "value": "The current regulatory framework includes potential new regulations that could affect product approvals, impacting commercial viability."
            },
            {
              "key": "Third Party Reliance",
              "value": "The company relies on third parties for clinical trials, which could impact the ability to secure regulatory approvals if they fail to meet obligations."
            },
            {
              "key": "Billing Complexity",
              "value": "Billing for diagnostic testing services is complex, requiring compliance with varying laws and regulations, which poses financial risks."
            },
            {
              "key": "Risks",
              "value": "The potential regulatory risks include government audits, billing disputes, and changes to billing codes that could impact revenue."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 50,
          "title": "Regulatory and Reimbursement Challenges",
          "data": [
            {
              "key": "Unfavorable Pricing Regulations",
              "value": "Diagnostic procedures enabled by Saphyr technology. Risk of harm to business."
            },
            {
              "key": "Reimbursement for Tests",
              "value": "Dependence on third-party payor coverage and CMS approval."
            },
            {
              "key": "Molecular Testing Lab Options",
              "value": "Various reimbursement coding options in the U.S. with primary genomic sequencing codes likely."
            },
            {
              "key": "American Medical Association",
              "value": "Added GSPs to clinical laboratory fee schedule."
            },
            {
              "key": "CMS Coverage Determination",
              "value": "Reimbursement guidelines for next-generation sequencing."
            },
            {
              "key": "European Coverage",
              "value": "Varied in countries with statutory insurance."
            },
            {
              "key": "Cost Containment Programs",
              "value": "Government interest in limiting healthcare costs."
            },
            {
              "key": "ACA Impact",
              "value": "Healthcare legislative reform broadening insurance access and imposing new transparency requirements."
            },
            {
              "key": "Inflation Reduction Act",
              "value": "Elimination of Medicare coverage gap beginning in 2025."
            },
            {
              "key": "Protecting Access to Medicare Act",
              "value": "Altered payment methodology under Medicare Clinical Laboratory Fee Schedule."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 51,
          "title": "Regulatory Compliance Issues",
          "data": [
            {
              "key": "Impact of ACA on healthcare costs and payments",
              "value": "The ACA may result in more rigorous coverage criteria and downward pressure on pricing for approved products."
            },
            {
              "key": "Medicare payment reductions",
              "value": "Any reduction in payments from Medicare or other government programs could reduce payments from private payors."
            },
            {
              "key": "Compliance with CLIA",
              "value": "CLIA compliance is essential for laboratory testing; failure to comply can lead to severe penalties."
            },
            {
              "key": "CLIA Inspection",
              "value": "The laboratory is subject to inspections every two years and can be inspected periodically."
            },
            {
              "key": "State laboratory licenses",
              "value": "Licenses are required in states like California, Pennsylvania, and Maryland."
            },
            {
              "key": "Healthcare fraud and abuse laws",
              "value": "Operations are subject to various healthcare fraud laws, including the federal Anti-Kickback Statute."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 52,
          "title": "Regulatory Environment and Compliance",
          "data": [
            {
              "key": "Federal False Claims Act",
              "value": "Prohibits knowingly presenting false claims for payment to federal government programs."
            },
            {
              "key": "Eliminating Kickbacks in Recovery Act (EKRA)",
              "value": "Prohibits payments for referrals to recovery homes and treatment facilities."
            },
            {
              "key": "HIPAA (Health Insurance Portability and Accountability Act)",
              "value": "Imposes criminal liability for defrauding healthcare benefit programs."
            },
            {
              "key": "HITECH Act",
              "value": "Imposes privacy and security obligations regarding health information."
            },
            {
              "key": "State Laws",
              "value": "Prohibits practices like billing for tests ordered or waiving deductibles."
            },
            {
              "key": "Consumer Protection Laws",
              "value": "Regulate marketplace activities that may harm consumers."
            },
            {
              "key": "Medicare Claims Reassignment Prohibition",
              "value": "Precludes reassignment of Medicare claims to other parties."
            },
            {
              "key": "Anti-Kickback Laws",
              "value": "State and foreign equivalents impose similar restrictions."
            },
            {
              "key": "Data Privacy Laws",
              "value": "Govern privacy and security of health data, with differing state regulations."
            },
            {
              "key": "Scrutiny by Regulatory Agencies",
              "value": "Involvement from DOJ and HHS Office of Inspector General on lab practices."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 53,
          "title": "Regulatory Risks and Intellectual Property",
          "data": [
            {
              "key": "Overview",
              "value": "This section discusses the potential regulatory issues related to healthcare laws and the risks associated with the company's intellectual property."
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Ensuring compliance with healthcare laws is costly. Violations could lead to significant penalties affecting operations."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Failure to protect intellectual property may reduce competitive advantage and increase litigation costs."
            },
            {
              "key": "Patent Portfolio",
              "value": "The company holds over 160 issued patents across various families, with ongoing research and patent applications."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 54,
          "title": "Intellectual Property Risks and Protection",
          "data": [
            {
              "key": "Summary of risks related to intellectual property",
              "value": "The company may face challenges regarding the validity and ownership of its patents and intellectual property rights. There is a risk of competitors infringing on these rights, and if the company's protections are inadequate, this could adversely affect its business."
            },
            {
              "key": "Potential court challenges",
              "value": "Legal actions may arise regarding the enforceability of patents and intellectual property, especially following recent Supreme Court rulings that limit patent protections for computational methods."
            },
            {
              "key": "Defensive measures",
              "value": "The company utilizes various strategies to protect its intellectual property, including patents, trademarks, trade secrets, and confidentiality agreements; however, these measures may not always provide adequate protection."
            },
            {
              "key": "Impact of competitive actions",
              "value": "Competitors may replicate or improve upon the company's technologies, which could undermine its market position if intellectual property rights are not sufficiently enforced."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 55,
          "title": "Intellectual Property Rights and Government Regulations",
          "data": [
            {
              "key": "Intellectual Property Rights",
              "value": "Rights in intellectual property discovered through government funded programs subject to federal regulations."
            },
            {
              "key": "Federal Regulations",
              "value": "Includes 'march-in' rights, reporting requirements, and preference for U.S. industry."
            },
            {
              "key": "Bayh-Dole Act Key Points",
              "value": "U.S. government rights in inventions developed under government funding include a non-exclusive, non-transferable license for governmental use."
            },
            {
              "key": "Commercialization Steps",
              "value": "U.S. government may require exclusive licenses if adequate steps have not been taken to commercialize an invention."
            },
            {
              "key": "Title Acquisition by Government",
              "value": "Government can acquire title to inventions if proper disclosures and applications are not filed."
            },
            {
              "key": "Reporting Requirements",
              "value": "Intellectual property generated must comply with reporting requirements which may require substantial resources."
            },
            {
              "key": "U.S. Manufacturing Preference",
              "value": "Any products embodying the invention must be manufactured substantially in the U.S."
            },
            {
              "key": "License Agreement with Princeton University",
              "value": "Dependence on technology licensed from Princeton University for products."
            },
            {
              "key": "Risks of License Loss",
              "value": "Loss of rights to technology could harm competitive position, business, and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 56,
          "title": "Intellectual Property Disputes and Regulations",
          "data": [
            {
              "key": "Summary",
              "value": "The company discusses potential risks and disputes associated with licensing intellectual property rights, emphasizing the importance of obtaining licenses on commercially reasonable terms and the impact of third-party claims of infringement."
            },
            {
              "key": "Risks Identified",
              "value": "Failure to obtain necessary licenses, inability to commercialize products, potential litigation costs, and the impact of adverse court decisions."
            },
            {
              "key": "Complexities in Licensing",
              "value": "Disputes may arise with licensors, including license interpretation, infringement claims, and obligations linked to licensed technology."
            },
            {
              "key": "Implications of Disputes",
              "value": "Adverse effects on product development and commercialization due to disputes over licensing terms and intellectual property rights."
            },
            {
              "key": "Industry Context",
              "value": "There is significant litigation surrounding patents and intellectual property rights in the industry, which could result in costly legal challenges."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 57,
          "title": "Litigation and Regulatory Risks",
          "data": [
            {
              "key": "summary",
              "value": "The company faces the risk of litigation related to patent infringement, which may result in substantial damages or diversion of resources. It could experience costs associated with defending against such claims, as well as potential losses from contractual obligations if outcomes are unfavorable."
            },
            {
              "key": "key_points",
              "value": "Infringement lawsuits may require the company to pay damages, face costly litigation, and could risk the enforceability of its patents."
            },
            {
              "key": "risks",
              "value": "The company may face claims that its consultants or contractors used or disclosed trade secrets from former employers, potentially exposing it to litigation."
            },
            {
              "key": "consequences",
              "value": "An adverse outcome in patent litigation may lead to the invalidation of patents or loss of proprietary positions affecting the company's ability to sustain operations and raise funds."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 58,
          "title": "Intellectual Property Rights and Litigation Risks",
          "data": [
            {
              "key": "Intellectual Property Claims",
              "value": "Former employees, consultants, advisors, or independent contractors may own rights in intellectual property and be obligated to assign rights to others."
            },
            {
              "key": "Litigation Risks",
              "value": "If a competitor has rights in patents, litigation may be necessary to defend against claims."
            },
            {
              "key": "Costs of Litigation",
              "value": "Litigation could result in substantial costs and distract management."
            },
            {
              "key": "Confidentiality Agreements",
              "value": "Confidentiality and IP assignment agreements generally protect inventions conceived during service."
            },
            {
              "key": "Challenges to IP Ownership",
              "value": "Claims may challenge inventorship or ownership of patents and intellectual property."
            },
            {
              "key": "Effectiveness of Agreements",
              "value": "Agreements may not always be honored or enforceable."
            },
            {
              "key": "Service Agreements with Third Parties",
              "value": "IP conceived for customers may be assigned to them, limiting future use."
            },
            {
              "key": "Global IP Protection Challenges",
              "value": "Protecting IP rights globally is costly and the effectiveness varies by country."
            },
            {
              "key": "Legal Enforcement Variability",
              "value": "Foreign laws may not protect IP as effectively as U.S. laws."
            },
            {
              "key": "Competitors in Unprotected Jurisdictions",
              "value": "Competitors may use technologies in countries without patent protection."
            },
            {
              "key": "Company Strategies for Patent Protection",
              "value": "Patent protection must be sought on a country-by-country basis, which can be expensive."
            },
            {
              "key": "Challenges in Enforcement Abroad",
              "value": "Certain countries have legal systems unfavorable to IP enforcement."
            },
            {
              "key": "Costs of Enforcing Patent Rights",
              "value": "Enforcement proceedings can divert focus from business operations."
            },
            {
              "key": "Recent Changes in Patent Law",
              "value": "Changes in U.S. patent law complicate efforts to stop infringing practices."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 102,
          "title": "Loan Agreement and Amendments Details",
          "data": [
            {
              "key": "Loan prepayment fees",
              "value": "3.0% of outstanding balance if repaid by March 14, 2020; decreasing percentages until 0% after March 14, 2022."
            },
            {
              "key": "End of term fee",
              "value": "$0.8 million, recognized as interest expense."
            },
            {
              "key": "Outstanding term loan payment",
              "value": "$17.0 million paid in full by December 31, 2021."
            },
            {
              "key": "Debt extinguishment loss",
              "value": "$2.1 million."
            },
            {
              "key": "Revolving line of credit",
              "value": "$5.0 million terminated upon payment of term loan."
            },
            {
              "key": "Covenants",
              "value": "Liquidity and revenue covenants required."
            },
            {
              "key": "Collateral",
              "value": "Collateralized by Company’s assets including intellectual property."
            },
            {
              "key": "Events of default",
              "value": "Material adverse impacts could trigger immediate repayment."
            },
            {
              "key": "Warrants issued",
              "value": "Issued for $20.0 million in proceeds with exercise price of $4.63, exercised in 2021."
            },
            {
              "key": "LSA amendment details",
              "value": "Extended deadlines, allowed credit card debt, waived revenue covenants."
            },
            {
              "key": "Equity Event",
              "value": "Defined conditions for partial payments and covenant breaches."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 118,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Number",
              "value": "10. 304)"
            },
            {
              "key": "Description",
              "value": "Commercial Single-Tenant Lease — Net, dated February 28, 2016, by and between Tesa Beach LLC and BioDiscovery, Inc."
            },
            {
              "key": "Number",
              "value": "10. 4"
            },
            {
              "key": "Description",
              "value": "Lease, dated August 22, 2016, by and between SFF BBC, LLC and Purigen Biosystems, Inc."
            },
            {
              "key": "Number",
              "value": "10. 4A"
            },
            {
              "key": "Description",
              "value": "First Amendment to the Lease by and between Purigen Biosystems Inc, and SEF BBC, LLC, dated August 22, 2016"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 122,
          "title": "Warrant Agreement and Anti-Takeover Provisions",
          "data": [
            {
              "key": "Exercise Price Adjustment",
              "value": "The exercise price and number of shares issuable upon exercise of the warrants may be adjusted upon the occurrence of certain events."
            },
            {
              "key": "Fundamental Transactions",
              "value": "If, at any time warrants are outstanding, we consummate any fundamental transaction, the holder will receive upon exercise the securities or other consideration."
            },
            {
              "key": "Beneficial Ownership Limitation",
              "value": "The number of shares that may be acquired will be limited to ensure total beneficial ownership does not exceed 9.99%."
            },
            {
              "key": "Transfer of Warrants",
              "value": "The warrants may be transferred at the option of the holders."
            },
            {
              "key": "Voting Rights",
              "value": "Holders do not have voting rights until the warrants are exercised."
            },
            {
              "key": "Warrant Agreement Obligations",
              "value": "We have agreed to maintain the effectiveness of the registration statement."
            },
            {
              "key": "Cashless Exercise",
              "value": "In the absence of an effective registration statement, holders may exercise the warrants on a cashless basis."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "Certain provisions may delay or discourage acquisition of control."
            },
            {
              "key": "Delaware Anti-Takeover Law",
              "value": "Subject to Section 203 of the DGCL, which imposes restrictions on business combinations with interested stockholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 162,
          "title": "Lease Information and Terms",
          "data": [
            {
              "key": "Allowance Rent",
              "value": "Rent Payment Address (section 3.3)"
            },
            {
              "key": "Tenant’s Percentage Share",
              "value": "11.95%"
            },
            {
              "key": "Permitted Use",
              "value": "General Office, laboratory, research and development, manufacturing and legally permitted ancillary uses"
            },
            {
              "key": "Service Hours",
              "value": "8:00 A.M. to 6:00 P.M. (“Business Hours”) Monday through Friday (except union holidays and legal holidays) (“Business Days”)"
            },
            {
              "key": "Letter of Credit",
              "value": "$400,000.00, subject to reduction pursuant to section 27.6 below"
            },
            {
              "key": "Tenant’s Address",
              "value": "At the Premises Attn: Klint Rose"
            },
            {
              "key": "Landlord’s Address",
              "value": "c/o PSAI Realty Partners, LLC, 155 Montgomery St., Suite 1600, San Francisco, California 94104"
            },
            {
              "key": "Landlord’s Broker",
              "value": "Newmark Cornish & Carey"
            },
            {
              "key": "Tenant’s Broker",
              "value": "Colliers International"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 171,
          "title": "Environmental Regulations and Tenant Responsibilities",
          "data": [
            {
              "key": "Tenant Obligations",
              "value": "Obtain necessary environmental permits and comply with all environmental laws."
            },
            {
              "key": "Hazardous Substances",
              "value": "Tenant must handle hazardous substances in compliance with applicable laws."
            },
            {
              "key": "Insurance Premiums",
              "value": "Any increase in insurance premiums due to hazardous substances is at Tenant's expense."
            },
            {
              "key": "Landlord's Rights",
              "value": "Landlord can inspect the premises for environmental compliance upon reasonable notice."
            },
            {
              "key": "Cleanup Responsibilities",
              "value": "Tenant may be required to perform cleanup if hazardous substances are identified."
            },
            {
              "key": "Liability Exemption",
              "value": "Tenant is not responsible for hazardous substances present before lease commencement."
            },
            {
              "key": "Removal Obligations",
              "value": "Tenant must remove hazardous substances upon lease termination."
            },
            {
              "key": "Definition of Hazardous Substances",
              "value": "Includes any material characterized as toxic, hazardous, or injurious to health."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 172,
          "title": "Environmental Laws and Tenant Liability",
          "data": [
            {
              "key": "Hazardous Substances",
              "value": "alkalis, chemicals, microbial matters (such as molds, fungi or other bacterial matters), biological agents and chemicals which may cause adverse health effects, including but not limited to, cancers and /or toxicity."
            },
            {
              "key": "Environmental Laws Definition",
              "value": "Any and all federal, state, local or quasi-governmental laws, statutes, ordinances, decrees, codes, rulings, awards, rules, regulations or guidance or policy documents relating to the protection of the environment and health and safety."
            },
            {
              "key": "Tenant Indemnity",
              "value": "Tenant shall indemnify and defend Landlord against all claims related to hazardous substances."
            },
            {
              "key": "Landlord's Maintenance Obligations",
              "value": "Landlord shall maintain public and common areas, roof, exterior elements, and mechanical and electrical systems in good order."
            },
            {
              "key": "Basic Services",
              "value": "Electricity, heating, air conditioning, and elevator service during Business Days."
            },
            {
              "key": "Excess Services",
              "value": "Additional utilities and services used by Tenant beyond Basic Services."
            },
            {
              "key": "Costs for Basic and Excess Services",
              "value": "Tenant shall pay for the cost of utilities, any Excess Services, and any measurements or installations related to those services."
            },
            {
              "key": "Temperature Balance Equipment",
              "value": "Equipment to restore temperature balance due to Tenant's usage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 175,
          "title": "Tenant Acknowledgements and Responsibilities",
          "data": [
            {
              "key": "Tenant Responsibilities",
              "value": "Tenant acknowledges that Landlord is not a 'participating owner' with respect to any alterations made to the Premises."
            },
            {
              "key": "Contractor Obligations",
              "value": "Tenant must obtain written acknowledgment from all contractors that they are performing work solely for the Tenant's leasehold interest."
            },
            {
              "key": "Mechanics' Lien Waiver",
              "value": "Contractor waives any right to impose a mechanic's lien on Landlord's ownership interest."
            },
            {
              "key": "Tenant's Maintenance Obligation",
              "value": "Tenant is responsible for maintaining and repairing the Premises at their own cost."
            },
            {
              "key": "Liens Management",
              "value": "Tenant must keep the Premises free from liens and has the right to contest any claims."
            },
            {
              "key": "Damage and Destruction Clause",
              "value": "If the Premises are damaged, Landlord will repair unless the damages require Tenant to pay for certain improvements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 177,
          "title": "Insurance Requirements and Responsibilities",
          "data": [
            {
              "key": "Additional Insured(s)",
              "value": "Shall be at no cost to Landlord or the other additional insured(s)."
            },
            {
              "key": "Umbrella Liability Insurance Policy Limit",
              "value": "Not less than $5,000,000 or higher if required by Landlord."
            },
            {
              "key": "Insurance for Movable Property",
              "value": "Full replacement cost of Tenant's movable furniture, equipment, trade fixtures, and personal property."
            },
            {
              "key": "Loss of Business Income Coverage Duration",
              "value": "Minimum of 12 months rental value."
            },
            {
              "key": "Right to Increase Coverage",
              "value": "Landlord reserves the right to increase coverage amounts as required by Landlord's lender."
            },
            {
              "key": "Insurance Company Requirements",
              "value": "Must be rated not less than A-:VIII in Best's Insurance Guide."
            },
            {
              "key": "Cancellation Notice Requirement",
              "value": "30 days' prior written notice to Landlord."
            },
            {
              "key": "Certificates of Insurance Submission Deadline",
              "value": "At least ten (10) days before the Commencement Date and before policy expiration."
            },
            {
              "key": "Tenant's Liability",
              "value": "Includes all liability assumed by Tenant under this Lease."
            },
            {
              "key": "Deductible Amounts Approval",
              "value": "Should not exceed amounts approved in writing by Landlord."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 178,
          "title": "Compliance With Legal Requirements and Assignment and Subletting",
          "data": [
            {
              "key": "Legal Requirements Compliance",
              "value": "Tenant must comply with all laws and regulations affecting the use or occupancy of the Premises."
            },
            {
              "key": "Assignment of Lease",
              "value": "Tenant cannot assign the lease without prior written consent of Landlord."
            },
            {
              "key": "Permitted Transfer",
              "value": "Transfer under specific conditions without Landlord's consent."
            },
            {
              "key": "Tenant Obligations",
              "value": "Tenant must pay Landlord's costs for processing assignments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 181,
          "title": "Default and Remedies Provisions",
          "data": [
            {
              "key": "Court or governmental authority action",
              "value": "A court or governmental authority appoints a custodian, receiver, trustee, or similar officer with respect to the Tenant or guarantor's property."
            },
            {
              "key": "Lease termination and remedies",
              "value": "Upon an Event of Default, the Landlord has the right to provide a termination notice to the Tenant, leading to the termination of lease and right to possession."
            },
            {
              "key": "Unpaid rent recovery",
              "value": "Landlord can recover from Tenant unpaid rent and further amounts necessary to compensate for the Tenant's failure to perform obligations."
            },
            {
              "key": "Tenant's rights waivers",
              "value": "Tenant waives the right to redeem occupancy post-termination of the Lease."
            },
            {
              "key": "Landlord's default notice",
              "value": "If Landlord defaults, Tenant must notify and allow 30 days to cure the default."
            },
            {
              "key": "Landlord's liability limitation",
              "value": "No personal liability shall attach to Landlord under this Lease."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 182,
          "title": "Eminent Domain and Lease Subordination",
          "data": [
            {
              "key": "Eminent Domain",
              "value": "The section covers the Landlord's rights in case the premises are taken under the power of eminent domain and details conditions for termination or adjustment of rent."
            },
            {
              "key": "Tenant Obligations",
              "value": "Tenant must perform acts within ten days as requested by the Landlord."
            },
            {
              "key": "Compensation",
              "value": "All awards and compensation from eminent domain shall belong to the Landlord."
            },
            {
              "key": "Temporary Taking",
              "value": "If the premises are temporarily taken for less than 180 days, rent will be abated proportionally."
            },
            {
              "key": "Subordination to Mortgages",
              "value": "The lease is subject to existing and future mortgages and trusts on the building."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 183,
          "title": "Lease Agreement Terms",
          "data": [
            {
              "key": "Article 23 Title",
              "value": "Surrender of Premises; Ownership and Removal of Trade Fixtures"
            },
            {
              "key": "Landlord Responsibility Regarding Non-Disturbance Agreement",
              "value": "Landlord is not required to expend funds for non-disturbance agreement."
            },
            {
              "key": "Tenant's Rights",
              "value": "Tenant must receive a written acknowledgment by Landlord to consider the surrender of premises."
            },
            {
              "key": "Conditions for Surrender of Premises",
              "value": "Tenant must return premises in good condition, removing personal property as required."
            },
            {
              "key": "Property Ownership After Surrender",
              "value": "Any property not removed by Tenant may be considered abandoned by Landlord."
            },
            {
              "key": "Article 24 Title",
              "value": "Sale"
            },
            {
              "key": "Landlord Liability After Sale",
              "value": "Original Landlord's liabilities terminate after sale; new owner is bound."
            },
            {
              "key": "Tenant's Attornment Obligation",
              "value": "Tenant agrees to attorn to new owner."
            },
            {
              "key": "Article 25 Title",
              "value": "Estoppel Certificate"
            },
            {
              "key": "Tenant's Obligations",
              "value": "Tenant must provide a certificate on request about lease status and defaults."
            },
            {
              "key": "Article 26 Title",
              "value": "Holding Over"
            },
            {
              "key": "Impact of Holding Over",
              "value": "Holding over without consent is a tenancy at sufferance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 188,
          "title": "ARTICLE 30 Notices and ARTICLE 31 Miscellaneous",
          "data": [
            {
              "key": "Communication Requirements",
              "value": "All notices must be in writing, can be hand delivered, sent by overnight courier, or certified mail."
            },
            {
              "key": "Effective Date of Notices",
              "value": "Notices are effective on the date of delivery."
            },
            {
              "key": "Joint and Several Obligations",
              "value": "If multiple Tenants, all are jointly responsible."
            },
            {
              "key": "Governing Law",
              "value": "This Lease is governed by the laws of the state where the Building is located."
            },
            {
              "key": "Late Payment Fee",
              "value": "If rent is late by 3 days, a late fee of 10% is charged."
            },
            {
              "key": "Legal Action Costs",
              "value": "The unsuccessful party in legal actions shall pay all costs and attorney fees."
            },
            {
              "key": "Jury Trial Waiver",
              "value": "Both parties waive the right to a jury trial."
            },
            {
              "key": "Exhibits Included",
              "value": "Exhibit A, B, C are part of the Lease."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 196,
          "title": "Rules and Regulations",
          "data": [
            {
              "key": "Exhibit",
              "value": "C"
            },
            {
              "key": "Regulations",
              "value": "Exhibit D 2"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 204,
          "title": "Change of Control Definition",
          "data": [
            {
              "key": "Document Title",
              "value": "S05-338: CDT AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT"
            },
            {
              "key": "Date",
              "value": "8/3/2021"
            },
            {
              "key": "Change of Control Definition",
              "value": "acquisition of ownership by any person or group of the capital stock of Purigen representing more than 50% of the voting power or equity value or sale of all or substantially all Purigen’s assets."
            },
            {
              "key": "Definitions",
              "value": "Definitions of 'Affiliate', 'Exclusive', 'Fully Diluted Basis', etc."
            },
            {
              "key": "Excluded Field of Use",
              "value": "Diagnostics in Developing Nations as defined in Appendix C."
            },
            {
              "key": "Licensed Field of Use",
              "value": "All fields excluding Excluded Field of Use."
            },
            {
              "key": "Licensed Patent",
              "value": "Patents and patent applications listed in Appendix F."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 208,
          "title": "Litigation Regarding Sublicensee Actions",
          "data": [
            {
              "key": "License Agreement Date",
              "value": "8/3/2021"
            },
            {
              "key": "Litigation Type",
              "value": "Sublicensee action seeking to invalidate patents"
            },
            {
              "key": "Royalty Payment Adjustment",
              "value": "Double payment during litigation; triple if patent claim is upheld"
            },
            {
              "key": "Jurisdiction",
              "value": "Santa Clara County"
            },
            {
              "key": "Certification Requirement",
              "value": "Annual certification by Chief Financial Officer"
            },
            {
              "key": "Government Rights",
              "value": "Subject to Title 35 Sections 200-204 of the United States Code"
            },
            {
              "key": "Diligence Requirement",
              "value": "Purigen must diligently develop and sell Licensed Products"
            },
            {
              "key": "Nonroyalty Sublicensing Consideration",
              "value": "Stanford to receive a portion of Nonroyalty Sublicensing Consideration"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 215,
          "title": "Infringement Procedure",
          "data": [
            {
              "key": "Date",
              "value": "8/3/2021"
            },
            {
              "key": "Agreement Type",
              "value": "Exclusive License Agreement"
            },
            {
              "key": "Parties Involved",
              "value": "Purigen and Stanford"
            },
            {
              "key": "Section 15.4",
              "value": "Purigen Suit: Rights and Procedures in suit against third parties."
            },
            {
              "key": "Section 15.5",
              "value": "Joint Suit: Procedures for joint actions by Purigen and Stanford."
            },
            {
              "key": "Section 15.6",
              "value": "Stanford Suit: Rights of Stanford to institute suit."
            },
            {
              "key": "Section 15.7",
              "value": "Conditions for naming Stanford as a party in the action."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 232,
          "title": "Amendment to Agreement",
          "data": [
            {
              "key": "Consent Requirement",
              "value": "Purigen cannot make any changes without Stanford's prior written consent."
            },
            {
              "key": "Litigation Costs",
              "value": "Purigen will bear the entire cost of the litigation, including expenses and counsel fees incurred by Stanford."
            },
            {
              "key": "Recovery from Litigation",
              "value": "Purigen will retain the entire amount of any recovery or settlement."
            },
            {
              "key": "Nonrefundable Fee",
              "value": "Purigen will pay Stanford a nonrefundable, noncreditable fee of $[***] within [***] days of signing."
            },
            {
              "key": "Signature",
              "value": "Signature by Mona Wan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 236,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Company",
              "value": "Bionano Genomics, Inc."
            },
            {
              "key": "Report Date",
              "value": "March 9, 2023"
            },
            {
              "key": "Report Type",
              "value": "Consolidated Financial Statements"
            },
            {
              "key": "Registration Statements",
              "value": "Form S-3 and Form S-8"
            },
            {
              "key": "Explanatory Paragraph",
              "value": "Regarding the Company’s ability to continue as a going concern"
            },
            {
              "key": "Accounting Firm",
              "value": "BDO USA, LLP"
            },
            {
              "key": "Location",
              "value": "San Diego, California"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 69,
          "title": "Supply Chain Disruptions Due to COVID-19",
          "data": [
            {
              "key": "Impact of COVID-19 on operations",
              "value": "Increased supply chain disruptions impacting production ability."
            },
            {
              "key": "Effects on Enrollment",
              "value": "Negative effects on enrollment in clinical studies."
            },
            {
              "key": "Operational Reductions",
              "value": "Operational reductions by manufacturing partners, suppliers, and customers."
            },
            {
              "key": "Impact on Financial Results",
              "value": "Decreased sales negatively impacting financial results in fiscal years 2021 and 2022."
            },
            {
              "key": "Long-term effects",
              "value": "Uncertain long-term effects of COVID-19 on business operations."
            },
            {
              "key": "Increased Costs",
              "value": "Increased costs to secure component parts and produce products."
            },
            {
              "key": "Market Recovery",
              "value": "Uncertainty regarding the pace of market recovery."
            },
            {
              "key": "Economic Conditions",
              "value": "Reduced product demand due to economic conditions."
            },
            {
              "key": "Future Impact",
              "value": "Potential material impact on operations, business, earnings, and liquidity."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 72,
          "title": "Gross Profit and Margin Analysis - Years Ended December 31",
          "data": [
            {
              "key": "Gross profit (loss)",
              "value": "2022: 4,459,000, 2021: 2,162,000, Change: 2,297,000, Percentage Change: 106%"
            },
            {
              "key": "Service and other",
              "value": "2022: 1,486,000, 2021: 1,712,000, Change: (226,000), Percentage Change: (13)%"
            },
            {
              "key": "Total gross profit",
              "value": "2022: 5,945,000, 2021: 3,874,000, Change: 2,071,000, Percentage Change: 53%"
            },
            {
              "key": "Product margin",
              "value": "2022: 22%, 2021: 17%"
            },
            {
              "key": "Service and other margin",
              "value": "2022: 20%, 2021: 32%"
            },
            {
              "key": "Total gross margin",
              "value": "2022: 21%, 2021: 22%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "esg_initiative",
          "page": 88,
          "title": "Liquidity and Going Concern",
          "data": [
            {
              "key": "Overview",
              "value": "The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and significant accumulated deficit since its inception."
            },
            {
              "key": "Cash Balance",
              "value": "As of December 31, 2022, the Company had approximately $5.1 million in cash and cash equivalents."
            },
            {
              "key": "Short Term Investments",
              "value": "$108.1 million."
            },
            {
              "key": "Working Capital",
              "value": "$121.4 million."
            },
            {
              "key": "Accumulated Deficit",
              "value": "$348.7 million as of December 31, 2022."
            },
            {
              "key": "Cash Used in Operations (2022)",
              "value": "$124.8 million."
            },
            {
              "key": "Going Concern Risks",
              "value": "Substantial doubt about the Company’s ability to continue as a going concern."
            },
            {
              "key": "Funding Needs",
              "value": "Management plans include raising additional capital through public or private equity or debt financings."
            },
            {
              "key": "Potential Risks of Financing",
              "value": "Existing stockholders may experience dilution, and new equity securities may have rights, preferences and privileges senior to existing stockholders."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "esg_initiative",
          "page": 170,
          "title": "Tenant Use and Environmental Matters",
          "data": [
            {
              "key": "Use of Premises",
              "value": "Tenant shall use the Premises only for the purposes described in the Basic Lease Information for Tenant’s business."
            },
            {
              "key": "Prohibited Activities",
              "value": "Tenant shall not do or permit anything that conflicts with any law or property insurance policy."
            },
            {
              "key": "Environmental Approval",
              "value": "Tenant may utilize certain hazardous substances with Landlord's approval."
            },
            {
              "key": "Equitable Allocation of Costs",
              "value": "Landlord has the right to allocate Operating Expenses based on occupancy."
            },
            {
              "key": "Property Taxes",
              "value": "Definition of Property Taxes includes various assessments levied on the Project."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 174,
          "title": "Alterations and improvements clause",
          "data": [
            {
              "key": "Landlord alterations approval",
              "value": "Landlord disapproves such plans and specifications, Tenant must revise them within 10 business days."
            },
            {
              "key": "Tenant responsibilities",
              "value": "Tenant pays for all work, including utilities, permits, fees, taxes, etc."
            },
            {
              "key": "Contractor approval",
              "value": "Tenant must engage contractors approved by Landlord."
            },
            {
              "key": "Alterations exceeding $100,000",
              "value": "Landlord may require security for payment and performance bonds."
            },
            {
              "key": "Builder's insurance requirement",
              "value": "Tenant must provide Builder's All Risk insurance if required by Landlord."
            },
            {
              "key": "Liability limitation",
              "value": "Landlord not liable for Tenant's contractor work or delays."
            },
            {
              "key": "Notice for construction commencement",
              "value": "Tenant must notify Landlord of construction start date 10 days in advance."
            },
            {
              "key": "All changes subject to approval",
              "value": "Tenant must submit all changes to Landlord for approval."
            },
            {
              "key": "Supervision Fee",
              "value": "Tenant pays Landlord 4% of Alteration costs as Supervision Fee."
            },
            {
              "key": "Ownership of Alterations",
              "value": "All Alterations become part of Landlord's property unless specified otherwise."
            },
            {
              "key": "Removal obligation",
              "value": "Tenant must remove Alterations and restore premises upon termination."
            },
            {
              "key": "Tenant's property",
              "value": "Movable furniture and trade fixtures belong to Tenant."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 31,
    "EUR": 31,
    "GBP": 2,
    "AUD": 12,
    "CAD": 10,
    "ZAR": 8
  },
  "sha1": "5a24fa827d172a7669eca206b2a5f47c2b19b48d"
}